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INTRODUCTION 
1. The mitochondrion 
Mitochondria arose around two billion years ago from the engulfment of an α-proteobacterium by a 
precursor of the modern eukaryotic cell 1. Nowadays they are the principal source of energy 
production and metabolism that are fundamental processes for the survival and wellbeing of the cell. 
Mitochondria are organelles with a double membrane, the outer (OM) and the inner membrane (IM), 
and together they delimit two aqueous compartments: the matrix, in the inner side, and the 
intermembrane space (IMS) (Figure 1).  
 
 
 
Figure 1: Mitochondrial structure. Mitochondria possess a double membrane: the outer 
membrane (OM) and the inner membrane (IM). Between the two membranes there is the 
intermembrane space (IMS), while inside, delimited by the IM there is the matrix 
(https://micro.magnet.fsu.edu/cells/mitochondria/mitochondria.html).  
 
The main function of mitochondria is exerted in the IM through the electron transport chain (ETC) 
that produce energy in the form of ATP via oxidative phosphorylation (OXPHOS). In the matrix, 
tricarboxylic acid cycle (TCA) enzymes generate electron carriers (NADH and FADH2), which donate 
electrons to the ETC. 
The ETC consists of four protein machines (I–IV), which through sequential redox reactions undergo 
conformational changes to pump protons from the matrix into the IMS. The proton gradient generated 
by complexes I, III, and IV is released through the rotary turbine-like ATP synthase machine or 
complex V, which drives phosphorylation of ADP to ATP 2,3. Complexes I and III also could lose 
some electrons that can react with O2 generating reactive oxygen species (ROS), including oxygen 
radicals and hydrogen peroxide, which may damage key components of cells, including lipids, nucleic 
acids, and proteins 4,5. 
Beyond ATP production, the inner-membrane electrochemical potential generated by OXPHOS is a 
vital feature of the organelle 6. Membrane potential is harnessed for other essential mitochondrial 
functions, such as mitochondrial protein import 7 and is used to trigger changes on the molecular level 
that alter mitochondrial behaviors in response to mitochondrial dysfunction. 
Besides the role in energy production and in other metabolic pathways involving carbohydrates (Krebs 
cycle) lipids, amino acids and iron, mitochondria play a central role in the programmed cell death 
process (apoptosis) that is important for the correct development of organisms, for tissue homeostasis 
and as a response to cellular stress or pathogens.  
Although mitochondria have maintained the double membrane character of their ancestors and the 
core of ATP production, their overall form and composition have been drastically altered, and they 
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have acquired myriad additional functions within the cell. As part of the process of acquiring new 
functions during evolution, most of the genomic material of the α-proteobacterium progenitor was 
rapidly lost or transferred to the nuclear genome 8 . What remains in human cells is a small, 
approximately 16 kilobase, circular genome, which is present in cells in a vast excess of copies 
relative to nuclear chromosomes. Mitochondrial DNA (mtDNA) contains 37 genes: 13 codify for 
proteins, 22 are tRNA, and 2 are for the ribosomal RNA subunits. We know from a combination of 
proteomics, genomics and bioinformatics analysis that modern day mitochondria are comprised of 
well over 1,000 proteins. The majority of the proteins present in this organelle are nuclear encoded 
and the composition changes with and between species in response to cellular and tissue-specific 
organismal needs 9–11. 
The nucleus-encoded proteins that make up most of the mitochondrial proteome are translated on 
cytosolic ribosomes and actively imported and sorted into mitochondrial subcompartments by outer 
and inner membrane translocase machines 7,12. 
 
1.1 Sorting pathways of mitochondria 
Translocation of proteins across organelle membranes is critical process for the cell survival. The 
targeting sequences carried by the proteins provide the specificity for the destination organelle, while 
the machineries that are designed to translocate the proteins into the various compartments provide the 
import. 
Different mechanisms are used by mitochondria for the import of such proteins, depending on their 
destination 13. The “mitochondrial portal” for all the proteins is TOM (translocator of the outer 
membrane) that permits the substrates to pass the OM. If the protein is a transmembrane protein and is 
carrying a non-cleavable signal, it becomes substrate of the SAM machinery (Sorting and assembly 
machinery of the outer mitochondrial membrane) that assists the β-barrel assembly and the α-helical 
folding of thus proteins in the outer membrane. TIM23 (Translocase of the inner mitochondrial 
membrane 23) and TIM22 (Translocase of the inner mitochondrial membrane 22) are the machineries 
assigned to the import of the proteins in the matrix and into the inner membrane, respectively. Proteins 
with a presequence containing a sorting signal or a bipartite presequence are substrates of these 
machineries. The OXA (Insertase/export machinery of the inner membrane) complex is responsible 
for the translocation of mitochondrial encoded proteins from the matrix into the inner membrane 13 
(Figure 2). 
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Figure 2: Sorting pathways of mitochondria. The translocase of the outer membrane (TOM 
complex) is the main entry gate into mitochondria. Subsequently, the precursor proteins follow 
different sorting pathways. SAM, sorting and assembly machinery; TIM22 complex, carrier 
translocase of the inner membrane; TIM23 complex, presequence translocase of the inner 
membrane; OXA, insertase/export machinery of the inner membrane; MIA, mitochondrial 
intermembrane space assembly (Adapted image from Chacinska et al., 2009). 
Instead of the other compartments, none of the proteins present in the IMS is encoded by mitochondria 
so, if the protein is a soluble cytein-rich IMS protein this could be a substrate for the disulfide relay 
system (DRS), an import machinery that uses a redox system for cysteine enriched proteins, to drive 
them in this compartment 13,14. The DRS is composed by two main proteins: Mia40 is the 
oxidoreductase that catalyzes the formation of the disulfde bonds in the substrate, while Erv1/ALR 
reoxidizes Mia40 after the import 14,15. 
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2. The Disulfide Relay System 
The IMS proteins Mia40 and Erv1/ALR represent the central components of the DRS. 
As said before, all IMS proteins are nuclear encoded and only a few of them contain MTS or internal 
targeting sequence. Most of them are cysteine-enriched proteins with conserved cysteine patterns that 
are recognised by Mia40. To be able to interact with Mia40 these proteins have to be kept in an 
unfolded state into the cytosol and this is achieved by cytosolic glutharedoxin in human cells and by 
the thioredoxin system in yeast 16,17. In this way proteins are able to pass the TOM pore and enter 
mitochondria. 
After the passage throughout the outer membrane via TOM pore, substrate proteins are recognised by 
Mia40 thanks to the MISS/ITS sequence via hydrophobic interactions 18,19 (Figure 3. (2)). 
Mia40 is an IMS protein composed by a highly conserved C-term domain that contains the catalytic 
CPC (cysteine-proline-cysteine) motif and a hydrophobic cleft. After the recognition of the substrate 
the thiolate anion of a cysteine in the substrate performs a nucleophilic attack on the oxidezed CPC 
motif of Mia40 (Figure 3. (3)). This finally results in an intermolecular disulfide bond that is 
subsequently resolved by another nucleophilic attack of the other thiolate anion (Figure 3. (4)) 20,21. At 
the same time, Mia40 is also able to induce a conformational change in the substrate, in particular in 
that hydrophobic region that is interacting with Mia40 (MISS/ITS sequence). This region in the 
substrate passes from a completely unfolded state to a-helix conformation as shown in Figure 3 22. 
Finally, the result of this reaction is an oxidized and folded substrate in the IMS and a reduced Mia40 
molecule (Figure 3 (4)). 
Once Mia40 has oxidized its substrate, the CPC motif remains in a completely reduced form and has 
to be re-oxidized for another cycle of import 21,23. Erv1 (Essential for respiration and vegetative growth 
1) in yeast and ALR (augmenter of liver regeneration) in human mitochondria are responsible for this 
process (Figure 3(5)).  
 
 
 
Figure 3: Oxidation of the substrate by Mia40. (1) Mia40 is present in an oxidized state in the 
IMS; (2) Precursors are recognized by Mia40 thanks to the MISS/ITS sequence and the 
intramolecular bond is formed; (3) The intermolecular disulfide bond is resolved and a folded 
substrate is released; (4) Mia40 has to be reoxidized by Erv1/ALR; (5) Once Mia40 is reoxidized 
Erv1/ALR can pass the electrons to the Cyt. C, and then to the O2  (Adapted image from Meisinger 
et al. 2010). 
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Human ALR is present as two alternatively-spliced forms: a long form (23 kDa), that is extensively 
present in the IMS and a short one (15 kDa) that lacks an 80 amino acids N-terminal extension and 
acts as an extracellular cytokine 24–26. In yeast Erv1 is present in one unique form that corresponds to 
the long human form of ALR and is present exclusively in the mitochondrial intermembrane space 27.  
Erv1 and ALR are sulfhydryl oxidase coupled with one molecule of FAD and acting as homodimer in 
solution. Both proteins present a CXXC motif that is engaged in the binding with the FAD molecule 
and a pair of conserved cysteines in their N-terminal domain, also called N-term shuffle domain or 
CRAC motif in ALR, that is responsible for the interaction with Mia40 (Figure 4) 21,28–30.  Erv1 and 
ALR present 40% of homology for the C-terminal domain that contains the CXXC motif for the 
binding of the FAD molecule, while the N-terminal domain is not conserved.  
 
 
Figure 4: Schematic representation of Erv1 and ALR proteins. Cysteines highlighted in black 
are conserved residues while cysteines highlighted in grey are more recently acquired residues. 
The first two conserved cysteines form the N-Term shuffle domain responsible for the electron 
transfer from Mia40 to the FAD molecule. Cysteines 142-145 in ALR and 130-133 in Erv1 form 
the CXXC domain that binds the FAD molecule (Adapted image from Sztolsztener et al. 2013). 
 
It has been demonstrated that ALR is able to regenerate Mia40 for a new import cycle when Mia40 is 
reduced 28,31. Indeed, ALR interacts with Mia40 through its N-terminal domain thanks to hydrophobic 
interactions with the hydrophobic cleft of Mia40 that is the same segment used by the protein to 
recognise and fold its substrate proteins. So using a “substrate mimicry” strategy this domain is able to 
mediate the electron transfer from Mia40 to Erv1/ALR 29,30. This interaction does not affect ALR N-
terminal domain but permits the electron transfer between the two proteins. The CPC motif of Mia40 
interacts with the CRAC motif of ALR and is able to pass its electrons to the two conserved cysteines 
(Figure 5).  
Once the electrons are passed, Mia40 is ready to start a new import cycle. The N-terminal shuffle 
domain of ALR, in turn, has to be reoxidized to become able to regenerate another Mia40 protein, so 
the electrons are passed from the CRAC motif of the N-terminal domain to the CXXC motif of the 
FAD binding domain, and then to the Cyt c that transfers the electrons to the respiratory chain 29. 
It has been proposed that the reaction of import and oxidation of Mia40 in yeast take place in a ternary 
complex with the substrate, Mia40 and Erv1. Bottinger et al. demonstrate that Erv1 is necessary for 
the conformational change required for the oxidation of the substrate. Erv1 is able to bind an 
alternative region of Mia40 upon binding of the substrate to ensure that semi-oxidized substrates are 
not released in the IMS 32. 
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Figure 5: Electron flow in a cycle of import. Oxidized Mia40 interacts with substrates and 
facilitates their stable folding by the introduction of disulfide bonds. A cascade of redox-active 
proteins transfers electrons from Mia40 to Cyt c oxidase, which converts oxygen to water. The 
flavoprotein Erv1 mediates the switch from two-electron to one-electron transfer (Adapted image 
from Herrmann et al. 2009).  
 
After passage of the electrons from Mia40 to Erv1/ALR, these electrons have to be passed to another 
component of the DRS, the Cyt c, in order to reoxidize Erv1/ALR that, in this way, is ready for 
another cycle of import (Figure 6) 21,33,34. 
Bihlmaier et al. demonstrate that Erv1 and the Cyt c can interact, and Erv1 directly passes the 
electrons to the Cyt c, connecting the DRS to the respiratory chain and preventing the generation of 
hydrogen peroxide. The same was also proved to occur in human cells for ALR 31. It was also shown 
that the redox state of Mia40 depends on the activity of the respiratory chain complexes. Indeed, in the 
absence of oxidized Cyt c or Cyt c oxidase, Mia40 is present in the mitochondria in a reduced state, 
whereas an increase of oxidized Cyt c lead to an increase of the oxidized form of Mia40. Mutation of 
other components of the respiratory chain (e.g. F1 F0 ATPase), however, did not change the redox state 
of Mia40 indicating a specific function of Cyt c in this process. Moreover, import in the absence of 
Cyt c or Cyt c oxidase is decreased and is hypersensitive to the treatment with reducing agents as DTT 
34. 
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Figure 6: Model for the interaction of the DRS and the mitochondrial respiratory chain. The 
electron flow from the imported proteins to the final electron acceptor oxygen is indicated. The 
cytochrome c–independent side reaction of Erv1 with oxygen is shown in light gray. Cyt c 
reductase and oxidase complexes are indicated as complexes III and IV, respectively. Q indicates 
the ubiquinone pool (Adapted from Bihlmaier et al. 2007). 
 
2.1 Cellular factors influencing the DRS 
Two of the most influencing factors of this redox import pathway are the IMS GSH pool and the 
percentage of molecular oxygen (pO2).  
The GSH pool of the IMS is interconnected to the one in the cytosol by the porins inserted in the OM 
of mitochondria (Figure 7) 35. Under normal physiological conditions 70% of Mia40 is oxidized 
thanks to Erv1 that efficiently avoid the accumulation of the reduced form of Mia40. Kojer et al. 
demonstrate that in yeast strains lacking Erv1, Mia40 can be reduced by GSH in vivo. In cells lacking 
Glr1 (Glutathione disulfide reductase 1) the recovery of Mia40 is impaired, so local GSH pool can 
provide the reducing equivalents to Mia40 35. 
According to these previous findings Bien et al. proposed an essential role of the GSH pool for the 
proper functioning of DRS. At physiological concentrations GSH is able to counteract the generation 
of incorrect intermediates and long-lived unproductive disulfide arrangements. In this way the 
mitochondrial import is more efficient and futile cycles of oxidation and reduction are prevented 20,21.  
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Figure 7: Mia40 pathway is influenced by cytoplasmatic GSH. (I) Reduced and unfolded 
substrates cross the outer mitochondrial membrane (II) and are recognized by oxidized Mia40. 
(III) Following the formation of an intermolecular disulfide bond, the substrate is released, 
oxidized and folded while Mia40 CPC motif is reduced. Mia40 is then reoxidized by Erv1 that can 
transfer electrons to cytochrome C or directly to oxygen forming H2O2. GSH has been shown in 
vitro to influence the oxidative folding of several substrates by promoting disulfide reshuffling. 
(IV) Free diffusion of GSH:GSSG from the cytoplasm to the IMS thanks to the presence of porins. 
The GSH pool in the cytoplasm also influences the redox state of Mia40 but the molecular 
mechanisms involved remain unclear (Adapted image from Ventura et al. 2013). 
 
 
Also pO2 is able to influence DRS pathway. It has been demonstrated that the electrons can be passed 
from Mia40 to Erv1 and then to either via Cyt c to oxygen or to oxygen in a direct way in vitro and in 
organello 33,34. Kojer et al. studied the influence of oxygen in yeast strains were complex III and IV of 
the respiratory chain were absent. In the presence of 20% O2 no difference was observed in 
comparison with the WT, instead in 1% O2 conditions Mia40 was more reduced when the complex IV 
was absent. So Erv1 is able to pass electrons to molecular oxygen via Complex IV in vivo, and at 
oxygen concentrations of 20% the re-oxidation of Mia40 can be efficiently driven by the direct 
interaction of Erv1 and oxygen in vivo 35. 
Hot13 protein was also proposed to have an influence in the redox state of Mia40. Hot13 (Helper of 
Tim 13) is a zinc-binding protein and is a chaperone for the assembly of the small Tim proteins in the 
IMS 36,37. Yeast strains lacking Hot13 present unchanged levels of Mia40 but a more abundant reduced 
form of the protein. Moreover in the presence of low concentration of GSH, the absence of Hot13 lead 
to a more reduced form of Mia40 36. Mesecke et al. demonstrate that Mia40 can physically interact 
with Hot13, but without the participation of disulfide bonds. 
Because it was demonstrated that the zinc binding stabilize the reduced form of Mia40 due to the fact 
that Erv1 cannot efficiently bind this form, it has been proposed that Hot13 is able to convert the zinc-
bind form of Mia40 in the zinc-free form, enabling Erv1 to oxidize it (Figure 8) 37. 
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Figure 8: Model for the influence of metal ions on protein import into the IMS. Imported 
proteins can be associated with zinc ions. These are passed through Mia40 to Hot13 and further to 
an unknown acceptor. Hot13-mediated demetalation of Mia40 presumably improves the 
reoxidation of the import receptor by Erv1 (Adapted image from Meseke et al. 2008). 
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3. Mia40 
Mia40 (Mitochondrial Intermembrane Space Import and Assembly Protein) is a protein that localize in 
the mitochondrial intermembrane space. Mia40 is a fundamental part of DRS and its main function is 
to translocate its protein substrates from the cytoplasm to the IMS of mitochondria and to assist their 
folding inside this space. The substrates of Mia40 are nuclear encoded proteins that fulfil their 
function in the IMS or in the matrix, through an import process that implicates the formation of 
disulfide bonds between Mia40 and the precursor protein 38. 
 
3.1 Yeast and human Mia40 structure 
3.1.1 Yeast Mia40 
Mia40 was firstly described in yeast by Chacinska et al. in 2004 as a component of the DRS. Yeast 
Mia40, also known as Tim40, is a nuclear encoded protein by the ORF JKL195w, it contains a 
cleavable presequence and is imported into mitochondria via TIM23 complex 38,39. 
Yeast Mia40 is composed by 403 amino acids and can be divided into two principal domains: the C-
term of the protein that contains the catalytic motif and the N-term that contains the transmembrane 
domain and the cleavable N-term presequence (Figure 9). Once this presequence is cleaved, Mia40 is 
anchored to the inner membrane thanks to the hydrophobic transmembrane segment while the large C-
term domain is exposed to the IMS. The C-term domain contains six cysteines and the replacement of 
one of these is lethal. In particular, the first two cysteines, Cys 296 and Cys 298, form a CPC motif 
able to bind to the target cysteine of the substrate, while the other four cysteines, Cys 307, 317, 330, 
and 340, form twins CX9C motifs that have probably only a structural function. The disulfide bonds 
between these residues are present in the fully oxidized form of the protein 38,39. 
Likewise other IMS proteins, this protein is principally constituted by two 13-residue α-helices that 
from an antiparallel hairpin, which are virtually connected by two disulfide bonds formed by Cys307-
Cys340 and Cys317-Cys330. The other two functional cysteines are exposed to the IMS lumen and 
they are able to attack the cysteine residues of the substrates.  
This structure confers to Mia40 a fruit-dish-like shape in which the hydrophobic residues of the 
helices are exposed to the outer space in a concave surface mainly formed by phenylalanine residues 
40,41. This concave surface has a very important role for the coupling with the substrates. Indeed, it has 
been demonstrated that the hydrophobic region is positioned in close proximity to the redox-active 
cysteines of the CPC motif, and serves as a binding region for the substrates and for the recognition by 
the so-called MISS or ITS (Mitochondrial IMS-sorting signal, or ITS for IMS-targeting signal) 
sequence present in the client proteins 18,19.  
 
 
Figure 9: Schematic representation of yeast Mia40. In the structure are present seven cystines 
residues, six of which are conserved. These residues form the CPC catalytic motif and the twin 
CX9C structural motif. The Matrix targeting signal and the transmembrane segment are located at 
the N-term (Adapted image from Sztolsztener et al. 2013). 
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3.1.2 Human Mia40 
Human Mia40 is a soluble IMS protein and belongs to the protein family whose members share six 
highly conserved cysteine residues constituting a -CXC-CX9C-CX9C- motif 42. Protein sequence 
alignment of the region comprises between amino acids 47 and 102 reveals a 75% similarity to S. 
cerevisiae Mia40 and 98% to D. Melanogaster (Figure 10). Outside this cysteine domain the similarity 
is low because, as said before, S. cerevisiae like S. pombe and other yeast species carry the large N-
terminal extension that is not present in the human Mia40.  
 
 
 
Figure 10: Mia40 sequence alignment. Alignment of the conserved CXC-CX9C- CX9C domain 
of Mia40 hortologs (Adapted image from Yang et al. 2012). 
 
Human Mia40, also known as CHCHD4.1, is encoded by CHCHD4 gene and exist in two isoforms, 
CHCHD4.1 and CHCHD4.2, which are produced by alternative splicing sites as shown in Figure 11 
42,43. Little is known about the human Mia40 because the majority of the studies in literature are 
focused on the yeast Mia40.  
 
 
 
Figure 11: Scheme of MIA40 human gene and protein. (A) Mia40 gene is formed by 4 exons. 
The isoform 1 (CHCHD4.1), is composed by exons 2, 3 and 4, the second form (CHCHD4.2) is 
lacking exon 2 but encodes exon 1(Adapted image from Yang et al. 2012). (B) Schematic 
representation of isoform 1protein (CHCHD4.1): the protein presents seven cystines residues, six 
of which are conserved (highlighted in black) (Adapted image from Sztolsztener et al. 2013). 
 
The shorter form (CHCHD4.1), which is nearly identical to yeast Mia40, presents seven cysteines 
residues: six of them are filogenetically conserved and is demonstrated to have the same function as in 
the yeast homologue 44. Cys4 at the N-terminal domain is not conserved. The longer form 
(CHCHD4.2) lacks exon 2 so it do not contain the Cys4, however different functionality or substrate 
specificity are still unknown (Figure 11 A).  
The CHCHD4.1 isoform (from here on referred to as Mia40) has an ubiquitous expression in human 
tissues and the highest levels of Mia40 were found in liver, brain and kidney at transcript and protein 
levels 42,43. The main function of the human protein, as the yeast one, is to introduce nuclear encoded 
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proteins into the IMS. It has been demonstrated that if the human Mia40 is expressed in yeast strains 
that lacks the endogenous Mia40, this form is capable to fulfil the function of the yeast 44.  Several 
features of Mia40 have been recapitulated in yeast models for the human DRS, including the import of 
IMS precursors and formation of disulfide-bonded Mia40 intermediate complexes followed by 
oxidation of IMS client proteins 44. 
In human Mia40 the CPC motif is formed by Cys53 and Cys55 (Figure 11 B). The cysteine 
responsible for the intermolecular disulfide bond is the Cys55. The mutation of this cysteine results in 
a loss of function of Mia40 that is no more able to interact with the substrate. On the contrary, 
mutation of Cys53 has not this dramatic effect: Mia40 is still able to interact with the substrates but in 
a less efficient manner 40,45–47. 
3.2 Canonical and non-canonical substrates of the DRS 
It is believed that Mia40 could recognise its substrates by the presence of the MISS sequence on these 
proteins. The MISS sequence is composed by anphipathic residues of the substrate with a specific 
succession of amino acids. This succession is specific for the class of protein considered: for example 
in the case of CX9C proteins the consensus is aromatic-XX-hydrophobic-hydrophobic-XXC 18,19, 
instead in the case of small Tim proteins it is LXXXCF.  
The sequence is not located at a precise point of the substrate protein but it can be everywhere in 
proximity to the cysteines bound by Mia40. For example, Cox17 protein presents the MISS sequence 
at its C-terminal domain, while Tim proteins present the sequence at the N-terminal domain 19. This 
sequence is docked onto the binding cleft of Mia40 and in both cases the signatures are in direct 
proximity to the critical cysteine residues, which attacks the redox-sensitive CPC sequence of Mia40.  
The MISS sequence serves as docking site to position the sequences in the binding cleft of Mia40 in 
an orientation that allows the interaction of the redox-active CPC motif of Mia40 with the cysteine 
residues in the client protein (Figure 12) 40. Because only unfolded proteins are able to traverse TOM 
pore, Mia40 is capable of redox-fold the proteins as a chaperone and release them in a stably 
conformation in the IMS. Mutants substrates in which individual cysteins are mutated are still folded 
as long as the MISS sequence is not destroyed 21,40.  
 
 
 
Figure 12: Sliding–docking model for the interaction of substrates with Mia40. (step 1, 
sliding) The substrate slides onto Mia40, where it is oriented by the MISS/ITS through 
noncovalent, mainly hydrophobic interactions in the cleft of Mia40. The correct Cys of the 
substrate is thus primed to make the disulfide with Mia40; (step 2, docking) The substrate now 
docks onto Mia40 via the covalent mixed disulfide bond between the substrate-docking Cys and 
the juxtaposed active site Cys of Mia40. Finally, complete oxidation releases the substrate in a 
folded state (Adapted image from Banci et al. 2010).  
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3.2.1 Canonical substrates 
Typical substrates of the DRS are small proteins, around 10 kDa, which destination is the IMS or the 
matrix. These proteins are cysteine enriched, they belong to the families of the twin CX3C and CX9C 
proteins and fulfil different functions in the mitochondria. CX3C and CX9C proteins have the same 
structure: they share a common core formed by two a-helices in an antiparallel orientation. These two 
helices are held together and stabilized by the disulfide bonds between the cysteins of the twin motifs, 
giving an helix-loop-helix conformation to the core 48. 
The family of the CX3C proteins is composed by five proteins in yeast, fungi and animals: Tim8, 
Tim9, Tim10, Tim12 and Tim13, and their orthologs. These proteins form hexameric or 
heteromultimeric complexes in the IMS and they act as chaperones for the hydrophobic proteins 
helping them to cross the lumen of the IMS 49. 
On the contrary, the family of the twin CX9C proteins, has a more wide and heterogeneous 
composition. There are 14 proteins belonging to this family in yeast and most of them are conserved in 
higher eukaryotes and also in humans. Notably some bioinformatic analyses suggest that the number 
of the proteins belonging to this family could be at least twice in humans than in yeast 50,51. Typical 
members of this family are Cox17 or Cox19 and their function is to assist the assembly and give 
stability to some of the proteins of the respiratory chain (i.e.: cytochrome b) 50,52. Some other proteins 
belonging to this family are Mdm35, a critical factor for the mitochondrial lipid homeostasis 53, and 
for importing Ups proteins, Yme1 and Som1 that are peptidases of the IMS. Interestingly, proteins of 
these families differ considerably in the primary sequence, except for the four cysteines of the CX9C 
motif and it has been demonstrated that no other residue is maintained invariant. However, the amino 
acids in key positions for the interaction with the hydrophobic cleft of Mia40 are hydrophobic residues 
in all of the proteins of this family 50. 
 
3.2.2 Complex substrates 
As well as the twin CX3C and CX9C proteins, other more complex proteins are imported in the IMS 
via Mia40. These proteins include Cox11 and Cox12, Sod1, and its copper chaperone Ccs1, ALR, the 
complex III subunits Qcr6 and Rip1, the two thioredoxin like proteins Sco1 and Sco2. 
Cox11 and Cox12 proteins contain two domains CX9C-CX10C that are really close to the twin motif 
proteins. Cox12 is part of the Cyt c oxidase and Cox11, like the other proteins discussed above, is an 
assembling factor for the Cyt c oxidase 54. Sod1 and Ccs1 are part of the anti-oxidative system that 
turns the superoxide ions into hydrogen peroxide. Sod1 is a dimeric protein and contains one disulfide 
bond per unit which is introduced by Ccs1 (Copper chaperone for Sod1) and facilitates the 
translocation of Sod1 into the organelle 55. Like Sod1 also Ccs1 has one structural disulfide bond that 
is introduced by Mia40 during import in mitochondria 56–58. ALR is itself one of the principal proteins 
of the DRS, and it has been proved to be itself a substrate for Mia40 59. The disulfide bond in Rip1 is 
introduced by Mia40 and is critical for its enzymatic activity 60,61. 
 
3.2.3 Novel substrates 
Recently, other novel substrates for Mia40 have been described in yeast and humans. Tim22 is a 
subunit of TIM22 chaperone complex in the IMS. This complex binds a specific class of proteins, the 
membrane-multispanning carrier family and TIM22 pathway helps these proteins during the 
integration in the IM 62.  Tim22 possesses only two cysteine residues that are supposed to form a 
disulfide bond. It has been demonstrated that Mia40 is able to bind Tim22 and form this disulfide 
bond. Moreover, the interaction is stabilized by hydrophobic interactions with the hydrophobic cleft of 
Mia40. Defects in the cleft of Mia40 result in a defective biogenesis of Tim22. Interestingly, Mia40 is 
able to bind Tim22 without any involvement of disulfide bonds, but with a reduced efficiency 62.    
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Another protein present within the IMS is Atp23, a protease required for the processing of the subunit 
6 of the mitochondrial ATPases (Atp6). Atp23 is mitochondrial encoded and is synthetized as a 
precursor protein. Mia40 is able to bind Atp23 and to introduce five disulfide bonds in this protein. 
Also in this case, Mia40 binds Atp23 only via hydrophobic interactions 63. 
Mrp10 (also known as CHCHD1) is a highly conserved subunit of the mitochondrial ribosome and is 
located in the matrix. It has been demonstrated that Mrp10 possesses an unconventional MTS 
sequence enriched in proline residues and is not processed by the matrix processing peptidase. As far 
as we know, this protein has four conserved cysteine residues that are oxidized by Mia40 during 
import. The semifolded protein with one disulfide bond is able to pass the inner membrane to localize 
in the matrix. Here, the protein could be found in a complete oxidized form in the presence of Mia40. 
Conversely, if Mia40 is silenced the protein in the matrix is only partially folded and degraded 
because is not able to be assembled in the ribosomes 64. 
Also the tumor suppressor protein p53 was found to localize in mitochondria through to the DRS and 
its import is respiration-dependent and activated by oxidative stress. Mitochondrial p53 is able to 
maintain the integrity of mtDNA, which is more susceptible to the oxidative damage owing to its 
structure and proximity to electron transfer reactions 65. 
Recently, the Apurinic/apyrimidinic endonuclease 1 (APE1) was also described as a possible substrate 
of Mia40. APE1 protein, the main human endonuclease, is a fundamental component of the Base 
Excision Repair (BER), a pathway involved in the DNA repair activity of damaged bases. It was 
already demonstrated that APE1 is localized for a small portion in mitochondria having a role in the 
mtDNA maintanence 66,67. In addition, Vascotto et al. demonstrated that APE1 localize in the IMS 
and, through a PLA (proximity ligation assay) analysis, they demonstrate the interaction between 
APE1 and Mia40 67. Data reported in this thesis depict the molecular mechanisms involved in the 
interaction between APE1 and Mia40 and the contribution of DRS in the maintenance and repair of 
mtDNA. 
 
3.3 The DRS and diseases 
3.3.1 Genetic disorders 
Because mitochondria are essential for energy production in eukaryotes, errors in their metabolism are 
normally associated with pathological states. 
Regarding the DRS pathway there are two known and well characterized genetic diseases associated 
with the mutation of DRS substrates. The first one is an X-chromosome-linked neurodegenerative 
disorder that implicates a mutation in TIMM8, one of the most studied substrates of Mia40 68. The 
disease associated with this mutation is the Human deafness dystonia syndrome, which leads to 
hearing loss, mental retardation and blindness. The mutation is located in the CX3C motif of TIMM8 
that means that the protein cannot be transported and properly folded in mitochondria via Mia40 69,70. 
Because of the improper folding the mutated protein cannot be assembled into the TIMM13 complex 
that is responsible for the import of TIM23, with deleterious effects for health. 
The second disorder associated with the DRS pathway involves ALR 71. The Autosomal recessive 
myopathy (ARM) is a recessive disorder in which the homozygous mutation R194H in the ALR gene 
is present. This condition is characterized by cataract, muscle hypotonia, hearing loss and 
developmental delay. This mutation affects the stability of ALR and enhances its degradation. ALR 
acts in the IMS as a homodimer and arginine 194 is usually located at the interface. R194H has a 
minimal effect on the enzymatic activity but affects the stability of the protein increasing the rate of 
dissociation of the FAD ribose and increasing its susceptibility to proteolysis 72. As a consequence, the 
biogenesis of Mia40 substrates is impaired 44. 
21	
3.3.2 Neurodegenerative disorders 
Over one third of genetic mutations associated with the inherited predisposition to neurodegeneration 
are functionally linked to mitochondria. 
Huntington disease (HD) is a genetically inherited disorder caused by the expansion of polyglutamine 
repeats in the huntingtin protein. This disease is additionally associated to mitochondrial dysfunctions, 
and abnormalities found in patient and mouse models are numerous and complex. It has been recently 
demonstrated that in mice affected by HD the levels of ALR were decreased with unchanged or 
slightly reduced Mia40 levels. Consequently the substrates of the DRS were altered, with reduced 
activity of the respiratory chain 73. 
A role in the Amyotrophic lateral sclerosis (ALS) was also proposed for Mia40. ALS affects motor 
neurons and is frequently associated with mutations in Sod1. In yeast Sod1 is imported in 
mitochondria with the help of Mia40. In human cells a mechanism was proposed trough which Mia40 
and Mitofillin, a component of the mitochondrial contact site and cristae organizing system (MICOS), 
have a role in the biogenesis of the pathogenic variants of Sod1 74. 
 
3.3.3 Cancer 
We know that cancer cells rely on the Wartburg effect to produce energy so they utilize glycolysis 
more than oxidative phosphorylation, but counter-intuitively mitochondrial biogenesis is linked with 
tumor progression 75. 
As said before p53 could be found in mitochondria to preserve the mitochondrial genome. p53 is 
mutated in many types of cancer as a strategy of the cancer cells to avoid apoptosis. The mutated form 
of p53 has several functional abnormalities and some of them are mitochondrial correlated. Normally 
p53 promotes aerobic respiration whereas the mutated form sustains the non-aerobic respiration 
enhancing the Wartburg effect and the escape from apoptosis 75,76. 
An increased expression of Mia40 has been found in many types of tumors as breast carcinoma, 
pancreatic ductal carcinoma and glioma and this increase has been associated with poor prognosis 43. 
Interestingly, there is a correlation between the expression of Mia40 and the activity of HIF-1α. Mia40 
has been proposed to promote the hypoxic response required for adaptation and tumor angiogenesis. It 
has been demonstrated that Mia40 can stabilize HIF-1α, however the mechanism has not been 
elucidated. Three different indirect mechanisms could explain a stabilization of HIF-1α: 1) an 
overproduction of ROS species by the complex III of the respiratory chain 77; 2) an increase of the 
consumption of oxygen by complex IV of the respiratory chain 78; 3) an increased concentration of 
complex II substrate succinate 79. If Mia40 is able to modulate the stabilization of HIF-1α in direct 
manner or indirectly with one of the three mechanisms proposed is currently object of study. 
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4. APE1/Ref-1 
APE1/Ref-1 (Apurinic/apyrimidinic Endonuclease/ Redox factor 1) is the major apurinic/apyrimidinic 
endonuclease in mammalian cells 80. APE1 is an essential and multifunctional protein that is 
ubiquitously expressed at high levels (104-105 copies/cell) in human cells 81, although it has a 
heterogeneous pattern of expression in different tissues and conditions 82. APE1 principal functions 
within the cell are the maintenance of genome stability, acting in the BER pathway, and the redox-
dependent transcriptional regulatory activity acting on several cancer-related transcription factors 81,82. 
These two main functions are exerted by two different domains of APE1: the C-term domain 
possesses the endonuclease activity, while the redox activity is performed by the N-term domain 83 
(Figure 13). 
 
 
Figure 13 Schematic representation of APE1 structure: First 35 amino acids are responsible for 
the nuclear localization, the protein-protein interaction and RNA metabolism. The N-term domain 
that spans from a.a. 35 to a.a. 127 is responsible for the redox activity and the C-tern domain is 
responsible for the DNA repair activity. Recently in this last domain also an TOMM40 interaction 
sequence was found (Adapted from Tell et al. 2010) 
 
 
Besides the endonuclease and the redox activities, other multiple functions were described for this 
protein (Figure 14). APE1 has a role in the RNA metabolism where it exerts endonuclease towards 
abasic RNA both in vitro and in vivo 84–87. Another function of the protein is the binding activity and 
transcriptional regulation of nCaRE sequences in the promoter region of genes, as APE1 promoter 
itself 88. An important role for the first 35 amino acids of APE1 was recently highlighted. This domain 
is essential for the protein-protein interaction with the majority of APE1 partners and for the 
modulation of its activities through different post-translational modifications 82,89,90. 
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Figure 14: APE1 functions. First 35 amino acids are responsible for the nuclear localization, the 
protein-protein interaction and RNA metabolism. The N-term domain that spans from a.a. 35 to 
a.a. 127 is responsible for the redox activity and the C-tern domain is responsible for the DNA 
repair activity. Recently in this last domain also an unconventional mitochondrial localization 
sequence was found. 
 
4.1 APE1 gene and transcriptional regulation 
4.1.1 APE1 gene 
APE1 is encoded by HAP1 or APEX gene in human cells, it is located on chromosome 14q11.2-12 and 
it spans approximately 3 kb of DNA 91. 
As shown in Figure 15, the gene consists of four introns and five exons, the first of which is not 
coding. The promoter region of the gene lacks a TATA box and only one CCAAT box is present, so a 
cluster of multiple transcription start sites is present in the proximal promoter region 92. The first exon 
of the gene harbors several putative CpG regulatory elements and some recognition sites for several 
transcription factors such as Sp1, USF, AP-1, CREB and ATF 82. Instead, in the distal promoter 
region, there are three nCaRE-B negative regulatory elements that can inhibit the APE1 gene 
transcription 93.  
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Figure 15: APE1 gene structure. APE1 gene spans 2,6 kb and consists of five exons and four 
introns. The first exon is non-coding (Adapted from Evans 2000). 
 
4.1.2 Transcriptional regulation 
Transcriptional regulation of APE1 gene is strictly correlated with the cell cycle. APE1 mRNA levels 
rise after G1-S phase thanks to the transcriptional activation of Sp1-2 that can bind APE1 promoter, in 
response to cell growth 94.  
p53 has also been proposed by Bhakat et al. as a negative regulator of APE1, through the recognition 
of a p53 binding element presents in proximity to the CCAAT box. The mechanisms are not being 
fully elucidated, but it was proposed that APE1can indirectly recruit p53 to APE1 promoter through a 
physical interaction with Sp1-1 subunit of Sp1 and inhibit APE1 gene transcription 95. 
APE1 gene contains other negative regulatory sites. As said before three nCaRE sequences are present 
in its promoter, one of type A and two of type B. Deletion of the nCaRE-B2 sequence strongly 
influences the negative regulation of APE1 gene. APE1 itself is able to bind this sequence suggesting 
the existence of an auto regulatory loop in which APE1 is able to bind its own promoter and inhibits 
its transcription (Figure 16) 96.  
APE1 gene transcription can also be enhanced by an inducible activation. It has been demonstrated 
that stimulation with TSH (Thyroid-stimulating hormone) can activate APE1 transcription 97. Subtoxic 
doses of ROS can also activate APE1 transcription probably through the binding of CREB and Egr-1 
factors upstream the APE1 transcription start site 98. 
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Figure 16: APE1 promoter. The distal promoter region of APE1 contains the nCa-RE sequences 
while the proximal promoter region contains binding sites for several transcription activator 
factors and the clustered transcription starting sites (Adapted from Tell et al. 2010). 
 
4.2 APE1 structure 
APE1 is composed by 318 amino acids, acts as a monomer inside the cell 91, and it is part of the EEP 
(endonuclease/exonuclease-phosphatase) family proteins, a divalent cation-dependent phosphoesterase 
superfamily 99.  
APE1 has a globular structure that can be divided in two, partially overlapping, domains: the N-
terminal domain and the C-terminal domain. Each domain is composed by six β-sheet strands 
surrounded by α-helices that together form an α/β sandwich 100 (Figure 17). Structurally and 
functionally, the N-terminal domain itself can be divided in two parts: the first 35 amino acids of this 
domain are non-conserved, completely unstructured and highly disordered 101. This peculiar feature 
gave APE1 important functional advantages for damage sensing, post-translational modifications, and 
protein-protein interactions 89,102 . The remaining part of the N-terminal domain is part of the globular 
structure and provides the redox activity of the protein. The C-terminal domain, completely structured, 
contains the Mg2+ binding site and is responsible for the endonuclease activity exerted through the 
BER pathway. 
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Figure 17: APE1 structure. Foundamental amino acids for the catalytic activity are highlighted 
in red and blue. The conserved four-layered α/β-sandwich structural core consists of two six-
stranded β-sheets surrounded by α-helices, packed together (Adapted from Miroshnikova et al., 
2016). 
 
4.3 APE1 functions 
4.3.1 The unstructured N-terminal domain  
As mentioned before, crystallographic studies demonstrated that the first 42 residues of APE1 N-
terminal domain are unstructured and highly disordered 101. For its intrinsic structural plasticity, this 
domain could provide important functional advantages to APE1. This region contains the bipartite 
nuclear localization sequence (NLS) that direct APE1 to the nuclear compartment 104. This domain is 
essential in mammals for the damage sensing and repair regulation through post-translational 
modifications. Indeed, the positively charged residues that are present in this region confer the 
capability to APE1, as other DNA binding proteins, to scan DNA for DNA damage 104. 
Another important function of this domain is the ability to interact with other proteins as 
Nucleophosmin (NPM1), a nucleolar protein that is able to regulate the DNA repair and the RNA 
degradation of APE1 86. APE1’s residues 27, 31, 32 and 35 are responsible for the binding with NPM1 
and it has been demonstrated that during genotoxic stress this residues can be acetylated in vivo. This 
modification leads to a reduction of affinity for NPM1 and to an increase of the endonuclease activity. 
The result is a relocalization of APE1 from the nucleoli to the nucleoplasm where the protein can 
perform its DNA repair activity 105.  
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4.3.2 The N-terminal domain: transcriptional factors activation  
The globular region of the N-terminal domain spans from amino acid 42 to amino acid 127 and is 
responsible for the redox activity of APE1 82,106. 
In 1992 APE1 was identified as a crucial activator of the DNA binding of transcription factors Fos and 
Jun subunits of the Activator protein 1 (AP-1) 107. Then, APE1 was described as a redox activator of 
several others transcription factors involved in many different processes as cell cycle regulation, 
apoptosis, angiogenesis and differentiation. p53 108, c-Jun 109, HIF1-α 110, NF-κB 111 are some of APE1 
substrates that are activated via reduction of critical cysteine residues, as shown in Figure 18. 
Moreover, APE1 targets could also be tissue specific (e.g. TTF-1 and Pax proteins) and their 
activation could have opposite effects on cell fate 112. 
 
 
Figure 18: Schematic representation of transcriptional factors activator of APE1. If APE1 is 
not present the transcription factor remains in a oxidized state and it cannot bind its DNA target 
sequence so the transcription is blocked, while if APE1 is present, the transcription factor can be 
reduced and activated to bind the target sequence in the promoter and start the transcription 
(Adapted from Tell et al 2005). 
 
The principal residues that are implicated in the redox activity of APE1 are Cys65, Cys93 and Cys99 
109,113. Structural studies highlighted that Cys65 is located in a hydrophobic pocket of the core structure 
of the protein and therefore it is inaccessible to the solvent, as the other two cysteines. As a 
consequence the cysteine residues would be unable to interact directly with the target cysteine residue. 
A model was proposed in which APE1 may undergo to a conformational change that can “open” the 
globular structure and expose the cysteine residues to the solvent, creating in this way a binding site 
that can accommodate different transcription factors 114. 
 
4.3.3 The C-terminal domain: DNA repair activity  
The C-terminal domain of APE1 is involved in the repair of DNA lesions being an essential 
component of BER pathway. BER is committed to the removal of small, non-helix distorting base 
lesions, as oxidative (e.g. 8-oxoG) or alkylation lesions, restoring the chemical DNA integrity. These 
lesions, if not repaired, could determine the accumulation of mutations during the replication phase 115.  
As shown in Figure 19, the first step in the BER pathway is the recognition of the damaged base by a 
glycosylase that removes the base and leaves an abasic site (AP-site). There are two major classes of 
glycosylases that can act in BER pathway: the monofunctional are able to remove the damaged base 
and present only this activity, while the bifunctional exhibit also a β-lyase activity 116. The abasic site 
is recognised by APE1 which cuts in a Mg2+-dependent mechanism the phosphodiester backbone at 
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the 5’ end of the lesion leaving a 3’-hydroxyl group (3’-OH) and a 5’ deoxyribose phosphate (dRP) at 
the upstream 3’ end and the downstream 5’ end, respectively 92.  
APE1 catalytic domain possesses only one catalytic active site and has a positively-charged semi-rigid 
structure able to interact with the abasic DNA to which it has a very high affinity.  Met270 and 
Arg177 residues are inserted in the minor groove and in the major groove respectively, creating a twist 
of the helix and retaining the product after the protein cut. Also the residues Asp70, Asn212, Asp283 
and Asp308 are involved in the protein/DNA interaction, while residues Glu96, Tyr171, Asp210 and 
His309, are involved and essential in the catalysis of the reaction 82,100,117,118. Asn212 is, in particular, 
the residue deputated to the recognition of the abasic site, mutation of this amino acid can disable 
APE1 to bind its substrate 93. His309 and Asp283 in particular involved in the maintenance of the 
conformation of the active site. Substitution of the residue His309 with an asparagine residue leads to 
a loss of the catalytic activity of the protein in both DNA and RNA, maintaining the ability of the 
protein to bind the substrate, resulting in a dominant-negative form of the protein. 93,102. Finally, to 
perform its endonuclease activity, APE1 needs two (Mg2+) magnesium ions as cofactors. One of these 
residues is bound by residue Glu96 ensuring the stabilization of the enzyme structure and a high 
endonuclease activity. Mutation of this residue gives a partial loss of the endonuclease activity of the 
protein 119,120.  
After APE1 activity on its substrate, the DNA is nicked and the repair can proceed with one of the two 
BER subpathways: the Short-patch (SP-BER) or the long-patch (LP-BER) pathways. The SP-BER is 
used by the cell for normal AP-sites, whereas, if several nucleotides are modified the LP-BER is used 
93. The termini that APE1 has generated are the substrate for the DNA polymerases. In the SP-BER, 
Pol-β (DNA polymerase β) is responsible for the insertion of the single nucleotide and finally the 
lesion is repaired by DNA ligase III and XRCC1. In the LP-BER there is a strand displacement that 
covers from two to several nucleotides surrounding the AP-site. In this case, Pol-δ, Pol-ε (DNA 
polymerase δ or ε) with the help of PCNA (proliferating cell nuclear antigen) and other factors are 
able to displace few nucleotides and to replace them. The 5’ dRP terminus left by the previous step is 
removed by FEN1 (Flap endonuclease 1) and then the repair is completed by DNA ligase I that 
restores the phosphodiester backbone 93.  
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Figure 19: BER pathway. The repair process is initiated by the recognition and removal of the 
modified base by either a monofunctional or bifunctional DNA glycosylase to leave an AP site. 
Excision by either one of the monofunctional DNA glycosylases is followed by incision of the 
DNA backbone 5′ to the AP site by APE1. The resulting single-strand break will contain either a 3′ 
or 5′ obstructive termini. End processing is then performed by Pol β or APE1 depending on the 
specific nature of the terminus. When end processing has produced the necessary 3′-OH and 5′-P 
termini the following BER steps diverge into two subpathways, short-patch and long-patch. In SP-
BER repair synthesis of the single nucleotide gap is by Pol β aided by the XRCC1 scaffold, and 
subsequent ligation by LIG3α finishes the repair. In LP-BER repair synthesis of the 2–13 
nucleotide gap is by Pol β, and/or Pol δ/ε aided by PCNA. A resulting 5′ flap is removed by FEN1 
and the final ligation step is performed by LIG1. 
 
4.3.4 APE1 endonuclease activity on abasic RNA 
Over the last few years emerging evidences indicate that certain DNA repair proteins are also involved 
in the RNA quality control processes, identifying damaged, chemically modified or oxidized RNA 
which may led to ribosomal malfunctioning, error-prone protein translation, and as a final 
consequence failed protein synthesis 121. In this regard, the first demonstration of APE1 enzymatic 
action on RNA in vitro was the identification of its RNase H-like activity on a DNA/RNA duplex 122 
and the capacity to cleave an AP site-containing ssRNA. It was found that APE1 can cleave AP sites 
contained in “pseudo-triplex” substrates designed to mimic stalled replication or transcription 
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intermediates, and configurations that resembles R-loop structures, suggesting a novel “cleansing” 
function that may contribute to the elimination of detrimental cellular AP-RNA molecules 123. Next, 
Lee and colleagues identified APE1 as the endoribonuclease responsible of cleaving a specific coding 
region of the c-myc mRNA. In this study, using E96A and H309N mutants of APE1, it was 
demonstrated that the endoribonuclease activity for c-myc RNA shares the same active center with the 
AP-DNA endonuclease activity. They also demonstrate for the first time the ability of APE1 to affect 
mRNA half-life in HeLa cells and therefore supporting its role in RNA metabolism 124.  
However, no further studies documented a similar activity toward other nuclear encoded messenger 
RNA. During the last decade, Tell and colleagues deeply investigated the uncanonical role of APE1 in 
RNA biology. In 2009 an interactomic study led at the identification and characterization of several 
novel APE1 partners which, unexpectedly, included a number of proteins involved in ribosome 
biogenesis and RNA processing 125. As mentioned before, among the different interacting proteins 
identified there was also nucleophosmin (NPM1), a nucleolar protein implicated in a variety of 
cellular processes, including ribosome biogenesis 126. It was demonstrated that APE1 is localized 
within the nucleolus and this localization depends on cell cycle and active rRNA transcription. NPM1 
stimulates APE1 endonuclease activity on abasic double-stranded DNA (dsDNA) but decreases APE1 
endonuclease activity on abasic single-stranded RNA (ssRNA) by masking the N-terminal region of 
APE1 required for stable RNA binding. Indeed, in APE1-knocked-down cells, pre-rRNA synthesis 
and rRNA processing were not affected but inability to remove 8-hydroxyguanine-containing rRNA 
upon oxidative stress, impaired translation, lower intracellular protein content, and decreased cell 
growth rate were found. These results supported the hypothesis that NPM1 exerted a fine-tuning 
control of APE1 endonuclease activity within nucleoli devoted to repair of AP damage on rDNA and 
the removal of oxidized rRNA molecules 125.  
More recently, our knowledge about the enzymatic activity of APE1 toward RNA was extended 
demonstrating its ability to recognize and efficiently process an abasic or oxidised ribonucleoside 5'-
monophosphate (rNMP) erroneously incorporated, and then damaged, into a DNA strand 84. Finally, it 
is from last year the demonstration of the association of APE1 with the miRNA processing complex 
DROSHA and its active role in the processing of miR-221/222 85. 
 
4.4 Post-translational modifications 
Several different types of post-translational modifications can occur in vivo for APE1 protein: 
acetylation, phosphorylation, ubiquitination, S-nitrosation and proteolysis 92. 
APE1’s acetylation is the most studied post-translational modification. Lys6 and Lys7 are the residues 
that targeted by the histone acetyl transferase p300 in vivo and in vitro. This modification is important 
for the binding of APE1 to the nCaRE sequences within the parathyroid hormone (PTH) promoter 127. 
Also lysine residues 27, 31, 32 and 35 are subjected to acetylation in vivo and they are crucial for 
APE1 interaction with rRNA and NPM1, for controlling is catalytic activity on abasic DNA and for 
APE1 subcellular distribution in the nucleoli 89,105. 
Several putative phosphorylation sites, located in both the nuclease and the redox regulatory APE1 
domains, have been identified in vitro for a broad range of kinases, as Casein Kinase 1 and 2 (CK-I 
and CK-II), Glycogen Synthase Kinase 3 (GSK-III) and Protein Kinase C (PKC). Phosphorylation 
may occur on serine/threonine residues and might be responsible in controlling macromolecule 
(protein-protein and protein-DNA) associations involved in redox regulation and in DNA repair. 
In 2009, Izumi and colleagues show that both in vitro and in vivo the E3 ligase MDM2 (murine double 
minute 2), a negative regulator of p53, ubiquitinates APE1 at one of the lysine residues 24, 25 or 27. 
Moreover, oxidative conditions can induce MDM2-mediated ubiquitination of APE1. Two years later, 
the same group gave further insights in the APE1 ubiquitination process, reporting an interesting 
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crosstalk between ubiquitination and phosphorylation of APE1 at Thr233. In particular, 
phosphorylation of APE1 may induce MDM2 activity, leading to augmented ubiquitination of APE1 
128. 
A truncated form of APE1 lacking its first N-terminal 33 or 35 amino acids, lately named APE1 
NΔ33, was first identified by Pommier et al. in 1998. To date, further studies are needed to elucidate 
the mechanisms responsible for the APE1 NΔ33 nuclear translocation, since the truncation leads to the 
loss of the nuclear localization signal. The truncation of the N-terminal of APE1 has been associated 
with different cell death programs. This irreversible posttranslational modification may represent a 
regulatory switch for controlling APE1 functions. Up to now, many unresolved question remain to be 
answered, regarding the identification of the proteases, the stimuli responsible for the generation of the 
truncated form and the effects of such modification on APE1 cellular translocation. 
APE1 contains three redox-sensitive cysteine residues, two of which (Cys93 and Cys310) may 
undergo S-nitrosation after nitric oxide stimulus and are responsible for APE1 reversible shuttling 
from nucleus to cytoplasm in a non canonical CRM1-independent manner, connecting APE1 to nitric 
oxide physiological and pathological processes 129. 
 
4.5 APE1 intracellular trafficking and localization  
APE1 exerts both nuclear and extranuclear functions and therefore it is of the utmost relevance to 
elucidate the molecular mechanisms involved in the translocation of this protein within the different 
subcellular compartments.  
Because of its function on the abasic DNA and as regulatory protein acting on several cancer-related 
transcription factors, APE1 has long been recognized as nuclear protein. In the 1998 the nuclear 
localization signal of APE1 was identified. The NLS is contained in the APE1 N-terminus and 
consists of a bipartite signal within the first twenty amino acids (residues 2-13) 130,131. Stimuli as 
oxidative stress and other signalling molecules such as TSH or calcium have been shown to stimulate 
APE1 nuclear translocation 98,132. Recently, Tell and co-workers showed a strong nucleolar pattern for 
APE1, maybe due to the protein–protein or protein-nucleic acids interactions in this compartment. 86. 
Despite the nuclear targeting sequence, a large number of studies indicated that in some cell types, 
with elevated metabolic and proliferative rates, APE1 localize within mitochondria and endoplasmic 
reticulum 82,133. Up to now a classic nuclear export sequence (NES) has not been found so the exact 
mechanism responsible for redirecting APE1 in the cytosol remains to be clearly elucidated. Recently, 
two different mechanisms were proposed to be responsible for the cytoplasmic translocation of APE1. 
S-nitrosation at Cys93 and Cys310 has been demonstrated to redirect APE1 in the cytoplasm in a 
CRM1-dependent manner 129 and a non-canonical mitochondrial targeting sequence has been found in 
the APE1 C-terminal domain (residues 289-318) 134.  
Mitochondria are the main cellular source of ROS and mtDNA is vulnerable due to the lack of 
histones and the proximity to the ETC. Thus, it has not been surprising the observation of different 
groups regarding the existence of a DNA base excision repair (mtBER) within mitochondria 130,135,136. 
Togheter with the mtBER apparatus, also APE1 has been found in mitochondria. One first study from 
Chattopardhay and coworkers hypothesized that the truncation of the N-terminal domain of the protein 
allows the protein to be imported in mitochondria, due to the lack of the NLS 137. However, more 
recent studies show that in different cell types APE1 full length is imported within mitochondria 67,138. 
All together, these data suggest that APE1’s subcellular distribution is very dynamic process (Figure 
20), and the purpose of this thesis is to elucidate the role of DRS in the trafficking of APE1 within the 
mitocohondrial compartment and the maintenance of mitochondrial DNA stability.  
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Figure 20: APE1 intracellular trafficking. APE1 subcellular distribution appears very dynamic. 
The main subcellular compartments where APE1 have been identified and its influence on cell 
physiology are highlighted. (Image from Scott et al. 2013). 
 
4.6 APE1 in cancer 
APE1 is a fundamental protein: deletion of both the alleles of Apex1 leads to embryonic lethality in 
mice 139 and triggers apoptosis in differentiated cells 140, suggesting its biological and clinical 
relevance in normal and tumoral cells. Defects in its activities have been linked to human pathologies, 
ranging from cancer to neurodegenerative diseases.  
Accumulation of oxidative stress and inefficient base excision DNA repair have been described for 
several degenerative disorders, including neurophatologies as Alzheimer disease (AD), Parkinson 
disease (PD) or amyotrophic lateral sclerosis (ALS) 141,142. Several observations suggest that an 
overexpression or an aberrant localization of APE1 is linked with cancer. APE1’s deficiency could 
lead to augmented mutagenensis and carcinogen susceptibility, due to the lack of a proper 
endonuclease activity on the BER pathway. Moreover, dysregulation in terms of atypical subcellular 
localization or expression, have been found in many cancers types, including prostate, pancreatic, 
ovarian, cervical and colon type 92,143. Indeed, APE1’s cytoplasmic relocalization and/or 
overexpression is associated with more aggressive pathology, reduced sensitivity to chemotherapeutic 
agents and a poor prognosis for the patients 144. The causes of this phenotype are still unknown. 
However, since one of the features of cancer cells is the high metabolic rate and the elevated amounts 
of ROS produced from the ETC, the hypothesis is that APE1 could have a role on the maintenance of 
the mtDNA integrity inside the mitochondrial compartment 145. 
Nowadays, APE1 represents a predictive marker for sensitivity of the tumor toward radio- or 
chemotherapy and a promising target for pharmacological treatment. The studies to determine the 
effect of inhibiting either the DNA repair or redox regulatory functions are still ongoing, and several 
studies suggest that the increase of AP activity accompanying tumorigenesis could explain the therapy 
resistance of these pathologies. APE1’s inhibitors could be used alone or in combination with other 
chemotherapeutic agent such as bleomycin, temozolomide or gemcitabine to enhance the cytotoxic 
effects 146. Few compounds were already reported as APE1’s redox (soy isoflavones, resveratrol and 
E3330) and DNA repair (CRT0044876, lucanthone, methoxyamine, compound 3 and 52) inhibitors 
143,147. Further studies are needed to identify new potent APE1 small molecule inhibitors, specific for 
one function of the protein, and to evaluate the side effects of combination therapies with APE1 
inhibitors.  
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5. The nucleoid  
Given their endosymbiotic bacterial origins, it is not surprising that the organization of DNA in 
mitochondria is similar to that of bacterial DNA. Bacterial genome is compacted by 104-fold of its 
volume to form the bacterial nucleoid and in a similar way the mitochondrial DNA is compacted and 
organized in discrete protein-DNA complexes distributed throughout the mitochondrial matrix 148. 
mtDNA was first described in the 1960s 149 and completely sequenced in 1981 by Anderson 150. 
Despite the differences between nucleoids in mammals and in yeast, most of the information on the 
structure and composition of the nucleoid comes from the studies on yeast that were fundamental and 
extremely informative in the understanding of the mammalian nucleoids. During the 1970s scientists 
were able to stain the mtDNA in vivo and notice sub-mitochondrial structures near the inner 
membrane, later called nucleoids, were the mtDNA was located. Each nucleoid can contain more than 
one mtDNA molecule and each mitochondrion can contain tens (for yeast) or hundreds (for 
mammalians) nucleoids. Moreover each nucleoid can be considered as the unit of genetic segregation 
in the mitochondria, as every nucleoid act as an independent genetic unit from the others. 
Although the mtDNA is the principal component and the one of greater interest of the nucleoid, this is 
not the only molecule composing this unit. The mitochondrial nucleoid is composed of a range of 
proteins with a diverse variety of functions that have coevolved with mtDNA, from DNA packaging 
and transcription to factors with broader signalling functions facilitating mtDNA’s integration into 
cell-wide metabolic and proliferative signalling networks. Moreover the mtDNA organization in 
nucleoids provides an efficient way to ensure that the mitochondrial genetic material is distributed 
throughout all the mitochondria in a cell and is responsive to cellular metabolic needs. 
5.1 Mitochondrial genome 
Mitochondrial DNA comprises 0.1-2% of the total DNA in most mammalian cells. There are several 
unique features of the mtDNA: in humans is circular, 16 kb long and inherited by the mother. It 
encodes two rRNAs, 22 tRNAs and 13 proteins, all of which are involved in the oxidative 
phosphorylation process (e.g. components of Complex I, Complex IV, Complex V and cytochrome b) 
151. As said before all others mitochondrial proteins are nuclear encoded. Another peculiarity of the 
mtDNA is its structure: mtDNA is double-stranded but the genetic information is not equally 
distributed between the two strands, most the information is contained in the heavy strand (purine 
rich) 152. The intragenic sequence is almost absent or limited to a few bases 153 and moreover mtDNA 
do not have histones, instead is organised in nucleoids structures, as mentioned before.  
5.2 mtDNA organization in nucleoids  
The first evidence of the organization of the mtDNA in discrete foci within the mitochondrial network 
in mammals has come from DAPI staining of HeLa cells mitochondria in 1991 154. This observation 
was further proved a few years later with the use of Picogreen 155 and confirmed by FISH experiments 
for the specific detection of mtDNA sequences 156. Another confirmation has come from time-lapse 
imaging experiments were it was possible to observe that larger-sized nucleoids were able to divide in 
smaller units 157,158 and bromodeoxyuridine (BrdU) incorporation experiments suggested also that 
replicating DNA can occur in these structures 157. 
A large number of experiments showed that multiple copies of mtDNA could be found in each 
nucleoid, usually from 2 to 10 copies each, depending on the cell line studied 157.  However, 
quantitative analysis of the size and mtDNA content of the nucleoid in cultured mammalian cells 
suggests that an average nucleoid may contain 5-7 mtDNA molecules packed in a space of 70nm 157, 
similarly at what happens to the bacterial genome. The tight packaging of the mtDNA is achieved 
thanks to the proteins present in the nucleoid that will be described later on in this chapter. Another 
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similarity with the bacterial DNA comes from the fact that both genomes seem to be membrane-bound 
with the help of specific protein partners. In the case of the mtDNA the concept of that the DNA could 
be physically bounded to the membrane was introduced right after the mtDNA discovery 159 and a lot 
of work was done trying to identify the protein responsible for this feature.  
5.3 Nucleoids protein composition 
As said before nucleoids are discrete protein-DNA units. The principal proteins that compose the 
nucleoid structure are proteins specifically associated with the DNA.  
Different studies have tried to identify the proteome of nucleoids in different cells lines, with different 
approaches 160. The first attempt to do such an analysis was made by Bogenhagen et al. in 2003, in 
Xenopus oocytes and since then a plethora of studies have identified and classified nucleoid associated 
components through biochemical fractionation studies. A number of proteins have been characterized 
for their role in different steps of mtDNA metabolism. It remains, however, to be elucidated whether 
or not all proteins involved in the different processes are permanently associated with the nucleoid 
even if their function is not always required or if dynamic association and dissociation events can 
occur. Recently a “layered-structure” (Figure 21) of the nucleoid was proposed based on the work of 
Bogenhagen et al. 161. In this study they adopted a different procedure for the isolation of nucleoids 
intended to identify proteins in close association with the mtDNA 162. 
Cross-linking with formaldehyde allowed to identify a subset of proteins more closely in contact with 
the DNA such as mtSSB and TFAM as expected, but also other proteins such as DNA polymerase g, 
mtRNA polymerase and a small number of other proteins considered now the components of the 
nucleoid core 160,161. Other components of the nucleoids were identified as associated with the DNA in 
native preparation, but not in the cross-linked preparation. The most interesting of these proteins is 
ATAD3 that seems to be the candidate for the attachment of the mtDNA to the inner membrane. A 
variety of other proteins were found to be in the nucleoid ranging over proteins needed for the mtDNA 
maintenance, replication and repair, to proteins belonging to mitochondrial transcription and 
translation processes. Transcription factors and replication related proteins, such as TFB1M, TFB2M 
mTERF, Pol g A, B and Twinkle, were found to be in native preparations, suggesting that the 
transcription of the mtDNA occurs in the core of the nucleoids 160,161. Proteins involved in 
mitochondrial translation were found in both native and cross-linked nucleoids fraction suggesting a 
less tight interaction with the protein of the core, indeed some mitoribosomal proteins, initiation and 
elongation factors are part of the peripheral part of the nucleoids. mtDNA repair proteins are also part 
of the nucleoid proteome. Among those there are the endonuclease APE1, DNA ligase III, a set of 
DNA glycosylases (NEIL1, OGG1, NTH1), BRCA1 and quite a few others. More recently, Cockayne 
syndrome group B protein (CSB) has been suggested to take part in base excision repair and in 
anchoring a DNA repair complex to the inner mitochondrial membrane with possible association to 
nucleoids 160,162. 
Overall, based on these results, they suggest that DNA replication and transcription can occur in the 
central core of the nucleoid, while RNA processing, translation and respiratory chain complexes 
assembly may occur in a peripheral zone 161. This is also in accordance with more recent studies that 
have identified mitochondrial RNA granules as entities located in close proximity to the nucleoids 
were this last processes can take place (Figure 23) 163. 
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Figure 21. Schematic of interactions at the mitochondrial nucleoid. Core nucleoid factors 
(gold) have known mtDNA-binding activity. Peripheral factors (blue) do not directly interact 
with mtDNA, but associate with the nucleoid via protein–protein interactions. ATAD3 (light 
blue) associates with mtDNA, the mitochondrial ribosome, and the mitochondrial inner 
membrane. Shown protein–protein and DNA–protein interactions are designated by black 
rectangles 164.  
 
Historically, the first protein identified in this context was Twinkle 165 that was discovered in 2001 and 
was shown to co-localize with mtDNA, while between the 70s and 80s the two principal proteins, 
tightly associated with the DNA were discovered: mtSSB and TFAM. This two proteins were the only 
two candidates resistant to high salt washes during the isolation of the mtDNA 166–170. 
mtSSB is the mitochondrial counterpart of the SSB protein (single-stranded DNA binding proteins, the 
mammalian Rim1P homolog) 171 in the nucleus and of SSB protein in bacteria. It is able to bind the 
single-stranded filament of the DNA while is not complemented with the other filament, to protect 
DNA for any kind of injury. mtSSB is an essential protein of mtDNA maintenance as it was shown to 
stabilize the replication intermediates and the D-loop structure 172. The presence of the protein in the 
nucleoids was showed in cell culture in mammals 173. and was confirmed by mass spectrometry 
experiments 174.  
The best-characterized and abundant protein binding duplex DNA is the HMG-box protein TFAM 
(Transcription factor A) that was identified as permanently associated with mtDNA 175.  
TFAM is the only factor that plays a clear structural role in the mtDNA organization in the nucleoids, 
similar to the role of histones for the nDNA in the nucleus or to the role of the hisones-like proteins in 
bacteria 176,177. This protein is probably the major factor responsible of the tight packaging of the 
mtDNA and thus plays a role in the mtDNA topology 178.   
TFAM is able to bind the double helix of the DNA and act as a packaging protein, probably mostly on 
the central region of the mtDNA because the estimation of TFAM concentration is too low for the 
coverage of the entire mtDNA molecule 176,179,180. From the first calculations was estimated that one 
molecule of TFAM can bind the DNA in regular intervals each 20 bp 181–183 but since the protein acts 
as a homodimer in the cell it was estimated that 2 molecules of TFAM bind the DNA each 35-40 bp 
181,182. However, it seems that TFAM can bind mtDNA with some sequence specificity allowing the 
interaction to be detected by DNase I footprinting 176,184. Still a number of laboratories have quantified 
the stoichiometry of TFAM binding to mtDNA with very different results depending on the cell type 
	36	
and organism studied. Some studies have suggested that there is sufficient TFAM to coat the mtDNA 
185 while others have reported much lower levels. An interesting study by Bogenhagen et al. showed 
that the ratio TFAM/mtDNA is developmentally regulated in Xenupus oocytes, suggesting that 
immature oocytes that are actively replicating and transcribing DNA have a lower ratio 
TFAM/mtDNA. On the contrary, in mature oocytes where mtDNA replication and transcription is 
repressed there is an accumulation of TFAM with an increased TFAM/mtDNA ratio 186. Somatic cell 
types generally require active transcription of mtDNA, so it is probable that they have a much lower 
TFAM/mtDNA ratio to provide subunits of the OXPHOS complexes and replication for mtDNA 
turnover 186.  TFAM has also a role in mtDNA transcription, in fact it markedly stimulates 
transcription initiation 187. 
5.4 mtDNA damage and repair 
Because of the lack of histones and chromatin structure and the proximity to the electron transport 
chain (ETC) the mtDNA is prone to the oxidative damage caused by the endogenous ROS produced 
by the ETC 188. Mitochondrial DNA suffers damage from a greater extent than does nuclear DNA 189. 
Because the mitochondrial membrane potential generates a negative charge on the matrix side of the 
inner membrane lipophilic cations, like many drugs and toxic chemicals, tend to accumulate inside 
mitochondria, specifically on mitochondrial membranes, so mitochondria import lipophilic cations 
from the cytosol and concentrate them up to 1000-fold becoming dangerous for mitochondria and cell 
survival 190.  
Oxidative damage to mtDNA may occur in the form of base modification, abasic sites and other 
various types of lesions 191. One of the most studied and common lesions due to the presence of ROS 
is the 8-oxoguanine (8-oxoG). 8-oxoG has been found to be a mutagenic lesion: mispairing of 8-oxoG 
with adenine results in a G-C to A-T transversion mutation during the subsequent round of replication. 
Early studies described 16-fold higher levels of 8-oxoG in mtDNA than in nuclear DNA 192 and that 
mtDNA damage is more extensive and persist longer than nuclear DNA damage in human cells 
following oxidative stress 193.  
Initially it was thought that DNA repair mechanisms were either non-existent or very inefficient in 
mitochondria and that damaged molecules of mtDNA were just simply degraded and the undamaged 
copies serves as template for the new mtDNA synthesis 194. However, recently studies have proved the 
presence of DNA repair pathways that can efficiently repair certain types of lesions 195. Among these, 
the major repair pathway present in mitochondria is the BER pathway (mtBER). DNA repair enzymes 
belonging to the BER pathway isolated from mitochondria include several types of glycosylases, as 
OGG1, UDG, MUTY and NTH 196–200 the AP endonuclease APE1 82,201 and DNA ligase III 135,202 
(Figure 22). Other proteins necessary for mtDNA repair were discovered to be strictly involved in 
these mitochondrial pathways without a nuclear homolog as DNA helicase Twinkle and DNA 
polymerase γ (Polγ) 203. 
In addition to the BER there are other pathways involved in the mtDNA repair such as Mismatch 
repair pathway (MMR) 204 and also the homologous recombination (HR) 205 and non-homologous end 
joining (NHEJ) 206 were described to be present in mitochondria. 
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Figure 22: mtBER pathway. mtBER pathway resembles the nuclear one. Both the SN-BER and 
LP-BER subpathways are present in the mitochondria. All of the enzymes are nuclear encoded 
and imported into the organelle, some are common between the nBER and mtBER, like APE1, 
all the glycosylases and FEN1, others, like Pol γ DNA2 and DNA ligase III are specifically 
dedicated to the mtDNA repair (Adapted from Copeland et al. 2008). 
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6. The mitochondrial RNA granules (MRGs): regulation and coordination 
of mitochondrial gene expression 
From their synthesis to their degradation mtRNA undergo several stages of maturation and 
modification for the correct production of mtDNA-encoded proteins. As mitochondrial DNA 
replication and transcription need to be spatiotemporal regulated to adapt to metabolic demand of the 
cell, the same must be for the basic stages of mitochondrial gene expression. To achieve this 
mitochondria have restricted mtRNA processing and maturation to dynamic nucleoprotein structures 
called mitochondrial RNA granules (MRGs), that may provide the regulatory function for the post-
transcriptional processing allowing all the mtRNAs to be fully mature before release for use in protein 
synthesis 207,208.  
6.1 Mitochondrial RNA granules protein composition 
Experiments performed with 5-bromouridine (BrU) aimed at tracking the progress of the nascent RNA 
transcripts showed that newly transcribed mtRNAs are found in discrete foci situated in close 
proximity to mitochondrial nucleoids (Figure 23) 157,209,210. To confirm and better understand the 
function of this structures in 2015 Antonicka et al. 211 characterized the proteome of the granules using 
GRSF1, a core component of the granule already described 209,210, as a bate. Some proteins found by 
the authors were already confirmed by the literature as RNaseP 210 and more interestingly the so called 
“mitochondrial degradosome” composed by hSUV3 and PNPase 212 confirming the hypothesis that 
MRGs are not only sites of RNA processing, but also of RNA degradation and turnover. Mass 
spectrometry analysis of the immunoprecipitated fraction showed a large number of proteins 
responsible for the post transcriptional processing of the primary polycistronic transcript as MRPP1, 2 
and 3, RNA-modifying enzymes as TFB1M, PTCD3, and the mitochondrial poly-A polymerase.  
Also proteins belonging to the mitochondrial translation machinery were present in the analysis as 
well as structural proteins of the small (mt-SSU) and large (mt-LSU) mitochondrial ribosomal 
subunits, aminoacyl tRNA synthetases, and factors involved in ribosome assembly and disassembly. 
These data suggest  that MRGs are also involved in mitochondrial ribosome biogenesis and in 
mitochondrial translation regulation, with a function analogous to that of the nucleolus where initial 
steps of ribosomal assembly are performed 213,214. Fractionation experiments suggested that nucleoids 
co-purify with mitochondrial factors involved in mtRNA metabolism, mitoribosome biogenesis and 
translation as well as with mitochondrial ribosomal proteins. As said before the latter has also been 
found in MRGs 161,215,216, so it has been suggested that early steps of mitoribosome assembly of MRPs 
occur in concert with mt-rRNA nucleotide modifications 217,218. This protein content overlap between 
the nucleoid and the MRGs suggest an intimate association of these two entities.  
It is possible that both mtDNA and its transcription products are portioned within non-membrane 
bound compartments to provide a greater degree of spatiotemporal regulation of mtRNA processing. It 
was in fact suggested by Jourdain and colleagues that immature RNA could be sequestered in the 
MRGs, away from mitochondrial translation process 219.  
Also the last stage of the mtRNA life was suggested to take place in specific foci, called D-foci 
(degradation foci) composed mostly by the mitochondrial degradosome 212,220. It has been shown that 
these foci co-localize with the MRGs, although it is still not clear whether they form a subset of MRGs 
or are separate entities with a distinct composition and purpose. Also several catalytic mitochondrial 
enzymes and other mitochondrial and non-mitochondrial proteins whose role remains to be established 
were found (Figure 23).  
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Figure 23: Rapresentation of nucleoids and mitochondria RNA granules in the 
mitochondrial matrix. mtDNA in contained in nucleoids, where also transcription of mt-mtRNA 
take place. Mitochondria RNA granules host the nucleolytic processing of the primary transcrtipt, 
maturation and modification of mt-mRNAs, mt-rRNAs and mt-tRNAs and mitoribosome 
assembly.  Decay of mt-mRNA seems to take place in foci co-localized with MRGs called D-foci, 
in which the degradosome can degrade the used and eventually damaged RNA.		
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7. mtRNA processing and metabolism 
7.1 mtRNA transcription and regulation 
mtDNA is transcribed as two unique, polycistronic molecules. Because both strands of the DNA 
contain genes, both strands are transcribed 153.  
Since 1982 it was believed that transcription takes origin from the HSP1 and HSP2 (H-strand 
promoter 1 and 2) in the heavy-strand and from LSP1 (L-strand 1) in the light-strand 221,222. The theory 
was that starting from HSP1, just upstream the mt-tRNAPhe, only the two mt-rRNAs and two mt-
tRNAs (Val, Leu) were transcribed from this point and the transcription was blocked at the mTERF1 
sequence. Instead the majority of the molecule is transcribed from HSP2 that gives origin to a 
transcript that comprehends almost all the length of the mtDNA 223–225.  
Indeed more recently was described a KO mouse for mTERF1 that does not present any defect in the 
H-strand transcription but tend to accumulate more antisense RNA species, meaning that mtTERF1 is 
probability used to terminates the L-strand transcript, preventing the formation of this antisense 
species 226.  Probably HSP1 and LSP1 only are responsible and sufficient for the transcription start.  
Regarding the transcription of the light-strand, LSP1 is the unique site where the transcription can 
start, although the majority of initiation events from this site stop 200 bp downstream the promoter, at 
the CSB2 site (conserved sequence block 2) 227. It seems that this short RNA strand is only used as an 
“RNA primer” by the polymerase to start the lagging-strand replication of the mtDNA 228.  
The basal machinery for the mtDNA transcription has been well studied in mammals and it is 
composed by a single subunit of the RNA polymerase (POLRMT) 229,230 and the transcription factors 
TFB1M and TFB2M 231,232. While the first one possesses a dimethyl-transferase function 233 , the 
second is needed for the transcription initiation 231,234. In humans also TFAM and the transcription 
elongation factor TFEM are required for the process 231,235,236. Also MRPL12, acting as a complex with 
POLMRT and TFEM, is needed for the processivity of the elongation phase and to prevent the 
termination of the transcription at CSB2 236–238.  
7.2 Transcript processing  
The transcription of mtDNA gives rise to two polycistronic transcripts that must be somehow 
processed to release the different RNA species. As shown in Figure 24, most of the mRNAs and mt-
rRNAs-coding regions are separated by mt-tRNAs. This RNAs are separated by each other according 
to the generally accepted mt-tRNA punctuation model 150,153.  
 
 
 
Figure 24: Schematic representation of the mitochondrial polycistronic transcript. mtRNA is 
transcribed in two polycistronic transcripts. The one transcribed from the HSP promoter contains 
12 ORFs encoding 12 subunits of the OXPHOS complexes, the two ribosomal RNAS and 13 
tRNAs, while the primary transcript transcribed from the LSP promoter encodes for only one 
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protein and 8 tRNAs. Black and grey triangles indicate the non-canonical junction between the 
gens that are not following the tRNA punctuation model (Image from Van Haute et al., 2015). 
 
 
The mitochondrial RNA-processing machinery initiates the cleavage of the mt-tRNAs sequences 
freeing the mt-rRNAs or mt-mRNAs that they intersperse.  However not all the mRNA and are 
flanked by a mt-tRNA coding sequence, as ATP6/8 and COIII or ND5 and Cyt B (Figure 24).  
Although it was reported the pentatricopeptide protein (PTCD2) seems to be involved in the 
processing of some of this RNAs as well as FASTKD5, the exact process by which these species are 
released is still unclear and object of study 211,240.  
It has been recently proposed that the early stages of the mitochondrial transcription can take place co-
transcriptionally inside the mitochondrial RNA granules. Indeed most of the proteins involved in the 
mt-RNAs processing were found to be part of the MRGs proteome 210,241,242.  
In particular the 5’-end of the mt-tRNAs is processed by the protein complex RNaseP, composed by 
MRPP1, 2 and 3 that are found in the granules 210,243. MRPP1 is a m1G9-methylase, while MRPP2 is a 
dehydrogenase also involved in the other cellular functions 244. These two proteins form a subcomplex 
that also participate in the tRNA modification 245. MRPP3 is responsible for the hydrolysis of the 
phosphodiester bond 246.  The KO of any of this proteins cause an accumulation of the RNA precursor 
molecule, reducing the stedy-state levels of the mature form of mt-tRNAs and some mt-mRNAs 
(Figure 25) 247.  
On the other hand RNaseZ or ELAC2 is responsible for the 3’-end processing of the mt-tRNAs, 
however this protein was not found to be part of the MRGs proteome 248,249. It was then proposed that 
the primary transcripts undergo a first round of processing partially co-transcriptionally inside the 
MRGs, while a second part of the maturation takes place later and outside the granules. Also in this 
case the knockout of the protein can cause the accumulation of mt-RNAs precursors (Figure 25) 247,249.  
Recently, other proteins were described in the MRGs that could have a function in the processing of 
the primary transcript.  GRSF1 (G-rich sequence factor 1) is a RNA-binding protein, shown to co-
localize with the newly synthesised mt-RNA and with MRPP1. The loss of the protein results in a 
decrease of the mature form of some transcripts 210,241. PTCD1 is another protein implicated in the mt-
RNA metabolism. It seems that this protein has a role in the coordination of the 3’-end processing and 
directly interacts with RNaseZ 247,250.  
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Figure 25: post-transcriptional maturation of mtDNA encoded RNAs. The primary transcript 
resulting from transcription is processed to release the individual mt-mRNAs, mt-tRNAs and mt-
rRNAs. The mitochondrial RNaseP consists of three subunits (MRPP1, 2 and 3) and cleaves the 
primary transcripts at the 5’-end of tRNAs. tRNAs are then relased after cleavage of their 3’-end 
by RNaseZ (ELAC2). Yellow dots represent RNA modofications (Image from Hällberg and 
Larsson, 2014). 
 
7.3 mt-tRNA processing and modification 
mt-tRNAs released form the primary transcript need to reach their mature form and stabilised 
conformation to be used during the translation process. mt-tRNAs undergo a different variety of 
chemical modifications that can be divided in to two categories: the ones able to confer the tRNA the 
correct structural stability and folding and the ones that coordinate the proper tRNA function altering 
their interaction with other factors (Figure 26) 239.  
One of the most important modifications found on the mt-tRNAs is found in the residues 34 and 37 
that result modified in almost all the tRNAs studied so far. The residue 34, indeed, is one of the three 
that matches with the corresponding base in the mRNA that has to be translated. Because of the 
degeneracy of genetic code we know that multiple codons must be recognised by a single tRNA. 
Degenerate codons contain the same 1st and 2nd positions as the others but contain a different 3rd 
position. Base in position 34 is the one that will pair with the 3rd base of the codon in the mRNA, and 
to allow this recognition the interactions between this two bases are non-standard, so the base can 
“wobble” 239.  
This position is often occupied by a U, which can pair with any of the four bases. However not always 
this is sufficient for the tRNA to correctly recognize the right codon, in some cases the presence of a 
purine or a pyrimidine in position 3 produces codons for different amino acids. The increase in the 
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discrimination by the wobble base required for accurate decoding is achieved through its post-
transcriptional modification 252.  
Several enzymes are imported into the mitochondrial matrix to modify these bases so that the mt-
tRNAs can reach their mature form.   GTPBP3 (GTP binding protein 3) 253, MTO1 (mitochondrial 
tRNA translation optimization 1) 254 and MTU1 (mitochondrial tRNA-specific 2-thiouridylase, 
TRMU) 255 that favour the base pairing with purines, preventing misreading phenomena.  
For the correct achievement of the translation efficiency sometimes also base 37 of the t-RNAs should 
be modified. This base is substrate of different enzymes like TRIT1 (tRNA isopentenyltransferase 1) 
256 and TRMT5 (tRNA isopentenyltransferase 5) 257 and then of CDK5RAP1 (Cyclin-dependent kinase 
5 regulatory subunit associated protein 1) 258.   
Another fundamental modification that tRNAs undergo to assure the correct aminoacylation in the 
acceptor helix are the modification of the discriminator base at the position 73 and the addition post-
transcriptionally of the CCA codon by TRNT1 259.  
 
 
 
Figure 26: Post-transcriptional modification of mitochondrial tRNAs. An example of a tRNA 
is represented in its secondary structure indicating the post-tracriptionary modificated bases with a 
circle. The details of chemical modification and the enzyme responsible (if known) for each mt-
tRNA position are given in boxes, indicating the base position number next to each box (Image 
from Van Haute et al., 2015).  
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7.4 mt-rRNA modification 
The mammalian mitochondrial ribosome is composed, as the cytosolic one, by two subunits of 
different sizes, the small subunit 28S (mtSSU) and the large subunit 39S (mtLSU) 260–263. Both of them 
are composed by the mitochondrial-encoded rRNAs 12S and 16S respectively, and the ribosomal 
proteins that are codified by nuclear genes and are imported to the mitochondrial matrix.  As all the 
other rRNAs, mitochondrial rRNAs undergoe post-transcriptional modifications to be functional, but 
differently from the cytosolic ones, the range of modifications is less wide and they do not need any 
nucleolytic processing (Figure 27) 239,264,265. 
 
7.4.1 Maturation of the 12S mt-rRNA 
Only five nucleotide modifications were found in the 12S rRNA: methylation of one uracil base 
(m5U429), methylation of two cytosine bases (m4C839 and m5C841), and dimethylation of two 
adenine bases (m62A963 and m62A937) 266. However, until now only two of these modifications were 
characterized.  
TFB1M is the enzyme responsible for the methylation of the two adenines that are located in the loop-
structure (Figure 27, right part) 267,268. In bacteria this part is responsible for the binding site of the 
large subunit 269, in humans the lack of this enzyme causes a decline of the mature levels of 12S, 
leading to a deficiency of assembled mtSSU and results in an impairment of mitochondrial translation 
268.  
NSUN4 (NOP2/sun domain containing family, member 4) is the enzyme that is responsible for the 
methylation of the cytosine residue in position 841 270,271. This modification is fundamental for the 12S 
folding in cooperation with the methylation in position 839.  
The enzymes responsible for the methylation in position 429 and 339 have not been identified yet. 
 
7.4.2 Maturation of the 16S mt-rRNA 
As the 12S rRNA, also 16S rRNA do not need any nucleolytic cleavage to be fully functional, but 4 
bases were found to be modified. Two methylation of guanosine (Gm1145 and Gm1370), one ribose 
methylation of uridine (Um1369) and one pseudouridylated base (Psi1397) were described 272,273.   
Methylation on the 2’-O-ribose of Gm1145 is catalysed by MRM1 and this enzyme is part of the 
MRG proteome 242,274,275. In yeast this methylation is fundamental for the stability of the large 
ribosomal subunit and for the ribosomal function 276.   
The other two methylated sites are located in the A-loop that is an essential component of the peptidyl 
transferase centre in the large subunit, and are involved in the interaction with the aminoacyl site of 
the mt-tRNA 264. G1370 and U1369 are modified by MRM2 and MRM3 respectively 242,274,275. As in 
the case of MRM1, both these enzymes are localised in the MRGs and are crucial for the success of 
mitochondrial translation and OXPHOS function. Loss of one of these two enzymes result in an 
aberrant assembly of the LSU and consequent ineffective translation process 275.  
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Figure 27: Post-transcriptional modifications of mitochondrial ribosomal RNAs. Schematics 
of the secondary structure of 12S and 16S mt-rRNAs indicating post-transcriptionally modified 
bases (circles) are shown. The details of chemical modification and the enzyme responsible (if 
known) for each mt-tRNA position are given in boxes, indicating the base position number next to 
each box (Image from Van Haute et al., 2015).  
 
7.5 mt-mRNA processing and metabolism 
mt-mRNAs are released from the primary transcript as described before, however, differently from the 
nuclear-encoded mRNAs, this molecules undergo a much simpler post-transcriptional modification. 
Stabilization of the mitochondrial mRNAs is very different and simpler than the stabilization process 
that take place for the nuclear-encoded mRNAs, while the degradation process have some hints that 
could remind the compartmentalisation and the degradation process that takes place in the cytoplasm 
239.   
 
7.5.1 mt-mRNA polyadenilation 
The first difference that we can find between the maturation process of the nuclear-encoded mRNAs 
and the mitochondrial ones is the lack of 5’CAP modification as well as the absence of introns.  
3’-end of mt-mRNAs is modified to have a poly-A tail much shorter than nuclear mRNAs that can go 
from 45 to 55 nucleotides, with some exceptions 277. Indeed ND6 mRNA was found not to have a 
poly-A tail and is immediately competent for translation, while ND5 can be either oligo-adenilated or 
not adenilated at all 277.  
Poly-A tails are synthesised by a non-canonical poly-A polymerase (mtPAP) that localize in MRGs 
suggesting again that the first maturation steps take place co-transcriptionally in the granules 278–281. 
Knockdown of mtPAP or a decrease in the polyadenilation lead to an impaired mitochondrial 
translation and the disruption of the mitochondrial respiratory function 279.  
The exact role of poly-A tail in mitochondrial transcripts is still unclear 282. Seven out of 13 mt-
mRNAs do not encode a complete stop codon for translation termination. Most of them are cut out 
when the mt-tRNAs are nucleolitically cleaved from the primary transcript often leaving a “U” or 
“UA”. For this reason,  it was suggested that the poly-A tail added after that cleavage has the function 
to complete the stop codons (Figure28) 150,153.  
Although the classical role of the poly-A tail is to stabilise and increase the half-life of the transcripts, 
in the mitochondrial compartment this is not always the case. It was shown that poly-A tail could 
decrease the stability of COI, COII, COIII and ATP6/8, while it increases the stability of ND1, ND2, 
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ND3, ND4, ND4L, ND5 and Cyt. B. The mechanism by which this transcript-specific role of 
polyadenilation remains to be elucidated 283–285.  
The phosphodiesterase 12 (PDE12), a mitochondrial 2’ and 3’ phosphodiesterase 283,286, is the protein 
responsible for the removal of the poly-A tail, but this activity was shown only in vitro and in cultured 
cells, after over-expression of the protein 283.  
 
 
Figure 28: Messanger RNAs encoded by mitochondrial DNA. The mRNAs contains no or short 
5’ non-coding sequences (yellow) preceding the first translation initiation codon (AGA, AGG, 
UAA, UAG) and short poly-A tail. Two of the mRNAa (ND4/ND4L and ATP6/ATP8) are 
bicistronic, and each contains two partly overlapping ORFs. The structure of each human mRNA 
is shown (Image from Hällberg and Larsson, 2014).  
 
7.5.2 mt-mRNA stability and decay 
Regulation of mRNA stability and turnover are fundamental in the control of gene expression and are 
usually mediated by protein complexes. The best characterised protein complex that is involved in the 
mtRNA stability is the LRPPRC/SLIRP protein complex, which prevents the degradation of the 
mtRNAs.  
LRPPRC is a leucin-rich pentatricopeptide repeat (PPR)-containing protein that binds RNA and is 
mainly present in the mitochondrial matrix 287. Knockdown of LRPPRC in mice results in drastically 
reduced steady-state levels of mRNAs, but not of the mt-tRNAs of mt-rRNAs, and determining 
reduced polyadenilation and transcripts processing defects, and impaired translation 288–292. 
LRPPRC is also able to block the action of PNPase (polynucleotide phosphorylase) that degrades 
RNA, while promoting polyadenilation by stimulating the activity of mtPAP 293. 
The other protein that acts in a complex with LRPPRC to stabilize mRNAs is the stem-loop-
interacting RNA binding protein (SLIRP) 294. 
Knockdown of one of the two proteins cause the decrease in levels of the other, moreover SLIRP 
alone is not able to have an effect on polyadenilation of the transcript 291,293. It was suggested that 
LRPPRC is able to stabilise a pool of translationally-inactive mt-mRNAs that are not associated with 
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the ribosome. It was also suggested that the LRPPRC/SLIRP complex could function binding the 
mRNA and preventing the formation of secondary structures, leaving the 3’-end of the mRNA 
available for the polyadenilation. This activity, as mentioned before, could also be involved in the 
suppression of the PNPase/hSUV3 mt-mRNAs degradation activity 291,293.  
Once the mRNAs, tRNAs and rRNAs are used several times for the translation of proteins, they might 
be degraded in order to eliminate aberrant or damaged transcripts. The best characterised protein 
complex dedicated to the mt-mRNA degradation in the mitochondrial matrix is the hSUV3/PNPase 
complex 212.  
hSUV3 is a NTP-dependent helicase that has more than one isoforms and at least one of these is 
localised in the mitochondrial matrix. This protein is able to unwind different DNA and RNA 
substrates. Szczesny et al. suggested that this helicase is involved in the degradation of the damaged 
mtRNAs and has a role in the decay of the properly processed RNA molecules 295–297.  
The other protein acting with hSUV3 is PNPase that is a polynucleotide phosphorilase able of 3’-to-5’ 
phosphorolysis and 5’-to-3’ RNA polymerization 298. For its role in RNA degradation PNPase is 
localized in the mitochondrial matrix, however some studies have recently shown the localization of 
the enzyme in the mitochondrial intermembrane space 299. For this multiple localization PNPase has 
been attributed to different processes in the RNA metabolism. In the mitochondrial matrix it takes part 
in the degradation process on RNA and in the polyadenilation process, while in the intermembrane 
spece it seems to play a role in the import of different RNA species from the cytoplasm 212,299,300.  
hSUV3/PNPase complex, also called “degradosome”, has been shown to partially co-localise with the 
MRGs, although it has been suggested that RNA degradation can take place in specialized foci, called 
D-foci 208,239.  
D-foci, besides containing the degradosome,  also localize with newly-synthetized mtRNA, similarly 
to MRGs, suggesting that a subpopulation of MRGs can participate in RNA processing of degradation 
mediated by the degradosome 212.  
Another protein potentially involved in the degradation of mtRNA is the RNA exonuclease REXO2. 
This 3’-to-5’ exonuclease acts as a homotetramer and degrades oligonucleotides in the matrix. Again, 
as for PNPase, REXO2 seems to have a dual localization, in the mitochondrial matrix and in the 
mitochondrial intermembrane space 301.  
It was suggested that, because the degradosome is expected to degrade RNA in small oligo-
ribonucleotides, it is possible that they become the substrate for REXO2 to complete later stages of 
decay 301.   
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8. Translation process in mitochondria 
8.1 Mitoribosome biogenesis and structure 
Mitoribosme biogenesis pathway can be divided in 6 different steps, some of which have been already 
discussed in the previous chapters of this thesis. First, of all 12S and 16S RNAs have to be transcribed 
and released from the primary transcript (chapter 8.2) (1). Then, mitochondrial ribosome proteins 
(MRPs), that are all nuclear-encoded, need to be imported in the mitochondria and modified if 
necessary (2). rRNAs have be to post-transcriptionally modified to be fully functional (chapters 8.3.1 
and 8.3.2) (3). 12S rRNA and SSU protein subunits must be assembled to form the small ribosomal 
subunit (4) and the same need to happen for the 16S rRNA and the LSU subunits (5). Finally, the two 
ribosomal subunits need to be assembled together (6) 217. As mentioned before, the rNRAs 
modification steps are largely co-transcriptional and took place in the nucleoid/MRGs, so it was 
suggested that the biogenesis of the mitoribosome is initiated in the nucleoid and then completed in 
the MRGs 207,211,217. 
The mammalian mitoribosome is composed by the LSU (39S) and the SSU (28S). The small subunit 
contains the 12S rRNA and 29 mitorobosome proteins, while the large subunit is composed by the 16S 
rRNA and 50 proteins 302. Interestingly 15 of the SSU subunits and 20 of the LSU subunts have no 
bacterial homologues, meaning that the mammalian mitoribosome has a RNA:protein ratio much 
lower than the bacterial or eukaryotic cytosolic ribosome 303. We know that the mitoribosome have 
bacterial origins and during evolution some of the rRNA segments were lost, probably substituted by 
ribosomal proteins. Besides the lack of bacterial homologs in the composition of the mitoribosome, it 
is likely that the structural and functional aspects have been conserved during evolution 251,304.  
The two mitochondrial subunits are connected by 15 inter-subunit bridges and only six of them are 
conserved in the bacterial ribosomes 262,305. In mitochondria these bridges are mainly made by protein-
protein interactions, while in bacteria the interaction are mostly between rRNAs. It was also observed 
by Kaushal at al. that the mRNA that should enter the SSU can enter in the structure through an 
mRNA entrance site lined with conserved mitochondrial specific proteins 262. Indeed, in mammals it is 
not known how the mt-mRNA is recognised and transported into this gate. However, it has been 
shown that differently from the requirements of bacterial and eukaryotic cytosolic RNAs, the addition 
of few nucleotides at the 5’-end can abolish the translation of mRNAs306.  
Another peculiar characteristic of the mitoribosome that is worth to be mentioned is that all the 
proteins that needs to be translated in the mitochondira are proteins of the respiratory chain and thus 
all of them are membrane proteins. Therefore mitoribosome have evolved to adapt and specialize for 
the translation of membrane proteins. Indeed, the mitoribosome seems to be normally bound to the 
inner membrane, avoiding the need to cycling between membrane-bound and unbound stages, which 
in contrast occur in bacteria and in the cytosol of eukaryotic cells 307. Furthermore, it was also 
suggested that polypeptides are co-translationally inserted in the inner membrane 308. The biogenesis 
of the mitoribosome includes the action of several enzymes to assemble the complete subunits. Many 
ribonucleoproteins (RNPs) are formed thanks to the action of GTPases and ATP-dependent RNA 
helicases 309. Energy derived from this reactions can modulate the conformational changes needed to 
form the RNP. Moreover, GTPases could act as placeholders for proteins that will be added to the 
structure later in the maturation of the ribosome. Another important function of GTPases in this 
context is the sensor function they could have: GTPases are usually active in their GTP-bound state, so 
they sense the GTP/GDP ratio, and adapt the mitoribosome assembly to match the nutrient availability 
of the cell 207,310.  
ATP-dependent helicases are necessary to unwind the RNA molecules, facilitating their interaction 
with the proteins or helping the displacement of the RNA from a ribonucleoprotein 311. DDX28 and 
DHX30 have been recently identified to be both involved in mitoribosome assembly 213.  
	50	
In the recent years a number of other factors were identified as important in the assembly and stability 
maintenance of the mitoribosome. For example, the enzyme mTERF3 that has a role in the mtDNA 
transcription has also a role in the biogenesis of the LSU 312 as for the Fas-activated serine threonine 
kinase family FASTKD2, the DDX28 helicase 211,213,313 and the mAAA-protease 314. MALSU protein 
and GRSF1 instead have been found to have a role in the biogenesis and stability of the SSU 241,315,316.  
8.2 The mitochondrial translation process 
As for the cytoplasmic translation in eukaryotic cells the mitochondrial translation process can be 
divided in four steps: initiation, elongation, termination and recycling (Figure 29) 207,317,318. Differently 
from the cytosolic translation, mitochondrial mRNAs have a different codon usage. In particular the 
UGA codon, which is usually recognized as a stop codon, is translated as a tryptophan, the AUA 
codon is translated as a methionine and AGA or AGG codons are not recognized by any mt-tRNA or 
protein factor 319,320.   
The initiation step starts with the recruitment of the mt-mRNA and the mtSSU, which is bound to the 
initiation factor mtIF3 to inhibit premature re-association with the mtLSU. The entrance of the mRNA 
in the mtSSU channel is aid also by the mS39 protein 321,322. AUG, AUA, AUU are the codons 
recognized by the mt-tRNA carrying the methionine in mitochondria and once the mt-tRNAMet is 
recruited by mtIF2 bound to GTP, this complex can bind the mtSSU. Although the tRNAMet-mtSSU 
can form a complex also in absence of a mt-mRNA, this becomes stable only in the presence of a 
positive codon:anticodon match. At this point the interaction with the mtLSU can follow, and the 
formation of the monosome sets off the hydrolysis of the GTP bound to mIF2 into GDP in 
concomitance with the release of the initiation factors 306,323.  
As mentioned before, mt-mRNAs present the start codon at the very beginning of the mature 
molecule, near to the 5’-end, and the efficiency of the translation strictly depends on the number of 
nucleotides positioned before the start codon 306. Two of mt-mRNAs ND4L/ND4 and ATP6/ATP8 are 
bicistronic transcripts and each of them contains two open reading frames, partially overlapping. It is 
not known if the two ORFs are translated with only one mRNA/ribosome interaction or if the two 
ORFs are translated into two separate moments. Moreover, it is not known how the translation 
efficiency is maintained in the case of the second ORF of both transcripts, since the 5’UTR of this 
ORFs consist of the upstream coding sequence 317.  
After the initiation the amino acid chain the elongation phase can start. In this step the mitochondrial 
elongation factor mtEF-Tu, a GTP molecule and a charged mt-tRNA form a ternary complex that 
enters the A-site in the mitoribosome. If there is no correspondence between the codon and the tRNA 
anticodon, the interaction between the complex and the mitoribosome is not stable and the complex 
dissociates. When there is the right correspondence the mitoribosome stimulates the hydrolysis of the 
GTP molecule in GDP and the consequent release of the mtEF-Tu factor 324. At this point, the peptide 
bond is catalysed at the peptidyl transferase centre (PTC) in the large subunit. The deacylated tRNA, 
that is now in the P-site, must be released to free the space for the dipeptidyl-tRNA, while the 
dipeptidyl-tRNA that is positioned in the A-site, must slide in the P-site. This is achieved with the 
interaction of the elongation factor mtEF-G1 that binds to the mitoribosome, changing the 
conformational structure of the monosome and allows the slide of the two tRNAs, while the 
deacylated-tRNA can pass through the E-site before being released. The elongation process continues 
this way until a stop codon is positioned in the A-site 263,322.  
During the termination phase the polypeptide chain is released from the tRNA and the mitoribosome 
must be recycled for another translation event.  The termination codon in human mitochondria is 
recognised by the release factor mtRF1a that in the presence of a GTP molecule promotes the release 
of all 13 proteins from the mitoribosome 325. As mentioned before, in human mitochondria codons 
UAA and UAG are used as stop codons. However, genes encoding COXI and ND6 do not terminate 
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with one of this codons, but with AGA and AGG, respectively 150. Mapping of the codons present at 
A-site in the human mitochondrial ribosome showed that also these two genes are terminated by an 
UAG. A possible explanation is that there is a -1 frame shift downstream of the termination codon, 
probably driven by structured RNA 277,326.  
Recently, another protein member of the mitochondrial release factors family, ICT1, was described to 
take part to the termination process. This protein has been suggested to take part in the termination of 
the synthesis of COXI and ND6. Besides, ICT1 is a component of the mitoribosome and it has been 
shown to have a hydrolase peptidyl activity on stalled ribosomes 327.  
After the release of the polypeptide chain, the monosome must be dissociated into the two subunits, to 
allow another translation event. The two recycling factors mtRRF1 and mtEF-G2 are the enzymes that 
promote the dissociation of the ribosome, the release of the mt-mRNA and the release of the 
deacylated mt-tRNA 207,328,329.  
 
 
 
Figure 29: Biogenesis of the mammalian mitoribosomes and the translation cycle. The 
biogenesis of mitoribosome requires that the 12S and 16S rRNA are modified and assembled 
along with the ribosomal proteins. The large subunit of the mitoribosome is belived to be anchores 
with the mitochondrial membrane, and the translation cycle requires several factors for the 
initiation, elongation and termination. The membrane anchoring of the mitoribosome is belived to 
facilitate the insertion of the newly synthetized proteins into the inner mitochondrial membrane. 
Recycling of the mitoribosome is not shown (Image from Van Haute et al., 2015).  
 
8.3 Regulation of mitochondrial translation 
Considering the dual genetic origin of the OXPHOS complexes, there is the need of a tight 
coordination between the synthesis of the mitochondrial-encoded subunits and the synthesis of nuclear 
encoded subunits and their import into the organelle to prevent the accumulation of non-complete 
complexes into the inner mitochondrial membrane. Most of the studies in this context have been made 
in yeast. The mitochondrial translation adapts to the nuclear translation of the subunits and to their 
import, which is the limiting step in the assembling process. This adaptation is unidirectional, 
mitochondrial translation depends on the cytosolic one, but inhibition of mitochondrial protein 
synthesis does not affect the translation efficiency of the nuclear-encoded subunits 208,330,331.  
Furthermore, yeast mitochondria possesses a variety of mitochondrial translation activators that can 
bind the 5’-UTR of the mt-mRNA. The exact mechanism by which these proteins can regulate the 
translation is still subject of study, but there are evidences that these activators can establish a 
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feedback loop whereby the absence of available subunits to form a complete OXPHOS complex can 
inhibit the translation of the associated transcript 207,208.  
In human mitochondria one activator was identified, namely TACO1 332. This protein seems to have 
an effect on the translation of MTCO1 gene, which encodes for COXI protein. Indeed, TACO1 
mutation result in complete absence of MTCO1 translation. However, the exact mechanism by which 
TACO1 coordinates the synthesis of COXI is not clear since MTCO1 has no 5’-UTR. It has been 
proposed that the protein can bind the start codon facilitating the initiation step or it could bind the 
nascent polypeptide chain stabilizing it 332.  
The coordination between the mitochondrial synthesis and the import of the nuclear encoded subunits 
is essential for the coordination of OXPHOS complexes assembly. In human mitochondria the 
MITRAC (mitochondrial translation regulation assembly intermediate of cytochrome c oxidase) 
complex was identified as a key element in this step 333.  This complex seems to coordinate the 
assembly of the cytochrome c oxidase complex COX with the translation of the mitochondrial-
encoded subunit COXI. As in the case of TACO1, the mechanism of this regulation is unclear but 
mutations in two of the MITRAC components, c12orf62 and MITRAC12, lead to the inhibition of 
COXI synthesis 334,335.  
Mitochondrial translation can be also regulated by post-translational modification of its actors 336. 
Mitoribosomal components can be phosphorylated or acetylated as a result of ATP, acetyl-CoA and 
NADH mitochondria levels. As mentioned before the mitoribosomal subunit mS29 can be found in 
association with GTP and the monosome 263,322. This protein has more affinity for mtSSU than the 
monosome, suggesting a possible regulatory role of GTP hydrolysis on mS29 337,338. Formation of the 
monosome can also be influenced by mTERF4-NSUN4, which interacts with the small subunit, 
promoting the binding with the large subunit of the ribosome 270,339.  
Finally several other mitochondrial subunits were found to be modified in proximity of domains 
crucial for translation such as the PTC or the PES (peptide exit site) 336.  
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9. mt-RNA processing, mt-translation and diseases 
Mitochondrial diseases are a class of heterogeneous disorders characterized by mutations in mtDNA 
or nuclear DNA that cause severe effects on mitochondrial respiration. Most of the pathologies 
resulting from mutation in mtDNA or the enzymes involved in mtRNA maturation and mitochondrial 
translation can have very wide spectrum of symptoms, always due to the inefficiency of the OXPHOS 
function.  Symptoms can vary from hearing impairment, epilepsy, retinal degeneration to loss of 
cognitive and motor function, cardiomyopathy lactic acidosis and developmental delay 340. The 
affected patients are always heteroplasmic 341 and a fraction of 60% or more of mutated mtDNA is 
needed to have the impairment of mitochondrial translation and the clinical manifestation of 
symptoms 340,341. Pathologies that results from these mutations are often lethal or with a neonatal or 
infantile onset and children with high levels of deleted mtDNA typically develop multisystem disease 
with more severe symptoms in respect to patients that have a less percentage of mtDNA mutations 342.  
A variety of mainly autosomal recessive mutations that impair mitochondrial translation are known, 
and some examples of mutated genes include those that encode for mRNA stability and 
polyadenilation factors (LRPPRC and mtPAP), tRNA modification enzymes (PUS1, MTU1 and 
MTO1), enzymes that aminoacylate tRNAs (DARS2, RARS2 and others), mitoribosomal proteins 
(MRPS16, MRPS22, MRPS28, MRPL3, MRPL12 and MRPL44), translation elongation and 
termination factors (mtEFTu, mtEFG1, mtEFTs and C12ofr65) and translational activator factors 
(TACO1) 340,343. 
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APE1 is a multifunctional protein with a fundamental role in repairing nuclear and mitochondrial 
DNA lesions caused by oxidative and alkylating agents. Unfortunately, comprehensions of the 
mechanisms regulating APE1 intracellular trafficking are still fragmentary and contrasting. Recent 
data demonstrate that APE1 interacts with the mitochondrial import and assembly protein Mia40 
suggesting the involvement of a redox-assisted mechanism, dependent on the disulfide transfer 
system, to be responsible of APE1 trafficking into the mitochondria. The MIA pathway is an 
import machinery that uses a redox system for cysteine enriched proteins to drive them in this 
compartment. It is composed by two main proteins: Mia40 is the oxidoreductase that catalyzes the 
formation of the disulfide bonds in the substrate, while ALR reoxidizes Mia40 after the import. In 
this study, we demonstrated that: (i) APE1 and Mia40 interact through disulfide bond formation; 
and (ii) Mia40 expression levels directly affect APE1's mitochondrial translocation and, 
consequently, play a role in the maintenance of mitochondrial DNA integrity. In summary, our data 
strongly support the hypothesis of a redox-assisted mechanism, dependent on Mia40, in controlling 
APE1 translocation into the mitochondrial inner membrane space and thus highlight the role of this 
protein transport pathway in the maintenance of mitochondrial DNA stability and cell survival. 
 
 
2. Isolation of mitochondria is necessary for precise quantification of mitochondrial 
DNA damage in human carcinoma samples 
Barchiesi A, Baccarani U, Billack B, Tell G, Vascotto C. 
Biotechniques. 2017 Jan 1;62(1):13-17. doi: 10.2144/000114491. 
 
The hepatocellular carcinoma (HCC) is the fifth most common cancer and the third cause of cancer 
mortality worldwide. Advances in diagnosis have improved the prognosis of HCC patients but it 
remains a fateful tumor because of its high rates of metastases and recurrence and the absence of an 
effective pharmacological therapy. Biomedical research relies on the use of animal models and 
human derived tissues for the study of human pathologies. Sub fractionation of cellular 
compartments, DNA isolation, and protein expression analyses are basic procedures in biomedical 
studies. However, the majority of protocols are specifically designed to carry out or genomic or 
proteomic studies. Here we describe a protocol that enables the simultaneous purification of nuclei 
and mitochondria from mouse liver, human healthy and HCC liver tissues suitable for proteomic 
analysis.  In addition, genomic DNA was isolated from the nuclear fraction and used as a template 
for PCR. Mitochondrial DNA (mtDNA) was purified and its level of damage was evaluated in 
tumoral tissues. Generally, for the measurement of DNA damage the mtDNA is not separated from 
the genomic: we demonstrated the need of using a purified mtDNA to obtain reliable data of the 
levels of damage on human biopsies of HCC. 
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3. DNA Repair Protein APE1 Degrades Dysfunctional Abasic mRNA in Mitochondria 
Barchiesi A, Oeljeklaus S, Jedroszkowiak A, Bazzani V, Borowski L. S., Szczesny R. J., 
Warscheid B, Chacinska A, and Vascotto C. 
Submitted to EMBO reports 
 
APE1 is a multifunctional nuclear/mitochondrial protein which plays a central role in the 
maintenance of genome stability and regulation of gene expression. Apart from these canonical 
activities, recent studies have demonstrated that APE1 is also enzymatically active on RNA 
molecules. The present study unveils for the first time a new role of APE1 in the metabolism of 
RNA in mitochondria. Our data demonstrate that APE1 binds and exerts endoribonuclease activity 
on abasic mitochondrial messenger RNA. Loss of APE1 determines the accumulation of damaged 
mitochondrial mRNA species determining impairment in protein translation and reduced 
expression of mitochondrial encoded proteins, finally leading to less efficient mitochondrial 
respiration. All these effects are rescued by the expression of a recombinant mitochondrial targeted 
form of APE1 protein. Altogether, our data demonstrate that APE1 has an active role in the 
degradation of the mitochondrial mRNAs and a profound impact on mitochondria well-being. 	
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AIMS 
Mitochondria are the main endogenous source of reactive oxygen species (ROS) production and its 
becoming apparent that ineffective functioning of respiratory complexes causes the progressive 
elevation in mitochondrial ROS. Like nuclear DNA, the integrity of mitochondrial DNA, as well as 
that of messanger (mRNA) and ribosomal (rRNA) RNAs, are also constantly threatened by exposure 
to damaging agents. Integrity of mitochondrial DNA and RNA is necessary for the cell survival under 
physiological conditions. 
APE1 is an essential enzyme in the DNA BER pathway, which is responsible for repairing both the 
nuclear and mitochondrial DNA lesions caused by oxidation and alkylation agents. Apart from its 
effect on DNA, recent findings highlight a novel role of APE1 in RNA metabolism as proved by its 
interaction with RNA processing proteins, its ability to recognize and cleave abasic RNA, and the 
control of miRNA processing. Unfortunately, comprehensions of the mechanisms regulating APE1 
intracellular trafficking are still fragmentary and contrasting.  
The purposes of this thesis have been: i) to characterize the molecular mechanisms responsible for the 
translocation of APE1 into the mitochondria; and ii) to evaluate if APE1 exerts endoribonuclease 
activity on mitochondrial RNAs. 
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MATERIAL AND METHODS 
1. Cell culture and treatments  
HeLa and Huh7 cells were grown in DMEM (Dulbecco’s modified Eagle’s medium), JHH6 cells were 
grown in William’s medium E, both supplemented with 10% foetal bovine serum (FBS), 100-U/ml 
penicillin and 10 mg/ml Streptomycin sulphate. One day before treatment HeLa cells were seeded 4 × 
106 cells/plate. For mtDNA damage measurements HeLa and JHH6 cells were treated with 400 mM 
and 1.2 mM of H2O2, respectively, in medium without serum for 15 min, and then cells were grown 
for 1 h in the presence of 10% FBS before harvesting. For cell viability analysis 5 × 104 JHH6 and 10 
× 104 Huh7 cells were seated on 96 multiwell plates and after 24 h treated with the reported amount of 
Methyl methanesulfonate (MMS) or H2O2 for 8 h in medium without FBS. For inducible silencing of 
endogenous APE1, HeLa cell clones were developed as described in Vascotto et al 67: Scr-1 and 
shRNA-APE1 were grown in DMEM (Dulbecco’s modified Eagle’s medium) supplemented with 10% 
foetal bovine serum (FBS), 100 U/ml penicillin and 10 µg/ml Streptomycine sulphate, x Blasticidin 
and x Zeocin. For inducible siRNA experiments, doxycycline (Sigma) was added to the cell culture 
medium at the final concentration of 1 µg/ml, and cells were grown for 9 days. Stable clones 
expressing APE1-FLAG and Empty vector were grown in DMEM (Dulbecco’s modified Eagle’s 
medium) supplemented with 10% foetal bovine serum (FBS), 100 U/ml penicillin and 10 µg/ml 
Streptomycine sulphate, 3 µg/ml Blasticidin and 100 µg/ml Zeocin and 350 µg/ml Neomicin. For 
mRNA half-life calculations Scr-1 and shRNA-APE1 cells were seeded 4x106 cells/plate 1 day before 
treatment and then treated with 500 ng/ml EtBr for 0,1,2,4 and 6 hours in DMEM supplemented with 
10% foetal bovine serum (FBS), 100 U/ml penicillin and 10 µg/ml Streptomycine sulphate. After the 
treatment cells were harvested and RT-PCR was followed. 
2. Transient transfection experiments  
One day before transfection cells were seeded in 10 cm plates at the density of 1.2×106 cells/plate. 
Cells were then transfected with 100 nM of either shRNA Mia40 scramble, shRNA APE1 scramble or 
PNPase scramble (controls) and shRNA Mia40 or shRNA APE1 (encoding for siRNA against Mia40 
or APE1 respectively) per plate using Oligofectamine Reagent (Invitrogen) according to the 
manufacturer’s instructions. Cells were harvested 72 h after the transfection. For overexpression of 
APE1 and Mia40 proteins, 2.5 × 106 cells/plate were seeded 24 h before transfection. Cells were then 
transfected with 2 mg of pCMV5.1 FLAG, C65S, C93S, C99S, C65S+C93S, C65S+C99S, Mia40-
HisTag, MTS-APE1-WT-FLAG, MTS-APE1-E96A-FLAG per plate using Lipofectamine Reagent 
(Invitrogen) according to the manufacturer’s instructions. Cells were harvested 24 h or 48h after the 
transfection. For transient APE1 silencing HeLa cells were seeded at the density of 1.2 × 106 
cells/plate. Then, cells were transfected with 6 mg of pSuper- scramble or pSuper-APE1, in order to 
obtain silencing of endogenous APE1, and with 6 mg per plate of pCMV 5.1 Empty, APE1WT, C65S 
or C93S to re-express APE1. Cells were harvested 48 h after the transfection.  
3. Preparation of total cell extracts and anti-Flag affinity purification  
For the preparation of total cell lysates cells were harvested by trypsinization and centrifuged at 250 × 
g for 5 min at 4°C. Supernatant was removed, and the pellet was washed once with ice-cold 
phosphate-buffered saline (PBS) and then centrifuged again as described before. Cell pellet was 
resuspended in lysis buffer [50-mM Tris-HCl (pH 7.4), 150-mM NaCl, 1-mM 
ethylenediaminetetraacetic acid (EDTA), 1% [wt/vol] Triton X-100, protease inhibitor cocktail 
(Sigma), 0.5-mM phenylmethylsulfonyl fluoride] at a cell density of 107 cells/ml and rotated for 30 
min at 4°C. After centrifugation at 12 000 × g for 10 min at 4°C, the supernatant was collected as total 
cell lysate (WCE). The protein concentration was determined using Bio-Rad protein assay reagent 
(Bio-Rad). For affinity purification analysis total cell lysates were incubated with anti-Flag M2 
affinity gel (Sigma) for 3 h at 4°C and then processed following the manufacturer’s instructions. 
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Proteins were eluted by incubation with 0.15 mg/ml 3xFlag peptide in Tris-buffered saline and then 
subjected to western blot analysis.  
4. Anti-Flag affinity purification from isolated mitochondria 
For affinity purification analysis 1mg of mitochondria from APE1-FLAG expressing cells and and 
CTRL cells was lysed in 50mM Tris-HCl pH 8.0, 300mM NaCl, 10mM MgCl2, 1mM EDTA pH 7.4, 
0,5% NP-40. The lysates incubated with anti-Flag M2 affinity gel (Sigma) for 3 h at 4°C and then 
processed following the manufacturer’s instructions. Proteins were eluted by incubation with 0.15 
mg/ml 3xFlag peptide in Tris-buffered saline (TBS) and then subjected to MS or Western blot analysis.  
5. Preparation of subcellular fractions  
Subconfluent HeLa and JHH6 cells were collected and suspended in Grinding buffer (250-mM 
sucrose, 1-mg/ml bovine serum albumin (BSA), 2-mM EDTA, pH 7.4) with 1:100 protease inhibitor 
cocktail. Cell suspensions were sonicated on ice under mild controlled conditions to disrupt selectively 
plasma membranes (4-s sonication one time). The homogenates were then fractionated by differential 
centrifugation at 800 × g and 16 000 × g at 4°C, to obtain the enriched cytoplasmic, nuclear and 
mitochondrial fractions. Samples were then subjected to Bradford analysis for the evaluation of 
protein content before separation on sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and western blot analysis. Purity of mitochondria and nuclei was evaluated using 
specific marker proteins (LSD1 for nuclei and ATP 5A for mitochondria) to ascertain the absence of 
cross contamination between the two compartments.  
6. Mitochondria isolation 
10*107 cells expressing APE1-FLAG encoding or control vector were seeded one day before the 
procedure. After 24h cells were washed twice with PBS 1X and scraped. After an additional wash 
cells were centrifuged at 1200 rpm for 4’ at 4°C. The cells were divided in two aliquotes and each 
aliquote was resuspended 6ml of MIB buffer (20mM HEPES pH 7.6, 1mM EDTA pH 7.4, 220mM 
mannitol, 70mM sucrose, 2mg/ml BSA, 0,5mM PMSF) and gently homogenized into a glass-glass 
potter with 20 strokes. The suspension was then transferred into a falcon tube and centrifuged at 650g 
for 5’ at 4°C. The supernatant, containing mitochondria was removed and kept on ice while the pellet, 
containing nuclei and unbroken cells, was homogenized again with 10 strokes to increase the final 
yield. The suspension was centrifuged again at 650g for 5’ at 4°C. The two supernatants were pooled 
together and centrifuged once again at 650g for 5’ at 4°C. The supernatant was carefully removed and 
centrifuged at 14000g for 15’ at 4°C while the pellet, containing mitochondria, was washed with MIB 
buffer supplemented with 1M KCl to remove proteins and nucleic acids attached to the outer 
membranes of mitochondria and then centrifuged 14000g for 15’ at 4°C. Finally the mitochondria 
were washed with MIB buffer w/o KCl and BSA and centrifuged again as before, supernatant was 
removed and the pellet was resuspended in MIB buffer w/o KCl and BSA, keeping mitochondria as 
concentrated as possible. Samples concentration was determined using Bio-Rad protein assay reagent 
(Bio-Rad). 
7. Western blot analysis 
The indicated amounts of total, cytoplasmic, nuclear or mitochondrial extracts were electrophoresed 
onto a 12% SDS-PAGE. Then, proteins were transferred to nitrocellulose membranes (Schleicher & 
Schuell). Membrane were saturated by incubation with 5% non-fat dry milk in PBS-0,1% Tween 20 
for 1 h at room temperature, and incubated with the specific primary antibody [anti-APE1 monoclonal 
(Novusbio): overnight 4°C, dilution 1:2000; anti-FLAG monoclonal (Sigma): 3 h at 25°C, dilution 
1:3000; anti-Actin polyclonal (Sigma): overnight at 4°C, dilution 1:2000; anti-ATP 5A monoclonal 
(Abcam): overnight at 4°C, dilution 1:10000; anti-NDUFA1 polyclonal (Abcam): overnight at 4°C, 
dilution 1:5000; anti–NDUFS1 polyclonal (Abcam) overnight at 4°C, dilution 1:10000; anti–MT-ND5 
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polyclonal (Abcam) overnight at 4°C, dilution 1:1000; anti–CO2 polyclonal (Abcam) overnight at 4°C, 
dilution 1:1000; anti–COXVIB monoclonal (Abcam) overnight at 4°C, dilution 1:1000; anti–MRPS15 
polyclonal (Abcam) overnight at 4°C, dilution 1:1000; anti–MRPL9 polyclonal (Novusbio) overnight 
at 4°C, dilution 1:1000; anti–TOMM20 polyclonal (Abcam) overnight at 4°C, dilution 1:1000; anti–
PNPase polyclonal (Abcam) overnight at 4°C, dilution 1:1000); anti-Mia40 polyclonal (gift from the 
lab- oratory of Prof. Matthias Bauer) overnight at 4°C, dilution 1:1000; anti-HisTag polyclonal 
(Sigma): overnight at 4°C, dilution 1:2000]. Membranes were washed three times with PBS-0,1% 
Tween 20 and incubated for 2 h with the secondary antibody. After three washes with PBS-0,1% 
Tween 20 signals were detected with Odyssey CLx scanner (Li-Cor Biosciences). Normalization was 
performed with polyclonal antibodies anti-Actin or with anti-TOMM20. Blots were than quantified by 
using ImageStudio software (Li-Cor Biosciences). 
8. DNA extraction and mtDNA damage measurement by quantitative PCR  
After treatments cells were harvested by trypsin and high- molecular weight DNA was isolated with 
the QUIAGEN Genomic-tip 20/G and G2, QBT, QC, QF buffers (all reagents are distributed by 
Qiagen) as described by the manufacturer. Briefly cells were resuspended in G2 buffer supplemented 
with 400 mg of RNase A and 6 mAU of proteinase K and incubated at 50°C for 2 h in a water bath. 
Samples were then applied to equilibrated columns, washed three times with QC buffer and then 
eluted with 1 ml of QF buffer twice. DNA was precipitated overnight at −80°C with the addition of 
700 ml of isopropanol and then centrifuged at 4°C, 15 000 × g for 1 h. DNA was washed with EtOH 
75%, centrifuged again and resuspended in 100 ml of Tris-EDTA buffer pH 8. Quantification of DNA 
was performed with Quant.iT-Picogreen dsDNA reagent (Invitrogen) according to the manufacturer’s 
instructions and DNA concentration was adjusted to 10 ng/ml. The number of mtDNA lesions was 
determined by Q-PCR. The following primers were used: Mitolong for 5’-TCT AAG CCT CCT TAT 
TCG AGC CGA-3’ and Mito rev 5’-TTT CAT CAT GCG GAG ATG TTG GAT GG-3’ which 
amplified an 8.9-kb mitochondrial fragment; and Mitoshort for 5’-CCC CAC AAA CCC CAT TAC 
TAA ACC CA-3’ and Mito rev, which amplified a 221-bp mitochondrial fragment. DNA was 
amplified using Elongase enzyme mix (Invitrogen). The polymerase chain reaction (PCR) was 
initiated at 94°Cwith hot-start for the complete denaturation of DNA and allowed to undergo the 
following thermocycler profile: an initial denaturation for 1 min at 94°C followed by 19 cycles of 
94°C denaturation for 1 min and 64°C annealing/extension for 11 min for the 8900 bp fragment and 
60°C annealing for 45 s and 72°C extension for 45 s for the 221 bp. A final extension at 72°C was 
performed for 10 min for both fragments. To ensure quantitative conditions a sample with the 50% of 
template amount was included in each amplification and, as negative control, a sample without the 
template was used. PCR products were quantified in triplicate by using Quant.iT-Picogreen dsDNA 
reagent. The mitoshort fragment was needed to calculate the relative amount of mtDNA copies and to 
normalize the lesion frequencies calculated with the mitolong fragment.  
9. RNA extraction and Real time-PCR  
Total RNA extraction from cells was performed using the NucleoSpin RNA kit (Macherey-Nagel 
GmbH & Co., Germany).  1 mg of total RNA was reverse transcribed using the iScript cDNA 
synthesis kit (bio-Rad), according to the manufacturer’s instructions. RT-PCR was performed with 
iQ5 multicolor real-time PCR detection system (Bio-Rad), according to the manufacturer’s protocol. 
The following primers were used: APE1_for (5’- CAG CAA GAT CCG TTC CAA -3’); APE1_rev 
(5’- TTG TCA TCG TCG TCC TTG TAA -3’); 18S_for (5’- 
CTGCCCTATCAACTTTCGATGGTAG -3’) and 18S_rev (5’- CCGTTTCTCAGGCTCCCTCTC -
3’); ND1_for (5’- ACACTAGCAGAGACCAACCG -3’) and ND1_rev (5’- 
CTGCGGCGTATTCGATGTTG -3’);  CO2_for (5’- CGTCTGAACTATCCTGCCCG -3’) and 
CO2_rev (5’- GGGATCGTTGACCTCGTCTG -3’); Cyt.b_for (5’- CCCACATCAAGCCCGAATGA 
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-3’) and Cyt.b_rev (5’- AGTAATAGGGCAAGGACGCC -3’); ATP6_for (5’- 
AACCAATAGCCCTGGCCGTA -3’) and ATP6_rev (5’- TATTGCTAGGGTGGCGCTTC -3’); 
NDUFA1_for (5’- CACTAACGGGGGCAAGGAAA -3’) and NDUFA1_rev (5’- 
ATCAACTCCAGAGATGCGCC -3’); Cyt.c_for (5’- AAACGCATGGGGCTCAAGAT -3’) and 
Cyt.c_rev (5’- TGACCACTTGTGCCGCTTTA -3’);  COXVIB_for (5’- 
TGGTGTCTTTGCTGAGGGTC -3’) and COXVIB_rev (5’- GTCTCCATGTCTTCCGCCAT -3’); 
GAPDH_for (5’-CCCTTCATTGACCTCAACTACATG -3’) and GAPDH_rev (5’- 
TGGGATTTCCATTGATGACAAGC -3’);  cDNA was amplified in 96-well plates using the 2X iQ 
SYBR green supermix (Bio-Rad) (100 mM KCl, 40 mM Tris-HCl [pH 8.4], 0.4 mM each 
deoxynucleoside triphosphate [dNTP], 50 U/ml iTaq DNA polymerase, 6 mM MgCl2 , SYBR green I, 
20 nM fluorescein, and stabilizers) and 300 nM of the specific sense and antisense primers in a final 
volume of 15 µl for each well. Each sample analysis was performed in triplicate. As negative control, 
a sample without template was used. The cycling parameters were denaturation at 95°C for 10 seconds 
and annealing/extension at 60°C for 30 seconds (repeated 40 times). In order to verify the specificity 
of the amplification, a melting-curve analysis was performed immediately after the amplification 
protocol and PCR products were separated onto 2% agarose gel. 
10. Expression and purification of recombinant proteins  
pGEX-3X expression plasmids (Sigma) containing either wild-type APE1 or APE1 C65S, C93S, 
C99S, C65/93S, C65/99S mutants or pGEX-4T expression vectors (Sigma) containing wild-type 
Mia40, Mia40 C55S mutant or the empty vector were transformed into Escherichia coli BL21 (DE3) 
cells (Stratagene). Bacterial cells were grown at 37°C to an absorbance of 0.8 OD measured at 600 nm, 
and then protein expression was induced with 1 mM isopropyl-b-D- thiogalactopyranoside. Induction 
was carried out for 4 h for GST-APE1 and GST and for 2 h for Mia40 at 37°C and then cells were 
collected by centrifugation at 4000 × g for 20 minutes at 4°C. Cells were resuspended in Lysis buffer 
(20 mM Tris HCl (pH 8.0), 250-mM NaCl, 0.1% [v/v] Tween- 20) with protease inhibitor cocktail 
(Sigma), sonicated five times for 30 s and then centrifuged at 16 000 × g for 30 min. Recombinant 
proteins were purified from the clarified extracts on an AKTA Prime FPLC system (GE Healthcare) 
using GSTrap HP columns (GE Healthcare). To remove the GST tag from GST–APE1, WT and 
mutant proteins were further hydrolyzed with factor Xa (five factor Xa units per milligram of 
recombinant GST-fused protein) for 4 h at room temperature (RT). The protease was then removed 
from the sample using a benzamidine HiTrap FF column (GE Healthcare), and the proteins were then 
purified on a GSTrap HP column to purifyAPE1 from the GST tag. The quality of purification was 
checked by SDS-PAGE analysis. Accurate quantification of all recombinant proteins was performed 
by colorimetric Bradford assays (Bio-Rad) and confirmed by SDS-PAGE (Supplementary Figures S1 
and S2).  
11. GST pull-down assay  
For GST pull-down experiments, 15 pmol of GST-Mia40 was added together with 15 pmol of APE1 
WT or APE1 C65S, C93S, C99S, C65/93S, C65/99S mutants, to 10 ml of glutathione-Sepharose 4B 
beads (GE Healtcare). Binding was performed in Binding buffer (1XPBS, 50 mM Tris pH 8.0, 50% 
glycerol, 0.5% NP40 and protease inhibitor) for 3 h under rotation at 4°C. The beads were washed 
three times with Washing buffer (1XPBS, 0.1%NP40, 10% glycerol and protease inhibitor). Proteins 
were eluted for 10 min with Elution buffer (50 mM Tris pH 8.0 and 10 mM GSH). Then, samples 
were dissolved in reducing lamely buffer (250 mM Tris-HCl pH 6.8, 8% SDS, 40%, Glycerol, 0.08% 
Bromophenol Blue,20% b-mercaptoethanol) or non-reducing lamely buffer (250-mM Tris-HCl pH 6.8, 
8% SDS, 40%,Glycerol, 0.08% Bromophenol Blue) and loaded onto 12% SDS-PAGE gels followed 
by western blot. The presence of APE1 and GST proteins was detected using anti-APE1 protein 
monoclonal antibody and GST mono- clonal antibody, respectively.  
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12. Endonuclease assay  
Endonuclease assay was performed by carrying out enzymatic reactions in a final volume of 10 ml. 
After mitochondrial purification, the protein content was quantified by Bradford and 25 ng of 
mitochondrial protein extract was dissolved in AP buffer (50 mM HEPES, 50-mM KCl, 10  
mMMgCl2,1 mg/ml BSA, 0.05% (w/v) Triton X-100, pH 7.5). Reactions were started by adding 100 
nM of double- stranded abasic DNA substrate obtained by annealing a DY-782-labeled 
oligonucleotide [5’-AAT TCA CCG GTA CCF TCT AGA ATT CG-3’] (Eurofins MWG Operon), 
where F indicates a tetrahydrofuran residue, with the complementary sequence [5’-CGAATT 
CTAGAGGGTACC GGT GAA TT-3’] and incubated at 37°C for the reported amount of time. 
Reactions were halted by the addition of Stop solution (96% (v/v) formamide, 10 mM EDTA, Xy- 
lene cyanol and bromophenol blue), separated onto a 20% (w/v) denaturing polyacrylamide gel and 
analyzed on an Odyssey CLx scanner (Li-Cor Biosciences). mtAPE1 endonuclease activity of control 
and Mia40 siRNA was measured in all five biological replicates. The percentage of substrate 
converted to product was determined using the ImageStudio software (Li-Cor Biosciences). For each 
time point reported in the diagram of Figure 3C the percentage of product formation and SD were 
calculated as the average of the biological replicates.  
13. Proximity ligation assay (PLA) 
To monitor the interaction between ectopic APE1 and endogenous Mia40 in living cells, the in situ 
Proximity Ligation Assay kit (Olink Bioscience) was used. HeLa cells were seated into a glass 
coverslip in the amount of 8 × 104 per 24 X multiwell plate, and then transiently transfected with a 
FLAG-tagged form of APE1 WT, or mutants. Twenty four hours after transfection, cells were fixed 
with 4% (w/v) paraformaldehyde, permeabilized for 5 min with Triton X-100 0.25% in PBS 1X and 
incubated with 5% normal foetal bovine serum in PBS-0.1% (v/v) Tween-20 (blocking solution) for 
30 min, to block unspecific binding of the antibodies. Cells were then incubated with the mouse 
monoclonal anti-FLAG FITC conjugated antibody (Sigma Aldrich) at a final dilution of 1:500 for 1 h 
an RT, in a humid chamber. After washing three times with PBS- 0.1% (vol/vol) Tween-20 (washing 
solution) for 5 min, cells were then incubated with a rabbit anti-Mia40 overnight at 4°C. PLA was 
performed following manufacturer’s instructions. Technical controls, represented by the omission of 
the anti-Mia40 primary antibodies, resulted in the complete loss of PLA signal. Images were acquired 
using a Leica TCS SP laser-scanning confocal microscope (Leica Microsystems) equipped with a 488-
nm argon laser, a 543-nm HeNe laser and a 63X oil objective (HCXPLAPO 63X Leica). At least 15 
randomly selected cells per condition were analysed. PLA-spots present in each single cell were then 
scored using the BlobFinder software (Olink Bioscience). Anti-FLAG staining forAPE1 was used to 
identify cell nuclei. Cell viability assay Cell viability was measured through the CellTiter 96 Aqueous 
One Solution Cell Proliferation Assay (Promega) according to the manufacturer’s instructions.  
14. Mitochondrial translation evaluation 
For the mitochondrial translation evaluation cells were seeded at a density of 1.7 x 106 in 6 mm petri 
dish the day before the experiment. After 24 h medium was changed with methionine/cysteine-free 
DMEM with the addition of FBS and Glutamine 1 mM and cells were placed in at 37°C for 1h. Then, 
emetine was added to the medium to a final concentration of 100 µg/ml and cells were further 
incubated for 10 minutes at 37°C. EasyTag™ EXPRESS35S Protein Labeling Mix was added to the 
medium to the final concentration of 200 µCi/ml and the labeling was performed for 1h at 37°C. Cells 
were then washed twice with PBS, collected and resuspended in lysis buffer [PBS, protease inhibitor 
cocktail, PMFS 200 mM, 0.1% DDM, Viscolase, 1% SDS], incubated on ice for 15 minutes and then 
centrifuged for 20 minutes at 14000 x g. The supernatant was collected, protein content quantified 
with Bradford reagent and protein extracts separated on SDS-PAGE at 15%. Gels were dried and 
digital autoradiography was used for gel analysis with Typhoon FLA 9500 (GE Healthcare) followed 
by use of ImageQuant software (GE Healthcare). 
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15. BN-PAGE analysis 
To test OXPHOS complexes stability, 500 mg of mitochondria isolated from Scr-1 and shRNA-APE1 
cells were lysed in 1X NativePAGE Sample Buffer (LifeTechnologies) with 6mg/mg mitochondria of 
Digitonin (Calbiochem) in a final volume of 50 ml. Samples were incubated on ice for 15’ and then 
centrifuged 20000g for 30’ at 4°C. The supernatant was transferred in a new tube and stored at -80°C. 
10 ml of NativePAGE 5% G-250 Sample Additive (LifeTechnologies) was added to the sample before 
electrophoresis. Electrophoresis was performed with the NativePAGE Novex Bis-Tris Gel System 
(LifeTechnologies) with 4-16% Bis-Tris gels, following manufacturer’s instructions. After 
electrophoresis the gels were stained with Comassie R-250 stain or subjected to a Western-blot 
analysis. 
16. mRNA accumulation and half-life calculation 
To measure the extent of mitochondrial mRNA accumulation, one day before transfection Scr-1 and 
shRNA-APE1 expressing cells were seeded in 10 cm plates at the density of 4.5 x 106 cells/plate.  
After 24h cells were treated with 500ng/ml EtBr in complete DMEM for the indicated times (0,1,2,4 
and 6 hours). After the treatment cells were collected and RNA extraction was performed using the 
NucleoSpin RNA kit (Macherey-Nagel GmbH & Co., Germany). 
17. Northern blot analysis 
Northern blot analyses were performed as reported by Szczesny and colleagues 220. PCR products of 
the following mtDNA fragments: 3652-4029 (ND1) and 7586-7900 (COX2) were used as templates 
for preparing strand-specific [α-32P] UTP labeled riboprobes. 
18. Analysis of mitochondrial mRNA half-life 
To calculate mitochondrial mRNA half-life, control (Scr) and APE1 shRNA clones were seeded at the 
concentration of 4 x 106 cells in 10 mm Petri dish the day before the experiment and then treated with 
500 ng/mL EtBr for 0, 1, 2, 4 and 6 hours in complete DMEM medium. After the treatment, cells were 
collected and RNA extraction was performed using the NucleoSpin RNA kit (Macherey-Nagel GmbH 
& Co.) and qRT-PCR was performed. Mitochondrial RNA stability was measured by metabolic 
labeling with 4-thiouridine as previously described by Borowski and colleagues 344. 
19. OXPHOS efficiency evaluation 
Oxygen consumption rate (OCR) was determined by direct measurement with a SeaHorse 
Extracellular Flux Analyzer XpE instrument (Seahorse Bioscience, Agilent Technologies, Santa Clara, 
CA, USA). The day before the measurement 6 x 104 cells and were seeded in XF cell culture 
microplates (Seahorse Bioscience, Agilent Technologies) in a volume of 100 ml and leaved under the 
hood for 1 hour in order to let the cells adhere to the bottom of the plate. Then the total volume of the 
wells were adjusted to 500 ml and the cells were leaved in the incubator O/N at 37°c and with 5% CO2 
pressure. The next day, cells were washed twice with PBS and incubated with XF assay medium 
supplemented with 10 mM glucose, 1 mM glutamine and 1 mM pyruvate (pH 7,4) and placed in a 
37°C incubator without CO2 for 1 hour. OCR for the mitochondrial stress test was determined 
following the manufacturer’s instructions. Briefly, ports in the cartridge plate were loaded with 1 µM 
oligomycin (port A), 1 µM FCCP (port B) and, finally, a mixture of 0,25 µM Rotenone and 0,25 µM 
Antimycin A (port C). Real time OCR was averaged and recorded three times during each conditional 
cycle. Then, cells were collected, lysed and total proteins content was measured by Bradford to 
normalize the amount of cells for each well. For the statistical analysis all the values were normalized 
for the Scr-1 clone.  
20. Mass spectrometric analysis of APE1-FLAG complexes.  
Each lane from Control and IP samples were cut into nine slices of equal size. Subsequent sample 
processing including reduction and alkylation of cysteine residues and proteolytic in-gel digestion 
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using trypsin were performed as described before 345. Peptide mixtures were analyzed by nano-
HPLC/electrospray ionization-tandem mass spectrometry using an Orbitrap Elite mass spectrometer 
(Thermo Fisher Scientific) connected to an UltiMate 3000 RSLCnano HPLC system (Thermo Fisher 
Scientific). For protein identification, MS raw data were searched against the UniProt Human 
ProteomeSet including isoforms (downloaded 09/2015) and a database containing common 
contaminants using the software MaxQuant/Andromeda (version 1.5.2.8) 346,347 with default setting 
except that one unique peptide was required for protein identification; the option "match between 
runs" was enabled. Label-free quantification of proteins identified in APE1-FLAG and control IPs was 
based on normalized MS intensities. For normalization, the MS intensity of individual proteins was 
divided by the summed MS intensity of all proteins detected per sample and multiplied with 1,000. 
The ratio of normalized MS intensities of APE1-FLAG versus control samples was calculated to 
identify proteins enriched in the APE1-FLAG IP. For further analysis, only proteins with at least 3 
MS/MS counts and a sequence coverage > 4% (in the APE1-FLAG IP each) that were detected 
exclusively in the APE1-FLAG IP or that have a ratio APE1-FLAG/control of > 5 were considered.. 
Assignment of proteins to mitochondria is based on Gene Ontology annotations (downloaded from 
UniProt, December 2017).  
21. Immunofluorescence  
For IF and PLA analyses, cells were seated into a glass coverslip in the amount of 8 x 104 per 24x 
multiwall plate. The day after, cells were fixed with 4% (w/v) paraformaldehyde for 20 minutes, 
permeabilized with Triton X-100 0.5% in PBS 1X for 5 minutes, and incubated with 5% goat serum in 
Duolink in situ solution A (Blocking solution) (Sigma Aldrich) for 1 h to block unspecific binding of 
the antibodies. Then, cells were incubated with primary antibody diluted in the Blocking solution in a 
humid chamber (anti-FLAG monoclonal (Sigma Aldrich): 2 h at RT, dilution 1:100; anti-APE1 
monoclonal (Novus): 2 h at RT, dilution 1:400; anti-BrdU polyclonal (Thermo Fisher Scientific): o/n 
at 4°C, dilution 1:400; anti-PNPase (Abcam): o/n at 4°C, dilution 1:200). After washing three times 
with Duolink in situ solution A for 5 minutes, cells were incubated with secondary antibody 
conjugated with Alexa Fluor fluorophore (Thermo Fisher Scientific) 1h30’ at RT, diluted 1:1000 in 
Blocking solution. Mitochondria were stained before fixation with Mito tracker Deep Red (Thermo 
Fisher Scientific) at a concentration of 100 nM for 15 minutes, followed by three washes in PBS 
before fixation.  
22. AP-sites quantification 
AP-sites were quantified following the protocol of  Tanaka et.al, with some modifications. Breifly, 10 
ug of total RNA were incubated with 2 mM ARP (N-(Aminooxyacetyl)-N'-biotinylhydrazine) in 
50 mM Na acetate buffer pH 5.2 for 40 min, at 37 °C. As a loading control we used an in vitro 
synthesized RNA encoding Xenopus elongation factor 1α gene, biotinylated at the 5'-end, that was 
added to the total RNA after the derivatization. The RNA and then the RNA was precipitated by 
ethanol. After resuspention with 10 ul of deionized water, an aliquot of 2 ul was put aside for 
quantifying total transcripts, and the rest of RNA was incubated with streptavidin magnetic-beads for 
20 min, at 60 °C. The beads were washed twice with solution A ((1M NaCl, 20mM Tris-HCl (pH7.5), 
5mM EDTA, 1% NP-40), three times with solution B (2mM Tris-HCl adjusted pH7.5, 0.5mM EDTA, 
1% NP-40) three times with solution C (4M urea, 10mM Tris-HCl adjusted pH7.5, 1mM EDTA, 1% 
NP-40) and 2 times with solution D (2mM Tris-HCl adjusted pH7.5, 1mM EDTA). Oxidized RNA 
was dissociated from beads by incubation of with 2.5 mM biotin solution at 90 °C, for 5 min, 
precipitated by ethanol and resuspended in deionized water. Precipitated and total RNA were used for 
cDNA synthesis (SuperScript™ III Reverse Transcriptase, Invitrogen). Complementary DNA was 
used for qRT-PCR (SYBR Green Master Mix from Biorad), according to the manufacturer’s protocol. 
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The oxidation levels of mRNAs were determined based on ∆Cq values between Cq of total RNA and 
oxidized RNA.  
23. Statistical analyses  
Statistical analyses on biological data were performed using the Microsoft Excel data analysis 
program for Student’s t-test analysis. p < 0.05 was considered as statistically significant. 
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RESULTS 
1. Role of MIA pathway in the mitochondrial internalization of APE1 
APE1’s localization is eminently nuclear although this protein is also present within the mitochondrial 
matrix, as an essential component of the mitochondrial BER (mtBER) pathway 67,348. Notably, the 
mechanisms regulating APE1 intracellular trafficking are still largely unknown. Recent data from our 
lab confirm the presence of APE1 within mitochondria in its full-length form and that, during the 
trafficking from cytosol to the mitochondrial matrix tends to accumulate within the IMS 67. Due to its 
molecular mass, APE1 must be imported in an active way into the organelle. In 2011 it was 
hypothesized that APE1 could be a substrate for the DRS pathway and the interaction of the two 
proteins was demonstrated to take place inside the mitochondria. The first part of this thesis focuses on 
the identification and characterization of the import machinery that mediates APE1 translocation into 
the mitochondrial compartment.  
  
1.1 APE1 and Mia40 interact through disulfide bonds 
In order to assess in vivo in a cell model the interaction between APE1 and Mia40, we transiently 
transfected HeLa cells with pCMV 5.1 plasmids expressing Mia40-HisTag, and APE1-FLAG (IP) or 
the empty vector as control (Mock). Then, APE1-FLAG was immunopurified and Mia40-HisTag 
protein was detected in the IP fraction (Fig. 30). To evaluate if the interaction between the two 
proteins involved the formation of a disulfide bond we produced recombinant Mia40 expressed in 
fusion with a GST tag at the N-terminus (rGST-Mia40) (Fig. 32), and recombinant APE1 (rAPE1) 
(Fig. 33) and quantified the interaction through GST pull-down assays. rGST-Mia40 was used as “bait” 
and rAPE1 was used as “pray”, while GST protein alone was used as negative control. APE1 was able 
to interact with Mia40 (Fig 30 left, lane 2), and incubation with a reducing agent (DTT) let to an 
almost completely loss of APE1 signal in the pull-down fraction (lane 3). Data from literature identify 
the Cys55 of Mia40 as the catalytically active residue responsible for the formation of the disulfide 
bond with its substrates 29. To verify if also APE1 formed the mixed disulfide bridge with Mia40 
through this residue, we performed GST pull-down assays comparing APE1’s binding activity of 
rGST-Mia40-WT with that of rGST-Mia40 C55S mutant form (Fig. 31). The mutant showed a 
significant reduction of affinity for APE1 (40±2%) but not a complete loss of binding as for other 
Mia40 substrates 52,65,349. These data demonstrate that Mia40 interacts with APE1 through the 
formation of a mixed disulfide bridge involving Mia40 Cys55. Moreover, the partial persistence of 
interaction even when Cys55 is mutated support the hypothesis of a non-covalent contribution to the 
interactions between the two proteins.  
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Figure 30. Mia40 Cys55 is responsible for the binding to APE1. (left) Western blot (top) and 
relative quantification (bottom) of the affinity purification analysis of HeLa cells expressing 
APE1-FLAG and Mia40-HisTag proteins. Control sample (Mock) and APE1-FLAG (IP) were 
immunoprecipitated under native conditions from total cell extracts, separated by 12% SDS-PAGE, 
and analysed by Western blot to evaluate the levels of each interacting partner by using specific 
antibodies (anti-APE1, anti-HisTag). Mia40-HisTag protein resulted enriched in IP fraction. 
(right) GST pull-down assay under reducing and non-reducing conditions. 15 pmoles of 
recombinant GST-Mia40 protein were used as bait, GST alone as control, and APE1 protein as 
prey. Interaction between the two proteins was disrupted after treatment with reducing agent (DTT 
20 mM). Under non-reducing conditions the complex formed by APE1 and Mia40 is visible and is 
disrupted when proteins were incubated with DTT (*: p<0.05). 
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Figure 31. GST pull-down assay of WT and Cys55 mutant Mia40 with WT APE1. (left) 
Western blot analysis of GST pull-down assay with increasing amounts of WT and cys55 Mia40 
mutant. (right) densitometric analysis of the GST-Mia40 bands. (*: p<0.05). 
 
		 
Figure 32. SDS-PAGE analysis of recombinant GST-Mia40 WT and C55S mutant proteins 
(left) 0.6 µg of recombinant GST and GST-Mia40 WT proteins were loaded and separated in a 
12% SDS-PAGE gel and stained with Bio-Safe Coomassie (BioRad) to evaluate the absence of 
contaminants after chromatographic purification. (right) Recombinant GST-Mia40 WT and C55S 
mutant quantification. Proteins were quantified through Bradford assay and then 0.3 µg of each 
recombinant protein were loaded and separated in a 12% SDS-PAGE gel and stained with Bio-
Safe Coomassie (BioRad). Reported amount of purified BSA were also separated and used for 
accurate titration of recombinant GST-Mia40 proteins. Image was acquired with Image Scanner 
(Amersham) and band intensity was measured with Image Quant TL (Amersham). Relative 
intensity of GST-Mia40 C55S is reported on the bottom. 
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After have verified the Mia40 cysteine responsible for the interaction with APE1, GST pull-down 
experiments were performed to identify which of APE1 redox cysteine formed a mixed disulfide 
bridge with Mia40. We expressed and purified recombi- nant APE1 single and double cysteine to 
serine mutants (C65S, C93S, C99S, C65S+C93S, C65S+C99S) (Fig. 33). As reported in Figure 5, the 
substitution of APE1 Cys93 and the substitution of both cysteine in position 65 and 93 with serine 
residues completely abolished the interaction of the two proteins confirming the residue Cys93 
ofAPE1 to be primarily involved in the disulfide bond formation with Mia40. The substitution of 
Cys99 (single and double mutants with Cys65) did not alter the interaction with Mia40. Interestingly, 
the substitution of Cys65 alone determined a stronger interaction with Mia40 than the WT protein 
(Figure 34). To further investigate in vivo the interaction between APE1 and Mia40, we performed 
PLA assay overexpressingAPE1-FLAGWT, Cys65 and Cys93 to Ser mutants and quantified the 
interaction with endogenous Mia40 (Figure 35). Presence of PLA signals demonstrated that ectopic 
APE1 interacted with endogenous Mia40 which is known to be present only in the mitochondria IMS. 
As reported in the histogram of Figure 6, APE1 C65S had a stronger interaction with Mia40 than the 
WT protein, while the C93S mutant showed PLA signals similar to that of the control reaction (Ctrl) 
where the primary antibody for Mia40 was omitted. Interestingly, the stronger interaction of APE1 
C65S was not accompanied by more efficient localization of APE1 in mitochondrial 67. This behavior 
is reminiscent of the conditional mutant mia40-4 in yeast that binds client proteins but is defective in 
the completion of their oxidative folding and ultimately their mitochondrial accumulation 350,351. 
	 
Figure 33. Recombinant APE1 WT and C65S, C93S, C99S, C65S+C93S, C65S+C99S 
mutants proteins. Proeins were quantified through Bradford assay and then 0.5 µg of each 
recombinant protein were loaded and separated in a 12% SDS-PAGE gel and stained with Bio-
Safe Coomassie (BioRad) to evaluate the absence of contaminants after chromatographic 
purification. To calculate the relative intensity of each recombinant proteins respect to the WT, the 
image was acquired with Image Scanner (Amersham) and band intensity was measured with 
Image Quant TL (Amersham). Relative intensity of all mutants are reported on the bottom. 
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Figure 34. GST pull-down analysis of APE1 mutants and WT Mia40. (top) Western blot and 
(bottom) relative histogram of GST pull-down analysis of recombinant APE1 (15 pmoles) WT and 
redox Cys65, Cys93, Cys99, Cys65+Cys93, and Cys65+Cys99 to Ser mutants. GST-Mia40 (15 
pmoles) was used as prey and GST (15 pmoles) alone as control. The binding of APE1 WT and 
mutants was normalized to the Western blotting signal of GST-Mia40 (*: p<0.05; *: p<0.01). 
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Figure 35. Representative immunofluorescence images (top) and histogram (bottom) of PLA 
analysis between ectopic flagged APE1 and endogenous Mia40. HeLa cells were transiently 
transfected with pCMV5.1-FLAG vector expressing APE1 WT, Cys65 and Cys93 to Ser mutants. 
APE1 expression was detected by using an anti-FLAG antibody (green), while PLA signal are 
visible as red dots. Control reaction was carried out omitting anti-Mia40 antibody and shows no or 
little PLA signal. White bar corresponded to 10 µm. Data reported in the histogram accounted for 
the average number of PLA signals of at least 15 randomly selected cells per condition. 
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We evaluated the effect of APE1’s redox-active cysteine mutation on the stability of the protein, by 
transiently transfecting HeLa cells with pCMV 5.1 vectors express- ing APE1 WT, Cys65, Cys93, 
Cys99, Cys65+Cys93 and Cys65+Cys99 to Ser mutants. Expression levels of ectopic flagged APE1’s 
mRNA were analyzed by RT-PCR not showing any major significant differences between the WT and 
all mutant forms (Figure 36, top). On the contrary, ectopic flagged APE1 protein levels in total cell 
extracts revealed a significant reduction of both the single C93S (33 ± 8%) and the double 
C65S+C93S (12 ± 8%) mutants, therefore supporting a pivotal role of Cys93 for the overall stability 
of the protein itself (Figure 36, bottom). Next, we assessed the effect of the expression of APE1’s 
C65S and C93S mutants on the levels of mtDNA damage. To down regulate endogenous APE1’s 
expression, we transiently transfected HeLa cells with a pSuper vector coding for an shRNA sequence 
that specifically target APE1’s mRNA, as well as a scramble sequence as a control, and re-expressed 
shRNA resistant APE1 WT, Cys 93 and Cys56 to Ser mutant forms (Figure 37). Then, we evaluated 
the effect on the stability of the mtDNA of these mutants by measuring the levels of mtDNA damage 
through a Q-PCR assay that allowed us to calculate the relative number of mtDNA lesions 352. As 
reported in the histogram of Figure 8, down regulation of APE1expression led to increased levels of 
mtDNA damage, while the re-expression of APE1WT rescued the phenotype. Remarkably, re-
expression of the redox C65S mutant did not rescue the phenotype, while the C93S mutant showed 
even higher levels of mtDNA damage compared to silenced cells. In conclusion, we proved that 
APE1’s Cys93 residue is necessary for the interaction with Mia40, and that the mutation of this 
residue determines the instability of the protein, inducing a mitochondrial stress condition that finally 
leads to the increase of mtDNA damage. 
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 Figure 36. mRNA (top) and protein (bottom) expression analysis of APE1 redox mutants in 
HeLa cells. 10 µg of total cell extracts from HeLa cells expressing APE1 WT or redox mutant 
were analysed by Western blot to evaluate the effect of mutation on APE1 stability. Mutation of 
Cys93 significantly reduces the accumulation of the protein within the cell respect to the WT form. 
Actin was used as loading control to normalize APE1’s signal intensity. 
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Figure 37. Western blot and mtDNA damage analysis of HeLa cells after endogenous APE1 
silencing and re-expression of APE1 WT, Cys65, or Cys93 to Ser mutant proteins. (top) 
Endogenous APE1 protein is significantly reduced after transfection while exogenous APE1 WT, 
C65S and C93S proteins are expressed. Actin was used as loading control. mtDNA damage 
analysis of HeLa cells after endogenous APE1 loss of expression and re-expression of ectopic 
APE1 WT, Cys65, or Cys93 to Ser mutant proteins. (bottom) Silencing of APE1 leads to increased 
levels of mtDNA damage rescued by the re-expression of APE1 WT. APE1 C65S and C93S 
proteins are not able to rescue the damage after APE1 silencing. 
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1.2 Mia40 is required for mitochondrial translocation of APE1 
Having demonstrated that APE1 interacts with Mia40, the next step was to test our hypothesis for an 
active role of this protein in controlling APE1’s translocation into the mitochondrial IMS. First, Mia40 
was overexpressed and the amount of APE1 within mitochondrial fractions was measured. A slight, 
but significant increase of the amount of mitochondrial APE1 form was observed (Figure 38). Next,	to 
prove the biological relevance of the MIA pathway in controlling APE1 mitochondrial translocation, 
HeLa cells were transiently transfected with specific siRNA against Mia40 (Mia40) and the relative 
scramble control (Ctrl). Seventy-two hours upon transfection, cells were harvested, mitochondria and 
nuclei isolated and the amount of APE1 and Mia40 was evaluated through western blotting analyses. 
Mia40 levels were significantly reduced (up to 90%) and consequently, a significant reduction ofAPE1 
levels (35 ± 7%) in mitochondria was observed, suggesting a direct role of Mia40 in controlling 
APE1’s mitochondrial translocation. On the contrary, no significant variation in APE1’s nuclear 
contents was observed (Figure 39). Then, to verify if the decrease of APE1 content resulted in a 
reduction of mitochondrial endonuclease activity, APE1’s enzymatic activity on abasic DNA was 
measured. A tetrahydrofuran (THF) containing dsDNA probe was incubated with equal amounts of 
mitochondrial extracts from Ctrl and Mia40 siRNA-transfected cells for the reported times. A 
significant decrease of endonuclease activity was apparent upon Mia40 knock down due to the 
reduction of APE1 amount in the mitochondrial fraction (Figure 40). To further support the 
physiological relevance of Mia40 in controlling APE1 trafficking, we measured the level of mtDNA 
damage in Mia40 siRNA-transfected cells, and under basal conditions, loss of Mia40 expression did 
not significantly affect mtDNA damage levels. However, when cells were treated with H2O2, the 
degree of damage was significantly increased, suggesting that the reduction in mitochondrial APE1 
amount, due to the loss of Mia40, affected the mtDNA repair capability and thus sensitizing cells to 
oxidative damaging agents (Figure 41). The same experiment was performed on the human 
hepatocellular carcinoma (HCC) cell line JHH6, by measuring the level of mtDNA damage in Mia40 
siRNA- transfected cells upon H2O2 treatment. The data obtained were consistent with the previous 
results on the HeLa cell line, therefore supporting the generality of the mechanism (Figure 41). These 
data demonstrate, for the first time, a direct role of the Mia40 protein in the import of APE1 into the 
mitochondrial compartment and its indirect role in controlling the stability of mtDNA upon oxidative 
damage. 
 
Figure 38. Western blot analysis of HeLa cells extract overexpressing Mia40. (top) Western 
blot analysis (top) of mitochondrial extracts from HeLa cells overexpressing Mia40-HisTag. HeLa 
cells were transiently transfected with pCMV 5.1 empty vector (Mock) or codifying for Mia40-
HisTag protein. (bottom) Densitometric analysis of mitochondrial APE1 levels highlights a 
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statistically significant increase of APE1 content into the mitochondrial fraction as consequence of 
Mia40 overexpression. Data are the mean ±SD of three independent experiments. 
 
	 
Figure 39. Western blot analysis of nuclear (NCE) and mitochondrial (MCE) HeLa cell 
extracts of Mia40 siRNA cells. Rapresentative image (top) and densitometric analysis (bottom) of 
mitochondrial and nuclear APE1 levels highlights a statistically significant reduction of APE1 
content into the mitochondrial fraction as consequence of Mia40 loss of expression. Data are the 
mean ±SD of five independent experiments. 
 		 
Figure 40. Endonuclease activity analysis of mitochondrial fractions from scramble (Ctrl) 
and Mia40-siRNA treated cells (siRNA). Data analysis reported in the diagram (bottom) shows 
that endonuclease activity is reduced after Mia40 silencing. 
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Figure 41. mtDNA damage analysis from HeLa cells (left) and JHH6 hepatic cell line (right) 
after Mia40 loss of expression under basal conditions and after H2O2 treatment (HeLa: 400 
µM; JHH6: 1,2 mM). Silencing of Mia40 leads to an increase of mtDNA damage under oxidative 
stress conditions. 
 
To prove that APE1 is necessary for the maintenance of the mitochondrial genome stability HeLa cells 
where endogenous expression of APE1 was knocked-down by siRNA technology in a conditional 
manner through a doxycycline-responsive promoter were used 102. Control HeLa cells, obtained after 
stable transfection with a scrambled sequence (Scr-1), or silenced HeLa cells bearing the APE1 
specific siRNA plasmid (shRNA), were treated with doxycycline for 10 days, mitochondria were 
isolated, and expression levels of APE1were evaluated by western blotting analysis. As re- ported in 
Figure 42 (left panel), APE1 mitochondrial expression in the shRNA expressing clone was strongly 
reduced, with protein levels less than 10% compared to the control. The endonuclease activity was 
also significantly reduced (Figure 42, right panel). The levels of mtDNA damage in the HeLa cell 
model upon APE1 knock down were then measured, and interestingly, lack of APE1 in shRNA 
expressing cells was sufficient to strongly increase the mtDNA damage under basal conditions (white 
bars) (Figure 43). Moreover, when cells were treated withH2O2 (gray bars) the mtDNA damage was 
significantly increased in shRNA expressing clone with respect to control. Altogether, our data 
support the essential role of APE1 for the repair of oxidative lesions and the repair of mtDNA. 
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Figure 42.  Western blot analysis and endonuclease activity of mitochondrial fractions 
(MCE) from control and APE1-shRNA stable clones. (left) APE1-shRNA cells show APE1 
reduction up to 90% respect to the Scr-1 cells. ATP 5A and LSD1 were used as mitochondrial and 
nuclear markers, respectively. A nuclear extract from HeLa cells was used as control to exclude 
nuclear/mitochondrial cross contamination. (right) In the same way the endonuclease activity 
analysis of mitochondrial extracts from Scr-1 and shRNA cells showed that the activity is almost 
abolished upon loss of APE1 expression. The conversion of the fluorescent tetrahydrofuran-
containing oligonucleotide substrate (S) to the shorter incised product (P) was evaluated for the 
reported times on a denaturing 20% (wt/vol) polyacrylamide gel. A representative image (top) and 
average values of incision percentage ±SD of three independent experiments (bottom) are shown.  
 
Figure 43. mtDNA damage analysis of Scr-1 and shRNA clones under basal conditions and 
after H2O2 treatment. Levels of mtDNA damage are increased in cells lacking APE1 both under 
basal and oxidative stress conditions. 
 
APE1’s extra-nuclear localization is a marker of poor prognosis in different cancers, such as 
hepatocarcinoma 353. However, up to now, the role of this aberrant localization in tumor progression 
has been unknown. In order to determine whether a correlation exists between Mia40 expression 
levels and the amount of mitochondrial APE1 protein form in tumor cells, subcellular fractionation 
was performed on two hepatoma cell lines in which we previously demonstrated that the expression 
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levels of APE1were significantly different, particularly in the cytoplasmic compartment 353: Huh7 
(well-differentiated HCC) and JHH6 (poorly differentiated HCC). Western blot analyses highlighted 
the existence of a direct correlation between the expression levels of Mia40 and the amount of APE1 
in the mitochondrial fraction of JHH6 cell extracts (Figure 44). To ascertain that the increased 
mitochondrial localization of APE1 was associated with increased resistance to genotoxic damage, 
both cell lines were treated with increasing amounts of the DNA alkylating agent MMS and cell 
viability was measured upon 8 h of treatment. As reported in Figure 16, JHH6 cells were significantly 
more resistant to the MMS treatment than Huh7 cells. The contribution of Mia40 to the increased 
resistance observed in JHH6 cells was verified. Down regulation of Mia40 expression by siRNA 
transfection in JHH6 cells caused a significant reduction of mitochondrial APE1’s levels (Figure 45) 
and a concomitant increased sensitivity to MMS and H2O2 treatments than seen	 in the control cells 
(Figure 46). In conclusion, our data support the general hypothesis for an unexpected role of the MIA 
pathway in chemoresistance by directly controlling APE1 translocation into mitochondria and 
therefore influencing the stability of mtDNA upon genotoxic damage. 
		 
Figure 44. Loss of Mia40 expression sensitizes JHH6 cells to MMS and H2O2 treatment. (top) 
Western blot analysis of total (WCE), cytoplasmic (CCE), nuclear (NCE), and mitochondrial 
(MCE) cell extracts from JHH6 (lanes 1-4) and Huh7 (lanes 5-8) cell lanes. (bottom) 
Densitometric analysis shows a direct correlation between expression levels of Mia40 and APE1 
(bottom). ATP 5A and LSD1 were used as mitochondrial and nuclear markers, respectively. 
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Figure 45. MTS cell viability assay on JHH6 and Huh7 cell lines. 8h MMs treatment of cells 
led to an increased sensitivity of Huh7 to the treatment. 
 
 
Figure 46. Western blot analysis of mitochondrial extracts of Mia40 siRNA and relative 
control from JHH6 cells. (top) Loss of Mia40 expression negatively affects the mitochondrial 
levels of APE1 protein. (bottom) MTS cell viability assay on control (Ctrl) and Mia40 siRNA 
JHH6 cells after 8 h of treatment with reported amounts of MMS (left) and H2O2 (right). 
Reduction of mitochondrial APE1 content as consequence of Mia40 silencing sensitizes cells to 
oxidative and alkylating treatments. 
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2. Uncanonical role of APE1 on mitochondrial messenger RNA 
Having established that APE1 can enter the mitochondrial compartment interacting with Mia40 and 
using the DRS pathway, our research interest was then focused on how APE1 can enter the 
mitochondrial matrix, were it can exert its function on the mtDNA. To identify the inner membrane 
space translocator responsible for the transport of APE1 from the IMS to the matrix we performed an 
IP-MS analysis on isolated mitochondria expressing a FLAG tagged form of the protein aimed at 
detecting the mitochondrial interactome of APE1. Interestingly the analysis revealed, besides the 
expected interacting proteins, a significant percentage of proteins belonging to the mitochodndrial 
ribosome and enzymes involved in the metabolism of mtRNA and translation. On the basis of this 
unespected results and on the basis of the recent literature stating the APE1 can have a role on the 
metabolism of RNA, we decided to pursue this line of research, trying to understand the role of APE1 
on the mitochondrial mRNA metabolism.  
2.1 APE1 interacts with ribosomal and RNA processing proteins in mitochondria 
To study the mitochondrial interactome of APE1 protein we used a HeLa based cellular model 
previously developed in our group 354 where it is possible to specifically re-express an ectopic siRNA 
resistant form of APE1 wild-type (APE1WT) with a 3XFLAG at the C-terminal on an inducible APE1 
siRNA background (Fig. 47). After nine days of doxycycline treatment to silence endogenous APE1 
expression, mitochondria from the control shRNA sample (Mock) and APE1WT clones were isolated, 
and APE1 was immune-purified under native conditions. Then, eluates were subjected to the MS 
analysis for the identification of mitochondrial interacting partners of APE1 protein. Of all proteins 
identifies, 160 fulfilled the filter criteria and have been considered as mitochondrial interacting 
partners of APE1. Then, proteins were clustered for their function (Fig. 48) and, interestingly, many 
resulted to be involved in RNA translation (MALSU1, MRRF, TUFM, TFSM, ICT1, detailed 
described in Table 1), RNA processing (PTCD3, GRSF1, DHX30, FASTKD2, PNPT1, TFAM, 
detailed described in Table 2), or be components of the mitochondrial ribosome (Fig. 48). The 
interaction with two components of ribosomal small (MRPS15) and large (MRPL9) subunits was 
validated through the Western blot analysis of a co-immunoprecipitated material from an independent 
experiment (Fig. 49).  
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Figure 47. Western blot analysis of total (TCE) and mitochondrial (MCE) protein extracts of 
cell clones used. Control (Scr), APE1 shRNA (shRNA), and APE1 knock-in (APE1WT) clones 
were treated with doxycycline for 9 days to silence endogenous APE1 protein and to express an 
ectopic FLAG-tagged recombinant siRNA resistant form (APE1WT). Anti-APE1 antibody was 
used to detect both endogenous and ectopic APE1, while the anti-FLAG was used to confirm the 
presence of ectopic APE1 into the mitochondrial compartment. Anti-LSD1 antibodies and anti-
ATPVA proteins were used as nuclear and mitochondrial markers, respectively. 
		 
Figure 48. Pie chart of protein classes resulted from MS analysis to interact with APE1 in 
mitochondria: For each category numbers of proteins and percentage are reported. 
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Table 1: Mitoribosome/translation related proteins. Panel of proteins belonging to the 
mitoribosome/translation raleted proteins calss reporting the protein name, gene name, function, 
and molecular weight based on UNIPROT database description.  
 
Protein name Gene 
name 
Function IP/Ctrl 
ratio 
MW 
Mitochondrial assembly of 
ribosomal large subunit 
protein 1 
MALSU1 May function as a ribosomal silencing factor. 
Addition to isolated mitochondrial ribosomal 
subunits partially inhibits translation. Interacts with 
mitochondrial ribosomal protein L14 (MRPL14), 
probably blocking formation of intersubunit bridge 
B8, preventing association of the 28S and 39S 
ribosomal subunits and the formation of functional 
ribosomes, thus repressing translation. May also 
participate in the assembly and/or regulation of the 
stability of the large subunit of the mitochondrial 
ribosome. 
 
APE1-flag 
only 
26,17 
Ribosome-recycling factor, 
mitochondrial (RRF) 
(Ribosome-releasing factor, 
mitochondrial) 
MRRF Responsible for the release of ribosomes from 
messenger RNA at the termination of protein 
biosynthesis. May increase the efficiency of 
translation by recycling ribosomes from one round 
of translation to another. 
 
APE1-flag 
only 
36,962 
Elongation factor Tu, 
mitochondrial (EF-Tu) (P43) 
TUFM This protein promotes the GTP-dependent binding 
of aminoacyl-tRNA to the A-site of ribosomes during 
protein biosynthesis. 
 
2,15 49,541 
Elongation factor Ts, 
mitochondrial (EF-Ts) (EF-
TsMt) 
TSFM Associates with the EF-Tu.GDP complex and induces 
the exchange of GDP to GTP. It remains bound to 
the aminoacyl-tRNA.EF-Tu.GTP complex up to the 
GTP hydrolysis stage on the ribosome. 
 
1,94 18,587 
Peptidyl-tRNA hydrolase 
ICT1, mitochondrial (39S 
ribosomal protein L58, 
mitochondrial) (MRP-L58) 
(Digestion substraction 1) 
(DS-1) (Immature colon 
carcinoma transcript 1 
protein) 
ICT1 Essential peptidyl-tRNA hydrolase component of 
the mitochondrial large ribosomal subunit. Acts as a 
codon-independent translation release factor that 
has lost all stop codon specificity and directs the 
termination of translation in mitochondrion, 
possibly in case of abortive elongation. May be 
involved in the hydrolysis of peptidyl-tRNAs that 
have been prematurely terminated and thus in the 
recycling of stalled mitochondrial ribosomes. 
6,98 21,905 
Large ribosomal subunits 
(31 out of 50) 
    
Small ribosomal subunits 
(14 out of 31) 
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Table 2: RNA related proteins. Panel of proteins belonging to the RNA related proteins class  
reporting the protein name, gene name, function, and molecular weight based on UNIPROT 
database description.  
 
 
Protein name Gene 
name 
Function IP/Ctrl 
ratio 
MW 
Transcription factor A, 
mitochondrial (mtTFA) 
(Mitochondrial transcription 
factor 1) (MtTF1) 
(Transcription factor 6) (TCF-
6) (Transcription factor 6-like 
2) 
 
TFAM Binds to the mitochondrial light strand promoter 
and functions in mitochondrial transcription 
regulation. Required for accurate and efficient 
promoter recognition by the mitochondrial RNA 
polymerase. Promotes transcription initiation from 
the HSP1 and the light strand promoter by binding 
immediately upstream of transcriptional start sites. 
Is able to unwind DNA. Bends the mitochondrial 
light strand promoter DNA into a U-turn shape via 
its HMG boxes. Required for maintenance of 
normal levels of mitochondrial DNA. May play a 
role in organizing and compacting mitochondrial 
DNA. 
 
4,28 20,096 
Polyribonucleotide 
nucleotidyltransferase 1, 
mitochondrial 
PNPT1 RNA-binding protein implicated in numerous RNA 
metabolic processes. Catalyzes the phosphorolysis 
of single-stranded polyribonucleotides 
processively in the 3'-to-5' direction. Mitochondrial 
intermembrane factor with RNA-processing 
exoribonulease activity. Component of the 
mitochondrial degradosome (mtEXO) complex, 
that degrades 3' overhang double-stranded RNA 
with a 3'-to-5' directionality in an ATP-dependent 
manner. Required for correct processing and 
polyadenylation of mitochondrial mRNAs. Plays a 
role as a cytoplasmic RNA import factor that 
mediates the translocation of small RNA 
components, like the 5S RNA, the RNA subunit of 
ribonuclease P and the mitochondrial RNA-
processing (MRP) RNA, into the mitochondrial 
matrix.  
 
APE1-flag 
only 
85,95 
FAST kinase domain-
containing protein 2 
FASTKD2 Plays an important role in assembly of the 
mitochondrial large ribosomal subunit. 
APE1-flag 
only 
81,462 
Pentatricopeptide repeat 
domain-containing 
protein 3, mitochondrial 
PTCD3 Mitochondrial RNA-binding protein that has a role 
in mitochondrial translation. 
14,16 78,549 
Serine--tRNA ligase, 
mitochondrial 
SARS2 Catalyzes the attachment of serine to tRNA(Ser). Is 
also able to aminoacylate tRNA(Sec) with serine, to 
form the misacylated tRNA L-seryl-tRNA(Sec), 
which will be further converted into 
selenocysteinyl-tRNA(Sec). ATP + L-serine + 
tRNA(Ser) = AMP + diphosphate + L-seryl-
tRNA(Ser). 
ATP + L-serine + tRNA(Sec) = AMP + diphosphate + 
L-seryl-tRNA(Sec). 
 
5,45 58,182 
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G-rich sequence factor 1 GRSF1 Regulator of post-transcriptional mitochondrial 
gene expression, required for assembly of the 
mitochondrial ribosome and for recruitment of 
mRNA and lncRNA. Binds RNAs containing the 14 
base G-rich element. Preferentially binds RNAs 
transcribed from three contiguous genes on the 
light strand of mtDNA, the ND6 mRNA, and the 
long non-coding RNAs for MT-CYB and MT-ND5, 
each of which contains multiple consensus binding 
sequences. 
 
2,50 36,613 
Putative ATP-dependent 
RNA helicase DHX30 
DHX30 Plays an important role in the assembly of the 
mitochondrial large ribosomal subunit. Required 
for optimal function of the zinc-finger antiviral 
protein ZC3HAV1 (By similarity). Associates with 
mitochondrial DNA. 
2,70 130,55 
 
 
 	 
Figure 49. Western blot analysis of an immunoprecipitated material to validate the 
interaction with mitochondrial ribosome subunits. shRNA (Mock) and APE1WT clones were 
treated with doxycycline for 9 days, then mitochondria were isolated and lysed under native 
conditions (Input) and immunoprecipitated with anti-FLAG (IP). The presence of small 
(MRSPS15) and large (MRPL9) subunit components were detected using specific antibodies. The 
interaction with mitochondrial base excision repair (mtBER) component FEN-1 was evaluated as 
the positive control. 
 
2.2 APE1 binds and processes abasic mitochondrial RNA 
Next, we assessed if, apart from interacting with mitochondrial proteins involved in RNA metabolism, 
the APE1was able to directly bind in vivo RNA molecules. Newly synthetized RNA was labeled in 
vivo with bromouridine (BrU) by 30-minute incubation of HeLa cells with 2.5 mM of BrU 355, while 
unlabeled cells (Bru-) were used as the control in PLA analyses (Fig 50). The presence of dots in the 
metabolically labeled cells (BrU+) confirmed the interaction between APE1 and RNA (Fig. 51). 
Moreover, to evaluate if the binding of APE1 increased upon oxidative stress, the cells labeled with 
BrU were treated with Antimycin A (AMA) at the final concentration of 25 µM for 30 minutes. AMA 
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is an inhibitor of the mitochondrial electron transport chain complex III which inhibition specifically 
induces mitochondrial oxidative stress 356. As for DNA, also RNA can undergo oxidative damage and 
the prevalent oxidized base in RNA is 8-hydroxyguanosine (8-OHG) which could be released leaving 
AP sites 357. The analysis has demonstrated that APE1 constitutively binds to RNA (70±21 PLA 
dots/cell) and that this binding is significantly enhanced by the induction of mitochondrial oxidative 
stress (179±24 PLA dots/cell). These data open up the possibility that APE1 could bind and exert 
endoribonuclease activity on abasic RNA (AP-RNA) (Fig. 51). To verify this hypothesis, we 
measured the extent of oxidative base loss in mitochondrial RNA as a function of APE1 expression 
using an aldehyde-reactive probe (ARP) 358. Oxidatively depurinated/depyrimidinated RNA species 
were specifically labeled with ARP, isolated with streptavidin magnetic-beads, and qRT-PCR was 
performed to evaluate the amount of ND1 and COX2 mRNAs. Loss of APE1 expression (shRNA) 
was associated with a significant increase in damaged mitochondrial RNA, while re-expression of 
wild-type APE1 (APE1WT) reverted this effect (Fig. 52, top). To support the specificity of the assay, 
the cells treated with AMA showed a higher amount of damaged RNA (Fig. 52, bottom). Altogether, 
these data support a new role of the mitochondrial form of APE1 protein in the metabolism of 
damaged mitochondrial RNA.			
 
Figure 50. In vivo RNA labeling with boromouridine. Immunofluorescence analysis of HeLa 
cells unlabelled (-BrU) or labelled (BrU) with bromouridine in vivo and treated (AMA) or not 
(Basal) with Antimycin A, 25 µM for 30 minutes. Nuclei were stained with DAPI, and BrU 
incorporation was detected using a polyclonal primary antibody anti-BrdU followed by incubation 
with a secondary antibody anti-Rabbit conjugated with an Alexa Flow 488 dye. The specificity 
was confirmed by the absence of any signal in unlabeled cells (Neg. Ctrl). Moreover, in the image 
is also visible how treatment with AMA did not affect the signal of BrU. White bars indicates a 
measure of 10 µm. 
DAPI BrU Merged
Neg.	Ctrl
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AMA
-BrU
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Figure 51. Proximity ligation assay analysis between APE1 and RNA. (top) Rapresentative 
image of PLA analysis performed to evaluate the interaction between APE1 and RNA under basal 
condition and upon induction of mitochondrial oxidative stress. HeLa cells unlabeled (-BrU) or 
labeled (BrU) with bromouridine in vivo were treated (AMA) or not (Basal) with Antimycin A to 
induce mitochondrial oxidative stress. PLA was performed using anti-APE1 and anti-BrdU 
antibodies. (bottom) Box plot reports the number of PLA dots counted in an average of 35 cells for 
each condition and the differences were found significant at a p-value of 0.01x10-15. White bars 
indicate a measure of 10 µm. (*: p<0.05). 		
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Figure 52. Quantification of abasic sites in mitochondrial RNA. (top) Quantification of abasic 
sites in mitochondrial RNA of ND1 and COX2 messengers in control (Scr), APE1 shRNA, and 
knock-in (APE1WT) clones. Precipitated AP-RNA and total RNA were subjected to qRT-PCR and 
levels of mitochondrial RNA damage were determined based on the difference in Ct value 
between oxidized and total RNA. (bottom) Quantification of abasic sites in mitochondrial RNA of 
ND1 and COX2 messengers in HeLa cells treated with AMA. As positive control of the assay 
used to evaluate the levels of mitochondrial mRNAs oxidation as consequence of APE1 loss of 
expression (Fig. 2B), HeLa cells were treated for 3 h with 100 µM of AMA to induce 
mitochondrial oxidative stress. Isolated RNA was derivatized by treatment with ARP, followed by 
purification with magnetic beads. Precipitated AP-RNA and total RNA were subjected to qRT-
PCR for ND1 and COX2. Levels of mitochondrial RNA damage were determined based on 
difference in Ct value between oxidized and total RNA. (*: p<0.05; **: p<0.01). 
 
 
2.3 Mitochondrial mRNA half-life is dependent on APE1 
Having established that APE1 binds RNA and that loss of mitochondrial APE1 expression determines 
the accumulation of AP sites on mRNAs, we used qRT-PCR to measure the levels of mitochondrial 
(ND1, CytB, COX2, ATP6) and nuclear (NDUFA1, CYC1, COX6B, ATPVA) encoded mRNAs 
codifying for proteins of the complexes I, III, IV, and V, respectively. While the expression of APE1 
did not affect the levels of the nuclear encoded mRNAs, all mitochondrial encoded primary transcripts 
(mt-mRNA) were significantly upregulated in APE1 shRNA clone (Fig. 53). In order to exclude the 
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possibility that the effect observed was due to the use of stable cell clones, HeLa cells were transiently 
transfected with a different APE1-specific siRNA. Also in this case, APE1 depletion was followed by 
a significantly increased expression of mitochondrial encoded mRNAs (Fig. 54). To establish if the 
observed rise in mt-mRNA levels was the consequence of an enhanced expression or of an impairment 
in the RNA degradation processes, mitochondrial gene transcription was specifically inhibited by 
treating cells with low concentrations of ethidium bromide (EtBr) 359. While control cells (Scr) showed 
a linear reduction of mRNA levels, in APE1 deficient clone (shRNA) mRNAs appeared to be more 
stable, thus confirming the hypothesis of an impairment in the mitochondrial RNA degradation 
processes in the absence of APE1 (Fig. 55). To further support these data, mitochondrial RNA 
stability of ND1 and CytB primary transcripts was measured by metabolic labeling with 4-thiouridine 
(4sU) as previously described by Borowski et al. 344. In accordance with the previous results, RNA 
half-life of ND1 (1.67±0.06 hours) and CytB (1.50±0.03 hours) of the control clones was significantly 
increased upon APE1 loss of expression ND1: 2.34±0.36 hours; Cyt.B (2.14±0.31 hours) (Fig. 56). 
 
Figure 53. qRT-PCR analysis of mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) 
encoded mRNAs. mRNA levels of mtDNA encoded genes ND1, CytB, COX2, ATP6 and nDNA 
encoded genes NDUFA1, CYC1, COX6B, ATP5A were measured on control (Scr) and APE1 
shRNA clones using specific primers. (*: p<0.05). 
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Figure 54. Effect of transient APE1 downregulation on mitochondrial mRNA expression. 
(top) Representative Western blot analysis of total cellular extract of HeLa cells transiently 
transfected with control (Scr) and specific siRNA for APE1. Protein expression was evaluated 
using anti-APE1 antibody, while anti-Actin was used as loading control. (bottom) qRT-PCR 
analysis of mitochondria (mtDNA) and nuclear (nDNA) DNA encoded mRNAs expression of 
HeLa cells where APE1 protein was transiently silenced by siRNA transfection. As in the stable 
clones, while the expression of APE1 did not affect the levels of the nuclear encoded mRNAs, all 
mitochondrial encoded primary transcripts resulted significantly upregulated as consequence of 
APE1 loss of expression. Data reported are the mean±SD of three independent biological 
replicates. (*: p<0.05; **: p<0.01). 
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Figure 55. qRT-PCR analysis of mitochondrial encoded mRNAs ND1, CytB, COX2, and 
ATP6 to measure mRNA half-life. Cells were treated with ethidium bromide to inhibit 
mitochondrial gene transcription and to measure the effect of APE1 expression on mt-mRNAs 
half-life. (*: p<0.05). 
 	 
Figure 56. Histogram represents the ND1 and CytB mRNA half-life. Half-life was calculated 
by metabolic labeling with 4-thiouridine (4sU). (*: p<0.05). 
 
 
 
 
 
B
Figure	3
A
0,0
0,5
1,0
1,5
2,0
0h 1h 2h 4h 6h
Re
la
tiv
e	
m
RN
A
le
ve
ls
EtBr 500	ng/mL
Scr-1
shRNA
CytB
* *
0,0
0,5
1,0
1,5
2,0
0h 1h 2h 4h 6h
Re
la
tiv
e	
m
RN
A
le
ve
ls
EtBr 500	ng/mL
Scr-1
shRNA
ATP6 *
0,0
0,5
1,0
1,5
2,0
0h 1h 2h 4h 6h
Re
la
tiv
e	
m
RN
A
le
ve
ls
EtBr 500	ng/mL
Scr-1
shRNA
ND1
* *
0,0
0,5
1,0
1,5
2,0
0h 1h 2h 4h 6h
Re
la
tiv
e	
m
RN
A
le
ve
ls
EtBr 500	ng/mL
Scr-1
shRNA
COX2
* *
0,0
0,5
1,0
1,5
2,0
2,5
ND1 CytB COX2 ATP6 NDUFA1 CYC1 COX6B ATP5A
Re
la
tiv
e	
m
RN
A
am
ou
nt
Scr
shRNA
*
*
**
mtDNA encoded nDNA encoded
C
Figure	3
0
0,5
1
1,5
2
2,5
3
ND1 CytB
RN
A	
ha
lf-
lif
e	
[h
]
Scr
shRNA
*
*
91	
2.4 APE1 mutant E96A is not able to exert enzymatic activity on mitochondrial mRNA 
species 
The majority of APE1 is localized within the nucleus where the protein exerts endonuclease activity 
on abasic DNA but also regulates in a redox-dependent manner the activity of several transcriptional 
factors such as NF-κB, HIF-1α, and p53. To confirm that the effects observed on mt-mRNAs were due 
to the absence of the mitochondrial APE1 rather than to its nuclear counterpart, we transiently re-
expressed on the background of APE1 shRNA clone an ectopic siRNA resistant APE1 form where the 
NLS at N-terminus was replaced by the mitochondrial targeting sequence (MTS) of MnSOD2 131. The 
Western blot analysis confirmed the expression of the two chimeric proteins, the enzymatically active 
MTS-APE1WT and the nuclease defective mutant MTS-APE1E96A 122 (Fig 57, top), while through the 
immune fluorescence analysis we proved that substitution of NLS with MTS led to the exclusion of 
the recombinant proteins from the nuclear compartment and their accumulation within the 
mitochondria (Fig. 57, bottom). Then, we measured the levels of mitochondrial mRNAs in APE1 
shRNA cells after the re-expression of the two ectopic recombinant forms of APE1 (Fig. 58). While 
the expression of the APE1WT was able to revert the phenotype reducing the levels of mt-mRNAs, the 
nuclease defective APE1E96A mutant only partially rescued the phenotype supporting the conclusion 
that APE1 exerts endoribonuclease activity on AP-RNA in mitochondria. qRT-PCR data were further 
validated by Norther blot analyses using specific probes for ND1 and COX2 mRNAs. In accordance 
with qRT-PCR analyses, mRNA levels were higher in APE1-deficient cells and the phenotype was 
restored by sole re-expression of APE1WT within the mitochondrial compartment. As before, the 
rescue effect was lost when the endonuclease defective form APE1E96A was expressed (Fig. 59). 
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Figure 57. Western blot analysis and immunofluorescence analysis of control (Scr) and 
APE1 shRNA clones. (top) Western blot analysis of clones treated with doxycycline and 
transiently transfected with empty vector (p5.1-Empty) or FLAG-tagged expression plasmids 
codifying for siRNA-resistant APE1 forms MTS-APE1WT and  MTS-APE1E96A. Anti-APE1 and 
anti-FLAG antibodies were used to detect endogenous and ectopic APE1 expression, respectively. 
Anti-Actin was used as loading control. (bottom) Representative image of immunofluorescence 
analysis of APE1 shRNA clone transiently transfected with FLAG-tagged expression plasmids. 
shRNA clone was transfected with plasmids codifying for siRNA-resistant APE1WT and 
mitochondrial targeted mutants MTS-APE1WT and  MTS-APE1E96A. Nuclei are stained with DAPI, 
APE1 with anti-FLAG conjugated with 488 dye, and mitochondria with Mitotracker DeepRed. 
White bars indicate a measure of 10 µm. 
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Figure 58. qRT-PCR analysis of mitochondrial DNA encoded genes. ND1, CytB, COX2, 
ATP6 measured on control (Scr) and APE1 shRNA clones treated with doxycycline and 
transiently transfected with empty vector (p5.1-Empty) or FLAG-tagged expression plasmids 
codifying for siRNA-resistant APE1 forms MTS-APE1WT and  MTS-APE1E96A. (*: p<0.05; **: 
p<0.01) 
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Figure 59. Northern blot analysis of RNA isolated from control (Scr) and APE1 shRNA 
clones.  Clones were treated with doxycycline and transiently transfected with empty vector (p5.1-
Empty) or FLAG-tagged expression plasmids codifying for siRNA-resistant APE1 forms MTS-
APE1WT and MTS-APE1E96A. Mitochondrial encoded ND1 (left) and COX2 (right) mRNAs were 
detected with the help of strand-specific radiolabeled riboprobes. Nuclear encoded 7SL RNA was 
used as a loading control. (top) Representative autoradiograms are shown. (bottom) Box plots 
show quantitation and mean±SD of four biological replicates. Statistical significance was 
calculated respect to the control sample (Scr-Empty). (n.s.: not significant; *: p<0.05; **: p<0.01). 
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2.5 Loss of mitochondrial APE1 negatively affects mitochondrial translation and 
respiration 
We proved that APE1 exerted endoribonuclease activity on mitochondrial AP-RNA and that damaged 
mRNA species were not efficiently removed in the absence of the protein. To deeply investigate this 
new function of APE1, we evaluated the downstream effects exerted by the accumulation of damaged 
mRNAs on the expression of mitochondrial encoded polypeptides. Western blot analyses were 
performed on Control (Scr), APE1 defective (shRNA), and knock-in (APE1WT) clones using specific 
antibodies for Complex I nuclear (NDUFA1 and NDUFS1) and mitochondrial (ND5) encoded 
proteins, and Complex IV nuclear (COX6B) and mitochondrial (COX2) encoded proteins. As a 
positive control, cells were also treated with chloramphenicol (CHF) for 24 hours to selectively inhibit 
mitochondrial protein translation 360. Although after APE1 silencing the amount of mRNA was higher 
in shRNA cells (Fig. 53, 54 and 58), we registered a significant reduction in terms of protein 
expression (Fig. 60). In details, COX2 levels were significantly lower both in shRNA cells and after 
CHF treatment, but the phenotype was reverted by the re-expression of APE1WT. However, expression 
of nuclear encoded COX6B subunit was also affected by APE1 silencing and CHF treatment. 
Concerning the protein of Complex I: expression of ND5 was slightly but significantly reduced after 
the silencing of APE1. However, also nuclear encoded NDFUFA1 and NDUFS1 expression were 
found to be downregulated. Indeed, also the positive control treatment with CHF elicited a reduction 
of protein levels, which could be explained considering that the assembly and stability of Complex I 
depend on the interaction and stability of respiratory complexes III and IV that serve as an anchor at 
the membrane to recruit Complex I into the respiratory chain 361,362. Therefore, to gain more 
knowledge on the effect of APE1 expression on the mitochondrial encoded polypeptides we analyzed 
the mitochondrial translation products. HeLa clones were treated with emetine to selectively block 
cytoplasmic translation, and then incubated with Met35S for one hour to label newly synthetized 
mitochondrial polypeptides. Samples were separated on SDS-PAGE and protein expression profile 
was visualized by autoradiography (Fig. 61, left). Densitometry analysis was performed to measure the 
levels of ND1, ATP6, and ND6 proteins, and confirmed significantly impaired expression in APE1 
shRNA that was rescued in APE1WT clone (Fig. 61, right). Altogether, our data have confirmed that 
APE1 exerts endoribonuclease activity on damaged mt-mRNAs contributing to the efficient 
functionality of mitochondrial translation processes. 
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Figure 60. Western blot analysis of total cell extract of control (Scr), APE1 shRNA and 
knock-in (APE1WT) clones. (top) Western blot analysis of clones treated with doxycycline for 9 
days. Specific antibodies for Complex I (NDUFA1, NDUFS1, ND5) and Complex IV (COX6B, 
COX2) proteins were used. Anti-Actin and anti-TOMM20 were used as loading controls. As a 
positive control, the cells were treated with chloramphenicol (CHF) for 24 hours to inhibit 
mitochondrial translation. (bottom) Histogram reports densitometric analyses of each protein 
relative to the control sample. (*: p<0.05; **: p<0.01). 
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Figure 61. Representative autoradiography image of SDS-PAGE electrophoresis of 
mitochondria translation analysis. (left) Rapresentative image of SDS-PAGE electrophoresis of 
control (Scr), APE1 shRNA and knock-in (APE1WT) clones after emetine/35S treatment. (top-right) 
Bands corresponding to ND1, ATP6, and ND6 were quantified and data were reported in the 
histogram (*: p<0.05; **: p<0.01). (top-bottom) Comassie stained gel used ad loading control.  
 
Considering that all 13 mitochondrial encoded polypeptides are components of the respiratory 
complexes I, III, IV and V, we evaluated the effect of APE1 loss of expression on mitochondrial 
respiration by examining the formation and stability of OXPHOS complexes and the respiratory 
parameters. BN-PAGE analyses highlighted the reduction in the stability of respiratory complexes I 
and III, while we did not observe any significant difference in Complex V (Fig. 62). Complex I is 
composed of seven mitochondrial encoded subunits (ND1, ND2, ND3, ND4, ND4L, ND5, ND6) that 
constitute its transmembrane domain. This explains how even the modest reductions in the expression 
levels of its subunits can affect its assembly and stability. This data was further supported by the 
measurement of Complex I activity, confirming that reduced complex stability determined a 
significantly lower activity in APE1 shRNA cells that was rescued in the knock in clone (Fig. 63). 
Complex III is a small complex composed of ten nuclear and only one mitochondrial encoded protein 
(CytB) but which is in the core of the complex and represents the central catalytic subunit of the 
complex. On the other hand, Complex V is a large complex composed of 29 proteins of 18 kinds, two 
of which (ATP6 and ATP8) are mitochondrial encoded. However, it has been demonstrated that 
although ATP6 mutation inhibits and destabilizes the ATP Synthase, it does not prevent the assembly 
and oligomerization of the complex 363. To provide the last proof for the direct role of APE1 in 
mitochondrial respiration, we conducted Seahorse analyses to measure the respiratory parameters, and 
confirmed significantly reduced basal respiration (60±10%), maximum respiration (62±22%), and 
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ATP production (53±4%) in APE1 shRNA clone as well as demonstrated that all parameters were 
efficiently rescued by the re-expression of APE1WT (Fig. 64). 
	 
figure 62. Coomassie staining of mitochondrial respiratory complexes. (left) Image from Scr, 
shRNA and APE1WT clones after BN-PAGE electrophoresis. (right) Bands corresponding to 
complexes I, III, and V were quantified and data relative to the control sample were reported in the 
histogram. (*: p<0.05). 
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Figure 63. In-gel activity analysis of respiratory Complex I. (left) Image from in-gel activity of 
respiratory complex I. (right) Bands corresponding to the activity (arrow) were quantified and data 
relative to the control sample were reported in the histogram (*: p<0.05). 
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Figure 64. Oxygen consumption rate evaluation of control Scr, shRNA and APE1WT clones. 
(top) Basal OCR was first evaluated, then cells were treated with the reported amounts of 
oligomycin, FCCP, rotenone and antimycin A, and OCR was measured three times after each 
injection. Diagram reports the OCRs of the clones relative to the Scr clone. (bottom) Histogram 
reports the basal respiration, maximal respiration, and ATP production capacity of clones 
extrapolated from the diagram. (*: p<0.05; **: p<0.01). 
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DISCUSSION AND CONCLUSIONS 
In the first part of this study, we investigated the role played by the interaction between Mia40 and the 
DNA repair protein APE1 in controlling its trafficking into the mitochondrial compartment and the 
involvement of the protein transport pathway, MIA, in the maintenance of the mitochondrial genome. 
APE1 is a ubiquitously expressed protein, which mainly localizes within the nuclear compartment but 
is also present in the mitochondrial IMS and matrix. Indeed, APE1 is a key protein in repairing small 
non-helix distorting oxidative, alkylated and abasic lesions of both the nuclear and mitochondrial 
genomes. Data reported in literature, concerning APE1 trafficking, are still scanty and in some case 
contrasting. With this research work we fulfill currently lacking information and depict a new model 
involving the MIA pathway that explains how APE1 is translocated into the mitochondrial 
compartment. Several data reported in literature demonstrate that APE1 is present within the 
mitochondria of mammalian cells in its full length form 66,67,134, therefore excluding the hypothesis of 
the involvement of a proteolytic process, as previously hypothesized, to be responsible of the NLS 
removal and the re-directioning of APE1 into the mitochondrion 137. Mitochondrial targeting signal of 
APE1’s has been identified in the region spanning the residues 289–318 where Lys299 and Arg301 
are the critical sites that, if mutated, completely abolish APE1 mitochondrial translocation under 
oxidative stress conditions 134. Previous studies have also shown that APE1 translocates into the 
mitochondria mainly through the TOM-dependent pathway, but detailed mechanisms have not yet 
been proposed 134. Our data demonstrate that after the passage through TOM channel, Mia40 is able to 
interact and bind APE1 by forming a disulfide bridge between APE1’s Cys93 and Mia40’s Cys55 
residues. Through GST pull-down experiments we demonstrated that mutation of Cys93 completely 
abolish the interaction with Mia40. Moreover, while mutating Cys65 to serine, we observed an 
increased interaction between the two proteins. This could be explained taking into account that when 
Cys65 alone is mutated, Mia40 is able to bind APE1’s Cys93 residue but cannot complete the reaction 
because of the lack of the second cysteine (Cys65), necessary for the disulfide bond formation. 
Therefore, the reaction is blocked explaining the increased interaction observed. Alternatively, the 
Cys65 mutant shows a higher affinity because this mutant has been demonstrated to adopt an unfolded 
structure, which exposes Cys93 residue therefore facilitating the interaction and the binding of Mia40 
364. While the C-term DNA-repair domain of APE1 is highly conserved among different species, the 
N-term redox domain is unique to mammals and has been acquired during phylogenetic evolution 114. 
Through its redox domain, APE1 exerts its activity by reducing key cysteine residues of a number of 
important transcription factors involved in both cell survival processes and apoptosis induction. In the 
N-term domain three cysteine residues (65, 93, and 99) are present. The current crystallographic 
structure was obtained in 1997 using a recombinant protein missing the first 35 N-terminal amino 
acids 100. The Cys65 is absolutely required for redox activity on nuclear transcriptional factors but in 
this model it appears as a buried residue, and therefore APE1 should undergo a local or a more 
extensive remodelling process to expose the Cys65 to the surface for the interaction with TFs 365. 
Cys99 is exposed on the surface of the protein but its substitution has no effect on redox activity. 
Cys93 is also a buried residue and before the determination of the crystal structure of APE1, it was 
proposed that Cys65 and 93 may form a disulfide bond 109. Indeed, in the crystallographic structure of 
APE1, Cys65 and Cys93 are positioned on opposite sides of a β sheet with a distance > of 8 Å apart 
and therefore a substantial conformational change in the structure of the protein would be required for 
a disulfide bond formation between these residues 109. Future studies are required to investigate APE1 
structure and structural changes but it is likely that APE1 is a multifunctional dynamic protein that in 
vivo may adopt different structural conformations to fulfill its activities.  In a previous work, we 
demonstrated that the majority of APE1 protein accumulates within the IMS 67. Here we showed that 
Mia40 is involved in the transport of APE1 into the IMS. However, a portion of APE1 is further 
translocated through a still unidentified mechanism, to the matrix where the mtDNA resides. 
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Accumulation within the IMS could represent a storage site of the protein or, alternatively, APE1 
could contribute to the redox homeostasis of the IMS within the glutathione (GSH)/glutathione 
disulfide (GSSG) and the reduced/oxidized thioredoxin systems. To assess the physiological relevance 
of the proposed import mechanism, we correlated the expression levels of Mia40 with the 
mitochondrial APE1 content and the stability of mtDNA. Experiments highlighted that loss of Mia40 
expression in HeLa cells determined a significant reduction of mtAPE1 form that consequently leads 
to increased levels of mtDNA damage as a consequence of oxidative stress induction. Therefore, our 
data clearly support a direct involvement of Mia40 in controlling APE1 trafficking into the 
mitochondria and, consequently, in the stability of mtDNA. It has already been reported that APE1 is 
upregulated and mislocalized in many tumors, including ovarian cancer, lung cancer, breast cancer, 
hepatocellular carcinoma, and others 353,366–368. In particular, a cytoplasmic relocalization of APE1 has 
been found to be associated with a higher aggressiveness of the tumor and a poor prognosis for the 
patient in HCC 353. Because Mia40 was also found to be upregulated in some tumors 43, we decided to 
analyse APE1 and Mia40 expression levels in two HCC cell lines with different degree of 
differentiation. Higher expression levels of Mia40 in the HCC poorly differentiated JHH6 cell line 
positively correlate with augmented levels of mitochondrial APE1 and consequently were associated 
with an increased resistance to the treatment with an alkylating agent with respect to the well-
differentiated Huh7 cell line. Also in this case, alteration in Mia40 expression and activity in JHH6 
cells upon silencing, determined a reduction of mitochondrial APE1 content, which resulted in an 
increased cellular sensitivity to alkylating and oxidative stress. Alkylating antineoplastic agents are 
lipophilic and have positive charges and therefore tend to accumulate within the mitochondria and 
generate alkylation lesions on mtDNA with 10-fold higher ratio respect to nDNA 189. APE1 
translocates into mitochondria increasing mtDNA repair rate and therefore, in our model, increased 
expression of Mia40 could lead to the promotion of cell survival. In summary, our data strongly 
support the hypothesis for a redox-assisted mechanism dependent on Mia40 in controlling APE1 
trafficking within mitochondria.  
 
Figure 42. Ape1-Mia40 interaction model.  After the passage through the TOM complex (1) 
Ape1 became substrate of Mia40 that catalize a disulfide bond between the Cys55 of Mia40 and 
Cys93 of APE1 (2). After the folding of APE1 and its release for Mia40 (3) the protein can 
interact with the translocase responsible for its passage in the matrix (4). One in the matrix 
compartment APE1 can exert its function on mtDNA (5).  
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Over the years, research on APE1 has been mainly associated with its role in the nuclear BER DNA 
repair pathway considering secondary for the cell fate the endonuclease activity of APE1 on the 
mitochondrial DNA. It is from the last decade that more research groups have directed their studies 
toward the biological relevance of APE1 extra-nuclear localization and also toward the 
characterization of uncanonical functions of this DNA repair enzyme, such as its RNA 
endoribonuclease activity 85,123,124,126. Our research merges these two aspects offering a completely 
new point of view in the study of APE1, and provides for the first time a direct proof of the essential 
role of this protein in mitochondrial RNA biology.  
In the second part of this thesis, with the idea of identifying the inner membrane protein complex 
responsible for the matrix internalization of APE1, we decided to perform an IP-MS analysis trying to 
identify the mitochodndrial interactome of APE1. The analysis of the data resulting from the 
experiment unveil that, in mitochondria, APE1 is mainly associated with ribosome components and 
RNA processing proteins. Next, we proved that APE1 not only interacts with RNA proteins but also 
binds RNA and that oxidative stress conditions enhance this binding. As for the DNA, also RNA can 
undergo oxidative damage forming 8-hydroxyguanosine (8-OHG) which could be released leaving AP 
sites 357 and measurements of mitochondrial mRNA AP sites confirmed  significantly higher levels of 
AP-RNA in the absence of APE1. Next, we extended our investigation demonstrating a direct 
correlation between the levels of APE1 in mitochondria and the half-life of mRNAs. Considering that 
the majority of APE1 localizes within the nuclear compartment where it exerts endonuclease activity 
and regulates gene expression by stimulating the DNA-binding activity of several transcriptional 
factors, it was necessary to discriminate if our observations could be related to the biological activity 
of the nuclear rather than of the mitochondrial form of APE1. For this purpose, rescue experiments 
were performed on the background of APE1 knockout cells by re-expressing a recombinant form of 
the protein that was targeted only into the mitochondrial matrix. Data confirmed that mRNA’s half-life 
was significantly longer in the absence of mitochondrial APE1 as a consequence of impaired 
degradation processes due to the loss of APE1 expression or re-expression of the endonuclease 
defective mutant E96A. Accumulation of non-functional mRNAs negatively affects mitochondrial 
translation processes and, as a final consequence, the assembly/stability of respiratory complexes and 
mitochondrial respiration. This study not only confirms and extends the emerging role of APE1 in 
RNA biology, but also reveals for the first time a new function of the mitochondrial form of this 
protein in mitochondria metabolism.  
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Figure 42. APE1 function on mt-mRNA metabolism and translation model. When APE1 is 
present in the mitochondrial matrix (top, 1a) it can bind to the abasic RNA present (2a) cleaving it 
and making it available for the degradation (3a). If APE1 is not present in the matrix (bottom, 1b), 
the damaged mRNA could not be cleaved (2b) leading to the stalling of the ribosome and shutting 
down the translation process (2c).  
 
Therefore, in the light of this observation, all data regarding the extra-nuclear localization of APE1 in 
correlation with tumorigenesis and tumor resistance could be re-interpreted considering APE1 as not 
only a DNA repair protein but also as a key component of the mitochondrial RNA degradosome. 
Despite molecular details of APE1 enzymatic activity were presented in this work, the possible 
involvement of other factors in this complex biological process have still to be investigated. Our study 
provides a rationale for targeting the mitochondrial form of APE1 as a promising therapeutic tool in 
cancer therapy. 
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